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All of old. Nothing else ever. Ever tried. Ever failed.
No matter. Try again. Fail again. Fail better.
– Samuel Beckett
There is excitement, adventure, and challenge,
and there can be great art in organic synthesis.
— R.B. Woodward
Alla mia famiglia.
E a chi ha sempre creduto in me.
iv
SOMMARIO
In questo lavoro di Tesi è stata affrontata la sintesi e l’applicazione in campo biome-
dico di α-amminoacidi non naturali in tre differenti progetti.
È stata messa a punto la sintesi “one-pot” di N-acetamido acrilato di mentile ot-
ticamente attivo e puro a partire da reattivi commerciali a basso costo, ottenendolo
in buone rese ed identificando il maggiore sottoprodotto di reazione. Tale acrilato
è stato utilizzato come accettore in reazioni di Michael per la formazione di nuovi
legami C-C e C-S, valutando l’induzione asimmetrica apportata dal (−)-mentolo.
Diversi nucleofili sono stati utilizzati e molteplici basi testate per cercare di ottenere
una conversione completa. Si è dunque indagata la possibilità di reazione della
molecola con opportuni nucleofili a dare cicli a cinque termini tetraidrotiofenici ed
altri intermedi a struttura di biciclo[3.1.0]esano e biciclo[4.1.0]eptano. Tutto ciò è
stato fatto nell’ottica di ottenere metodi alternativi per la sintesi di analoghi a strut-
tura costretta del glutammato, in precedenza identificati da Ely Lilly come potenti,
selettivi e attivi agonisti dei recettori mGluR.
Il secondo progetto, svolto presso il laboratorio del Professor Matteo Zanda
all’Università di Aberdeen, riguarda la sintesi di piccoli peptidi contenenti arginina
ed analoghi dello stesso amminoacido. I piccoli peptidi sono costituiti dal residuo
argininico accoppiato con differenti basi a struttura picolinica, mentre gli analoghi
contengono un sostituente alfa-metilico ed un triplo legame, od un gruppo triflu-
orometilico ed il triplo legame – purtroppo questa parte del progetto non è stata
conclusa per motivi di tempo. L’interesse per questo tipo di analoghi e peptidi
risale al fatto che l’arginina è il substrato per le Nitric Oxide Synthase, classe di en-
zimi coinvolti nella regolazione del rilassamento muscolare e della pressione san-
guigna attraverso la sintesi di ossido nitrico a partire dal summenzionato ammi-
noacido. I substrati progettati e sintetizzati, grazie alla loro struttura, risultano po-
larizzabili per mezzo di spettroscopia NMR e tecniche particolari con molecole di
paraidrogeno. Così, sarebbe possibile preparare specifici “tracers” per Risonanza
Magnetica, permettendo una facile e sicura rivelazione di malattie attraverso una
semplice e veloce scansione. Infatti, alcuni dei peptidi sintetizzati e polarizzati sono
stati testati in vitro e risultano compatibili con l’enzima. Infine, è stato messo a
punto un sistema per la determinazione del contenuto di controione trifluoroac-
etato all’interno delle molecole.
Il terzo progetto ha riguardato l’individuazione e la messa a punto di una via
alternativa alla sintesi a poco costo dell’amminoacido 2,6-dimetil-L-tirosina, un po-
tente analogo della tirosina usato in peptidi attivi sui recettori degli oppiacei. Come
reagente di partenza è stato utilizzato un derivato analogo dell’estere di Hage-
mann. Tale reagente è stato utilizzato come punto di partenza per due vie sin-
tetiche: una stereoselettiva grazie all’impiego di un sintone chirale a struttura 2,5-
dichetopiperazinica, ed una seconda che ha visto come reazione-chiave una reazione
di Michael per l’introduzione del residuo amminoacidico.
viABSTRACT
In this PhD Thesis work, the synthesis and the biomedical application of non natu-
ral α-amino acids was accomplished in three different projects.
A “one-pot” procedure for the synthesis of optically active and pure methyl
N-acetamido acrylate starting from cheap and commercial sources was developed
and fine-tuned, obtaining the target compound in good yields and identifying the
major reaction by product. This acrylate was used as acceptor in Michael reaction
conditions for the formation of new C-C and C-S bonds, evaluating the asymmetry
induced by the (−)-menthol. Different nucleophiles were used and different bases
were tested in order to obtain a full conversion. After that, reaction of the aforemen-
tioned molecule with opportune nucleophiles to synthesise five-membered tetrahy-
drothiophene rings and other intermediates with a bicyclo[3.1.0]hexane and bicy-
clo[4.1.0]heptane structure was investigated. The project was undertaken in order
to find new synthetic ways obtain constrained glutamate analogues, which have
been identified by Eli Lilly as potent, selective and active agonists of mGluR recep-
tors.
The second project, developed in the laboratory of Professor Matteo Zanda at
the Univesity of Aberdeen, is focused on the synthesis of small arginine-containing
peptides and arginine analogues. The small peptides are obtained by simple cou-
pling of the amino acid residue with different picolyl amines, while analogues of
the parent amino acid will contain a triple bond and a methyl or trifluoromethyl
substituent on the α-carbon of the amino acid skeleton. Interest in these two type
of compounds was risen because arginine is a substrate for Nitric Oxide Synthase,
a class of enzymes involved in the regulation of muscular relax and blood pressure
through nitric oxide synthesis starting from the aforementioned amino acid. The
designed and synthesised substrates result being able to polarise their signal under
specific NMR conditions in the presence of parahydrogen. In this way, a possibility
towards the synthesis of of specific and target-focused tracers for Magnetic Reso-
nance Imaging would be achieved, allowing for a simple and secure detection of
illness via a simple and quick MRI scan. Indeed, some of the synthesised com-
pounds polarise and are substrates for the Enzyme. On the last note, a method for
the determination of the amount of trifluoroacetic counter-ion was developed.
The third project is focused on the development of an alternative synthetic route
for the cheap synthesis of 2,6-dimethyl-L-tyrosine, a potent amino acid analogue to
tyrosine and employed in peptides which target opioid receptors. An analogue of
Hagemann’s ester ’s was used as starting point for the entire process and it was
used in two synthetic pathways. The first one is stereoselective in the fact that
involves alkylation of the chiral synthon 2,5-diketopiperazine, while in the sec-
ond one the key-step involves a Michael addition for the introduction of the amino
acidic residue.
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Introduction
Chemistry is said to be one of the most complicated sciences. Yet almost everything
which is around us today is related to or has been made by chemists, from the
shining rubber of the car’s dashboard and the catalysts in the car’s exhaust, to the
new drug targeting malaria or the new analytic technique to investigate and isolate
metals and other pollutants in water or country soil.
As was beautifully stated in a recent paper by K. C. Nicolau, “chemistry is the
scientific bridge that connects the macrocosm with the microcosm, our perceived
visible world with the invisible world of atoms and molecules. [...] The power of
chemistry is primarily derived from its ability to understand molecular structure,
synthesize it, and build function within it through molecular design and synthesis.”
[1]
In fact, the chemists are applying old and new techniques to produce, improve,
analyse and rationalise all the goods and substances which are now available in
the world. They are also working on envisaging new ones, progressing past the
constant challenges and eventually finding new answers to old problems.
Still in the words of KCN, “one of the most vital and valued subdisciplines of
chemistry is the science of organic synthesis, without which much of science and
industry would have remained paralyzed and sterile.” [1]
Organic chemistry is fairly young, having started to develop in the 19th century,
with the serendipitous synthesis of urea by Friedrich Wohler [2], who treated silver
isocyanate with ammonium chloride, as shown in the following reaction.
AgNCO+NH4Cl −→ (NH2)2CO+AgCl
This simple yet surprising reaction for the era was just the beginning of a series
of reactions which enabled chemists to reach more and more complex structures. It
also allowed them to start addressing the problem of solving the structure of natural
products, and gave input to begin new investigations, which ended in providing
some serendipitously discovered material and goods, answers to human needs at
the time. An outstanding example is the discovery of synthetic dyes; mauveine is
shown in Figure 1.0.1 on the following page, found by a young William H. Perkin on
his quest for quinine. In the mid 19th century, when he discovered his non-fading
dye and developed the processes for the mass-production and use of his new dye,
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FIGURE 1.0.1: The two major components of mauveine.
coloured substances were highly valued and much sought after as raw materials. [3]
Dye research also led to the introduction of sulfonamides in 1936, and therefore to
the development of the original sulpha drugs against bacterial infections.
As it has been said, synthesis, with complementary analysis, was often a matter
of utilitarian necessity rather than the creative, elegant art form revealed by the
work of many of the great synthetic chemists who characterised the second half of
the 20th century. And “chemistry blossomed between the two World Wars, at an
ever-accelerating pace of discovery. Work done in chemical physics and physical
chemistry did much to transform notions of how molecules are held together, how
bonds are formed and broken, and how reactions occur.” [4]
Organic synthesis made interesting progress too; for example, scientist R. B.
Woodward, in April 1944 finally accomplished a first total synthesis of the elusive
molecule of quinine 1, [5] whose supplies during the Second World War were scarce
for the Allies Army.
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SCHEME 1.1: Quinine 1 and Taxol 2, two of the most sought after natural prod-
ucts.
In the words of R. B. Woodward, which are reported at the beginning of this
work, an organic synthesis can be considered mostly an adventure: the chemist is
tackling one simple compound but facing a series of problems and challenges which
can be depressing at points, but also enlightening and exciting and lead to the final
achievement of the synthesised final product. Many are in fact routes which could
be undertaken for just one step, but the outcomes can be so different, just because
of the reactivity of the molecule. There can be also failure along the way, but trial
and error are part of the deal a chemist signs. Moreover, even in the most detailed
and best planned strategy there could be unexpected failure because of the unusual
reactivity of an intermediate. It is therefore necessary for a chemist to be open
minded and not surprised by the constant trials on the way.
But this outstanding giant of organic chemistry started an era where organic
chemistry grew up, and new reagents, reactions, concepts and strategies have been
devised and can be employed. This “new era was brought about by an array of
technological advances in instrumentation that brought structural representations
closer to real materials and their properties. This reification was realised through
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physical data collected by infrared (IR), ultraviolet (UV), and NMR spectroscopies,
mass spectrometry (MS), and X-ray crystallography instruments. The plethora of
data on large numbers of compounds allowed for generalisations and rules that fa-
cilitated structural elucidations of natural and synthetic compounds and, to some
extent, made obsolete the methods of analysis of the past, namely elemental analy-
sis, degradation, and reactivity. ” [1]
The Woodward era was followed by an even more impressive period of expan-
sion led by Elias J. Corey: new principles and theories like retrosynthetic analysis
and rational strategy design, new reagents and catalysts, but also the demonstra-
tion of the strong connection between natural products synthesis to biological in-
vestigations and medical applications were brought to the world-wide attention of
chemists. [1]
Nowadays, new principles like atom economy, stereo control, simplicity and
scalability, and environmental impact are orienting the development of the disci-
pline. And there is therefore evolution over the years from synthesis to synthesis,
based on the previous findings but always learning from the master of synthesis
which is nature, with its high yielding processes and stereocontrol.
There are in fact themes or trends of compounds whose synthesis continue to be
explored and tuned, according to the state of the art of the moment and the capac-
ity of the research group. Two examples are the aforementioned quinine 1, whose
story almost spans the history of Organic Chemistry [4], and the taxol 2 with its
seven total syntheses in over two decades. [6–15]
Corey’s fundamental work “also demonstrated and inspired the design and syn-
thesis of natural product analogues for the purpose of biological investigations as
well as process development for the large-scale production of pharmaceuticals.” [1]
In fact, the advent of new techniques and computer-aided drug-design, and the pos-
sibility given by high-throughput screening techniques for biological essays opened
the way for the organic chemists and their collaborating biologists to study not only
what effect a natural compound could have, but also the biological impact a modi-
fication of a natural scaffold could have in the organism.
An example is sucralose 3, the main ingredient in commercially available sweeten-
ers, shown in Scheme 1.2. This molecule is quite similar to the parent compound,
sucrose 4, the only difference being three hydroxyl groups replaced by three chlo-
rine atoms. This makes the sweetener rather indigestible but also about 600 times
sweeter than the natural, starting material. Moreover, as it contains fewer than 5
calories per serving the US FDA allows it to be sold as “zero calorie”.
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SCHEME 1.2: Synthetic scheme for transforming sucrose into sucralose.
As stated earlier, lots of compounds have an important role nowadays because
of their useful biological activity: in fact they exert their action by interacting with a
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specific site within a biomolecule, i.e. an enzyme or a receptor. This site is made by
chiral building blocks, normally amino acids and carbohydrates, which have a spe-
cific structure and spatial configuration and are present as a singular enantiomer.
It is therefore important to notice that the stereochemistry of a molecule has im-
portant and profound effects on the interactions and the consequent biological re-
sponse.
In most cases, in fact, two enantiomers can have very different activity levels
and can be considered two different compounds biologically speaking. This is due
to the fact that these two molecules can be metabolised with different speed or by
different paths because of their different interactions with enzymes and receptors,
which are chiral molecules. An outstanding case is thalidomide.
A racemic mixture needs then to be resolved in order to get the two compounds
and test them separately, while employing the methods of Asymmetric Synthesis
can clearly lead to obtaining a preponderance or even just one of the two enan-
tiomers. This can be achieved by employing chiral reagents, solvents, or catalysts
because the transition states of the reactions would then be diastereomeric and at
different energy levels, leading to the preferred formation of just one of the enan-
tiomers or diastereomers.
It is then possible to start from the so-called chiral pool, a collection of cheap, readily
available enantiomerically pure natural products, usually amino acids or sugars,
from which pieces containing the required chiral centres can be taken and incorpo-
rated into the product.
There could be employment of a chiral catalyst on a prochiral substrate with an achi-
ral reagent: the new stereogenic centre is formed when the chiral catalyst will put
in contact substrate and reagent.
A final way to accomplish an asymmetric synthesis is the employment of chiral
auxiliaries that can be attached to the prochiral substrate just for the reaction, in or-
der to obtain a diastereomeric mixture. Like reagents from the chiral pool, a chiral
auxiliary needs to be enantiomerically pure, economical and easy to install and to
remove.
1.1 Amino acids
In this thesis work the attention was focused on obtaining amino acids by labora-
tory synthesis. A few methods have been developed by chemists during the 20th
century, and are reported in the following Scheme 1.3 on the facing page. Notable
and classic routes are Gabriel and Strecker synthesis, which are simple and low cost.
In Gabriel synthesis the initial reaction of the α-bromoacid with the potassium salt
of phtalimide is followed by hydrazinolysis to yield the amino acid anche the cyclic
hydrazine.
Strecker synthesis is characterised by a multicomponent reaction, in which the alde-
hyde, the ammonia and the cyanide concur to the formation of the α-aminonitrile
which, upon hydrolysis, gives the expected α-amino acid.
In the final method, the crucial step is the attack of the primary or allylic/benzylic
bromide by a carbanion; moreover, it is interesting to note that the acetamidoma-
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SCHEME 1.3: Classic synthetic strategies for synthesising amino acids.
lonate intermediate is very versatile and the C−H bond can be easily activated by
a base.
These routes can be easily tuned in order to obtain all the different natural amino
acids and, as it has been said already, they are simple and low cost. The only big
draw-back is that the final product is a racemic mixture that has to be resolved in
order to obtain the pure enantiomers.
To overcome this problem, stereoselective synthesis of amino acids has been de-
veloped over the years, as it is shown in the following Scheme 1.4. In the first case,
COOH
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(B) Enantioselective alkylation to (R)-(4-chlorophenyl)alanine.
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(C) Proline-catalized enantionselective amino acid synthesis.
SCHEME 1.4: Principal anantioselective strategies for synthesising amino acids.
a chiral catalyst is used to hydrogenate the double bond of the α-amino alkene. It
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is obvious that this route is very expensive, although highly efficient and the enan-
tiomeric excess is such that it is possible to obtain the pure (S) enantiomer.
In the second case, the acid and basic moiety of the α-amino acid are protected as
ester and imine functions respectively. The alkylation is stereocontrolled by the
organocatalyst (+)-cinconine, a phase transfer catalyst which exerts its deprotonat-
ing action in the organic medium; in its protonated form, it returns back to the
aqueous phase where the inorganic base regenerates it to come back to the organic
phase.
The last example is a proline-catalised synthesis of amino acid: the proline, an
amino acid used in catalytic quantities, or an organocatalyst, is used to promote
and catalyse the condensation of the aldehyde with the azadicarboxilate in a stere-
oselective fashion, with high ee. Then, after oxidation of the aldehyde to carboxylic
acid and hydrogenation to get rid of the benzoyl moieties, the final amino acid is
obtained with high enantioselectivity. [16]
Some unusual amino acids can be found naturally, in particular cyclic amino
acids like aminocyclopropanecarboxylic acid or coronamic acid 5, the biogenetic
precursor of ethene, which is in turn involved in the ripening of the fruit. The
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SCHEME 1.5: Synthesis of coronamic acid.
carbanion from the malonate ester forms a three-membered cycle in the first step
by nucleophilic substitution. After conversion of the ester and hydrolysis of the
least hindered one, the carboxylic acid is transformed into acyl chloride and then
isocyanate via Curtius rearrangement. The product is then finally hydrolysed to
give the amino acid. [17]
More complicated manipulations of the scaffold could also be undertaken and
explored, like the addition of substituents in order to gain steric effects or develop-
ing the amino acid around a cyclic structure in order to impose the molecule a single
conformation. Two examples, 2’,6’-dimethyl-L-tyrosine 6 and (−)-(1R,4S,5S,6S)-4-
Amino-2-thiabicyclo[3.1.0]hexane-4,6-dicarboxylic Acid 2,2-Dioxide 7, are shown
in the following Scheme 1.6. The first compound 6 is a tyrosine analogue bearing
OH
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COOH
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O
NH2
H
6 7
SCHEME 1.6: Constrained amino acids.
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two methyl groups on the aromatic ring. This allows it to be used in place of nor-
mal tyrosine in small peptides active on the opioid receptors with higher affinity
for the receptor than the normal amino acid. The second compound 7, known also
as LY404039, [18] is a potential and nonclassical antipsychotic agent now in clinical
trials based on glutamic acid structure. Its bicyclo[3.1.0]hexane structure allows it
to be in a very constrained form and in just one conformation: for this reason, there
is a higher affinity of this substrate than the normal glutamic acid to the target re-
ceptor, rendering it highly interesting and more potent than others.
The conformational rigidity on arginine backbone and its effect on the affinity of the
obtained analogues on the biological target has also been studied [19], and insights
on the mechanism and the preferred conformation for the substrate were gained in
this manner.
Beside all of this, chemists have developed means of coupling amino acids with
each other in order to synthesise polypeptides and proteins. Over the years, the
technique evolved and became state of the art, but it is based on a few important
steps: protection, activation, coupling and specific deprotection, as it is possible to
notice from the Scheme 1.7. Amino acids are in fact characterised by two different
+H3N COO-
+H3N COO-P1HN COO-
H2N COP2P1HN COX
N-protection
Activation C-protection
Coupling
P1HN CONH COP2
Specific deprotection
H2N CONH COP2 P1HN CONH COOH
SCHEME 1.7: Steps for the synthesis of a simple dipeptide.
reactive moieties – they are bifunctional compounds – and have at least one active
stereocentre, hence the special care in their handling to avoid racemisation.
Both amine and acid moiety require protecting groups to be applied and removed
selectively and under mild conditions. For the amino group, the protecting group is
placed in order to decrease the nucleophilicity of the amine and hence avoid its par-
ticipation in the coupling reaction; nonetheless, it needs to be removed under mild
conditions in order not to cleave the peptidic bond just formed. The most used
are the benzyloxycarbonyl 8 (Z or Cbz) and the tert-butoxycarbonyl 9 (Boc) groups
alongside the Fluorenylmethyloxycarbonyl 10 (FMOC), shown in the Scheme 1.8 on
the following page. Protection of the carboxyl group is needed in order to prevent it
from participating during the coupling reaction. The most used and usual method
is achieved by acid esterification with methanol, ethanol or tert-butanol.
It is obvious that the coupling reaction is carried out between a free amino acid car-
boxylic group and the free amino group of another amino acid, as shown in Scheme 1.7.
There is although need to enhance the electrophilicity of the carboxylate group by
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SCHEME 1.8: Amine protecting groups.
introducing a good leaving group on the acid moiety: the most used at the moment
is the “active ester” method, and the most known and commonly used reagent is
the DCC 11, although it has been superseded by EDC 12 and some new reagents.
The carboxyl oxygen atom acts as a nucleophile, attacking the central carbon in
DCC and thus forming the so-called O-acylurea. DCC is temporarily attached to the
former carboxylate group, which is now an ester group, making nucleophilic attack
by an amino group by the attaching amino acid to the former carbonyl group more
efficient. With this method, although, some racemisation might occur: to solve this
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SCHEME 1.9: A few examples of activating agents for amino acids coupling
reactions.
problem, triazoles derivatives have been introduced. The most important ones are
1-hydroxy-benzotriazole 13 (HOBt) and 1-hydroxy-7-aza-benzotriazole (HOAt) 14.
These substances can react with the O-acylurea to form an active ester which is less
reactive and less in danger of racemization. HOAt is especially favourable because
of a neighbouring group effect. Alternatives to HOBt and HOAt have also been in-
troduced because of the dangerous effects these reagents can exert. One of the most
promising and inexpensive alternatives is ethyl 2-cyano-2-(hydroxyimino)acetate
known as Oxyma Pure 15, which is not explosive and has a reactivity between
HOBt and HOAt. Newer developments omit the carbodiimides totally, and the
active ester is introduced as a uronium or phosphonium salt of a non-nucleophilic
anion: two examples of the two categories of compounds are, respectively, HATU
16 and PyBOP 17. [20]
After the coupling takes place and the peptide bond has been formed, the follow-
ing step is the deprotection of the unwanted protecting group on the newly formed
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peptidic chain in order to continue with the synthesis of the peptide, or a final de-
protection step to obtain the pure compound.
The technique describers so far involves the classical approach of liquid-phase
peptide synthesis. This method has although been replaced in most labs by solid-
phase synthesis, but the underlying principles of the two techniques remain the
same. A few words on this latter technique are deserved.
Solid-phase peptide synthesis (SPPS), pioneered by Robert Bruce Merrifield, re-
quires the peptide to be “immobilised” on the solid phase and retained during a
filtration process, whereas liquid-phase reagents and by-products of synthesis are
flushed away. The general principle of SPPS is one of repeated cycles of coupling-
wash-deprotection-wash. [21]
Introducing a new moiety or functionality or replacing a carbon atom with a
halogen atom are just a few examples of the variety of means the chemist can exploit
in order to achieve higher diversity and different effects.
It needs to be mentioned, finally, that amino acids are useful synthons in or-
ganic chemistry: they constitute a big part of the so-called chiral pool from which
asymmetric synthesis can start from. In fact, compounds can incorporate the chiral
carbons of the amino acid into their carbon skeleton or the amino acid’s chirality can
be used to induce asymmetry in reaction which would not usually be asymmetric.
An interesting example of the first case of employment of amino acids in asym-
metric synthesis is reported in Scheme 1.10: L-alanine 18 is transformed into α-L-
mycaminoside 19. The asymmetric carbon atom is incorporated into the ring sys-
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SCHEME 1.10: Elaboration of alanine into different sugars.
tem and its chirality is able to induce and control the chirality of the contiguous
asymmetric centres.
L-alanine 18 is deaminated with nitrous acid and elaborated to the anomeric mix-
ture of compounds 20 and 21. This last compound is the common intermediate of
a series of interesting sugars: methyl α-L-amicetoside 22, α-L-mycaminoside 19 and
α-L-oleandroside 23.
An example of the second case is the so-called Schöllkopf Bis-Lactim Amino
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Acid Synthesis: amino acids can be converted to diketopiperazines or mixed dike-
topiperazines and undergo a variety of reactions resulting in high asymmetric in-
duction. [22–24]
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H2N COOCH3
CH2RNH2
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24
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SCHEME 1.11: Formation and alkylation of Schöllkopf Bis-Lactim ether for the
asymmetric synthesis of amino acids.
Glycine and (R)-valine 24 are easily converted to a diketopiperazine 25 with
high yields. A twofold methylation with methyloxonium tetrafluoroborate forms
the bis-lactim ether 26. Lithiation with η-BuLi of the prochiral position on C-3 oc-
curs regiospecifically to form the charged species 27, which can react with various
electrophiles.
This is the step that decides the stereoselectivity of the method: one face of the car-
banionic centre is shielded by steric hindrance from the isopropyl residue on valin-
ine. The reaction of the anion with an alkyl halide will form the alkylated product
28 indicating that the alkylating agent approaches C-3 trans to the isopropyl group
at C-6, with a diastereoselectivity of up to 95%.
In the final step the heterocyclic ring is cleaved by careful acidic hydrolysis to pro-
duce the regenerated chiral auxiliary methyl L-valinate and the (R)-amino acid ester
29 which can be separated from each other.
The scope of the faction can be further extended to include preparation of unsat-
urated amino acids, or even α-methyl amino acids, as reported in [25]. Neverthe-
less, the method is limited to the laboratory for the synthesis of exotic amino acids,
as industrial applications are not known. A major disadvantage of this method is
the limited atom economy.
1.2 The synthetic target – Project 1
Compounds with a bicyclo[3.1.0]hexane structure are quite well-known in the phar-
maceutical industry because of their constrained and rigid scaffold. An example is
the well-known patented amino acid LY354740 30 by Eli Lilly. The cyclopentane
ring is condensed with a cyclopropane ring, mimicking a cyclohexane structure but
not giving way to the famous boat equilibrium typical of these last structures. In
this way, molecules based on such a scaffold can show high affinity with the recep-
torial site of interest as they are not submitted to usual conformational movements
that can lower the lingand-receptor interaction.
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It was for these reasons and the possibility to study the affin-
ity and understand the conformational configuration of the glu-
tamate in the CNS that the group of James A. Monn reported
the synthesis of the constrained amino acid in 1997. [26] It is
in fact well known that L-Glutamic acid is the principal excita-
tory amino acid neurotransmitter in the mammalian central ner-
vous system. It exerts its effects via activation of two types of
receptors: those which form ligand-gated cation channels (ionotropic glutamate
receptors, iGluRs) and those which are coupled via G-proteins to intracellular en-
zyme systems which influence the production of second messengers (metabotropic
glutamate receptors, mGluRs). There are currently eight distinct mGluR proteins
(mGluR1-8), and this bicyclic amino acid has been designed specifically to target
mGluR 2 receptors, and – as it has been reported in the aforementioned work – the
conformational restrictions imposed on the glutamic acid structure render it highly
potent and selective toward the biological target.
Further developments on this molecule has led the group to explore different
decorations and substitution on the cyclopentane framework. [27, 28] Eventually
the group addressed the problem of studying the effects of the presence of an het-
eroatom on the ring. In particular, it was finally synthesised, modelled and tested
compound LY404039 7. [18] They found out that the oxidised sulphur atom can add
interactions similar to those of the natural, parent compound. In fact, the oxygen
atoms of the oxidised sulphur stabilise furthermore the structure of the molecule
inside the target receptor, rendering this molecule a useful tool for exploring the
effects of mGlu2/3 receptor activation in mammals.
There is in fact widespread occurrence of thia-ring systems in natural com-
pounds and drugs. In particular, dihydro- and especially tetra-hydrothiophenes
have attracted attention because these are recurring ring system motifs in natural
and non-natural products displaying a broad spectrum of biological activities. [29]
A few examples are biotin 31, an essential coenzyme, unnatural L-nucleoside 32
which displays potent anti-HIV activity without significant toxicity and Sulopenem
33. However, despite the importance of these scaffolds and the high benefits in
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SCHEME 1.12: Three tetrahydrothiphene-containing molecules: biotin 31, the
unnatural L-nucleoside 32 and Sulopenem 33.
a variety of applications, few methods for their asymmetric synthesis have been
reported, and only over the past decade has this topic emerged as an important
research area.
A few methods have been developed to synthesise substituted tetrahydrothio-
phenes, either involving carbon-carbon or carbon-sulfur bond formation reactions.
In 1952 Grob and von Sprecher described a nitroaldolization approach to the thio-
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SCHEME 1.13: Approaches to thiophene synthesis. A. Overman approach. B.
Karlsson approach. C. Castillon approach. D. Benetti et al. approach.
phane ring system in their efforts to synthesise biotin. [30]
More recently, Ponce Molina and Overman reported a new method for the stere-
ocontrolled synthesis of a variety of acyltetrahydrothiophenes by acid-promoted
condensation of mercapto allylic alcohols and carbonyl compounds or by rear-
rangement of suitable oxathiolanes, the ring-formation step being based upon a
carbon-carbon bond formation. [31]
In another approach that has been recently developed by Castillon et al., a thioether-
ification reaction was the key step for synthesising homochiral substituted tetrahy-
drothiophenes by carbon-sulfur bond formation. [32]
In the same period, Karlsson et al. exploited 1,3-dipolar cycloadditions – a C-C
bond forming strategy – of sulfur-containing 1,3-dipole to α,β-unsaturated acyl
derivatives dipolarophiles, which resulted in the formation of trans-3,4-disubsti-
tuted tetrahydrothiophenes. [33]
A final approach was studied in the group where part of this thesis work was de-
veloped: it consisted in the use of the commercially available 1,4-dithiane-2,5-diol
in a domino Michael-Henry reaction with nitroalkenes in situ generated [34] – more
on the domino reaction in 1.2.2 on page 17.
The strategy entailed on the use of as a suitable bifunctional reagent possess- ing a
sulfur nucleophile able to undergo Michael intermolecular addition to in situ gen-
erated nitroalkenes producing an intermediate nitroalkane adduct, which bears a
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suitably placed aldehyde group required for the subsequent intramolecular Henry
nitroaldol reaction
The synthetic target for the first project is represented by compound 7. Although
the tested compound failed clinical trials for phase III, [35] it remains an interesting
synthetic target. It is always challenging to introduce and fuse two carbon rings
together, not to mention the interesting feature of the presence of an heteroatom
on the main cycle. The original synthesis envisaged by Monn et al. starts from
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SCHEME 1.14: Original synthesis for constrained amino acid LY404039 as re-
ported by Monn et al. [18, 27]
optically active and pure compound 30, which is protected as ester on the acid moi-
ety and as Boc-anhydride on the amine moiety, and oxidized on the sulfur atom
to sulfone. After removal of the protecting groups, final compound 7 is obtained.
Compound 30 is obtained from thiophene 34, which is cyclopropanated to 35. Upon
hydroboration and oxidation of the introduced hydroxyl moiety, hydantoin cycle is
constructed 36 to give upon hydrolysis the amino acid moiety. Resolution and sepa-
ration of the two optical antipodes would result in optically active and pure 30. [18,
27]
1.2.1 Cyclopropanation Reaction
There are three types of stereoselective cyclopropanation reactions from olefins,
which are shown in Scheme 1.15 on the following page: the halomethyl-metal-
mediated cyclopropanation reactions (a), the transition metal-catalyzed decompo-
sition of diazo compounds (b), and the nucleophilic addition-ring closure sequence,
also called Michael-Initiated Ring Closure (c) and (d). [36]
The chemistry for the first type of reaction shown above has been developed by
Simmons and Smith during the 1960s with the discovery and use of reagents of the
type IZnCH2I for stereospecific conversion of alkenes to cyclopropanes. [37] A ma-
jor advantage of this approach is its excellent compatibility and chemoselectivity
as it has a wide scope, being applicable to a variety of olefins and compatible with
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SCHEME 1.15: Main type of reactions for the cyclopropane formation.
several functional group like enamines, enol ethers, esters, ketones.
Further developments led to the substitution of the original Zn/Cu couple with the
more practical and easy to handle ZnEt2 by Furukawa and co-workers in 1966. [38] [39]
Other cyclopropanating reagents of the proposed general structure MCH2X have
also been prepared. For example, samarium carbenoids were generated by the use
of a samarium/mercury amalgam in conjunction with CH2I2 by Molander [40],
while Yamamoto discovered the analogous R2AlCH2I reagent, which displays a
unique reactivity that complements that of the zinc- and samarium-mediated cy-
clopropanation reaction. [41]
The synthetic utility and scope of these reagents is clearly illustrated by the
chemoselectivity observed in the cyclopropanation of geraniol Scheme 1.16. [42]
The allylic alcohol group can be cyclopropanated in the presence of an isolated
SCHEME 1.16: Cyclopropanation of the geraniol. [42]
olefin with zinc- or samarium-derived reagents. Conversely, the aluminium reagent
can convert the isolated olefinic group into the corresponding cyclopropane with
outstanding chemoselectivity. Optimization of the reaction conditions has shown
that zinc-based reagents could also be effectively used to achieve good chemoselec-
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tivities in that reaction. The reason behind this selectivity is thought to involve a
prior coordination of the zinc or samarium reagent with the hydroxy group or the
corresponding metal alkoxide to direct the addition of methylene to the neighbor-
ing alkene, in fact enhancing the rate of the reaction. Along with steric effects, it has
been the main controlling element for the high stereocontrol in these reactions.
On the other hand, the cyclopropanation of olefins using the transition metal-
catalyzed decomposition of diazoalkanes – case (b) in Scheme 1.15 on the facing
page – is one of the most extensively studied reactions of the organic chemist’s ar-
senal, with inter- and intra-molecular version being developed and studied over
the years.
The most exhaustively studied and employed diazo reagents for intermolecular
cyclopropanation reactions are the α-diazoesters used in presence of a metal cat-
alyst. Usually, Rh, Ru, Co, and Cu metal carbenes react faster with electron-rich
alkenes, whereas Pd metal carbenes are optimal for electron-deficient alkenes. An
example of this methodology is reported in Scheme 1.17 where compound 37 is
cyclopropanated with the aid of ethyl diazoacetate in presence of a palladium cata-
lyst. [43]
OTBS
NHBoc
EtOOC H
NHBoc
OTBS
EtOOC H
NHBoc
OTBS
EtOOC H
NHBoc
OTBS
EtOOC H
NHBoc
OTBS
N2CHCOOEt
Pd(OAc)2
88%
15% 18% 52% 15%
37
SCHEME 1.17: Example of a cyclopropanation reaction of a double bond by
decomposition of diazo-compound in presence of a metal catalyst.
When both functionalities of the diazo unit and the alkenes are in the same
molecule, an intramolecular cyclopropanation is possible with the appropriate cat-
alyst, thus producing bicyclic products. In contrast to the intermolecular reaction,
only one diastereoisomer is obtained when forming five- or six-membered rings.
However, it is important to consider the chemoselectivity, as, in some cases, the
C-H insertion may become the major pathway.
Most of the successful systems involve cyclization of either γ, δ-unsaturated dia-
zocarbonyl or δ, e-unsaturated diazocarbonyl systems, leading to fused [3.1.0] or
[4.1.0] bicyclic systems, as reported in Scheme 1.18 on the following page, where
the diazoketone 38 rearranges to give the aforementioned [4.1.0] structure 39. [44]
The last methods for the generation of the cyclopropane ring are based on the
ring closure initiated by a Michael reaction, exemplified by situations (c) and (d)
in Scheme 1.15 on the preceding page: a conjugate addition to an electrophilic
alkene produces an enolate ion which subsequently undergoes an intramolecular
ring closure – Michael-initiated ring closure (MIRC) reactions. [36] Two eventual-
ities fall under this category: in case (c) the leaving group is present on the nucle-
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SCHEME 1.18: Intramolecular cyclopropanation reaction.
ophile molecule, while in case (d) the formation of cyclopropanes is obtained by
nucleophilic addition to electrophilic substrates containing a leaving group. The
first method was previously shown in Scheme 1.5 on page 6 for the synthesis of
coronamic acid 5, whilst the second method is exemplified particularly by the use
of sulfur ylide reagents.
Usually this type of reactions are nonstereospecific, and both (E)- and (Z)-olefins
give the trans-cyclopropanes. The most outstanding example was reported by Co-
O
Me3S(O)I + NaH
Me2S(O)-CH2
DMSO, 50°C
95%
O
40 41
SCHEME 1.19: MIRC reaction.
rey [45] on the cyclopropanation reaction of (R)-(−)-carvone 40 with methylen di-
methylsulfoxonium in situ generated to provide the desired cyclopropylcarvone 41
in 95% yield, as a single diastereoisomer, which results from the attack of the ylide
on the less hindered face. Its homologue ethyl (dimethyl sulfuranylidene) acetate
(EDSA) has been described by Payne. [46], and reacts with α, β-unsaturated es-
ters, ketones, aldehydes and nitriles to afford cyclopropanated adducts as mixtures
of diastereomers depending on the substrate. This compound and its applications
with MIRC reaction has been studied by several groups in the world, particularly
by Monn et al. at the Eli Lilly research centres. In fact, this compound, in pres-
ence of DBU or of catalytic amounts of TMG reacts with cyclic or acyclic substrates
in cyclopropanation reactions studied for the preparation of bicyclo[3.1.0]hexane-
2-one-6- carboxylic acid ethyl ester. [47, 48] This procedure was further developed
and scaled-up, as reported in [49].
Nitrocyclopropanes are an emerging area of interest as they have been recog-
nised widely as a useful and riveting synthetic target in recent years. Several groups
approached the synthetic problem, developing also an enantioselective version of
this cascade reaction. Bromonitromethane was the chosen reagent: it rapidly un-
dergoes conjugate addition reaction to α, β-unsaturated enone system; subsequent
elimination of the bromine atom would yield the cyclopropylated adduct. [50] An
example is the recently reported nitrocyclopropanation of suitable 2,5-dihydrothio-
phene-3-carbaldehydes 42 by De Risi et al. and shown in Scheme 1.20 on the next
page. [51] These compounds are expected to act as Michael acceptors toward the
anion of bromonitromethane, through an Iminium ion activation with DL-proline in
the presence of basic co-catalysts such as TEA or NaOAc forming 6-nitro-3-thiabi-
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cyclo[3.1.0]hexane-1-carbaldehyde derivatives, possibly through a subsequent in-
tramolecular alkylation cyclization, with diastereoselectivities depending strongly
on the substrate.
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SCHEME 1.20: Approach to the synthesis of 6-nitro-3-thiabicyclo[3.1.0]hexane-
1-carbaldehyde.
1.2.2 Tandem reactions
A “domino” or “tandem” reaction consists of series of a consecutive intramolecular
reaction which allows for the synthesis of usually cyclic compounds in high a fast
and clean way, with high atom economy; finally, a lot of molecular complexity is
generated effectively at once.
The inspiration for this type of reactions is of course taken from Nature: squalene
43 is oxidised and then enzymatically cyclized to give lanosterol 44, a steroid which
can be further elaborated by the organism into other steroidal compounds.
HO HO
43 45 44
SCHEME 1.21: Nature’s tandem reaction for the synthesis of Lanosterol: squa-
lene 43 is enzymatically oxidised to squalene epoxide 45 by squalene monooxy-
genase, and then the enzyme lanosterol synthase complete the cascade reaction
to yield lanosterol 44.
The aforementioned MIRC reaction mentioned in the previous section as a strat-
egy for synthesising cyclopropyl compounds can be considered an example to such
a class of reaction employed in the chemical lab routine. Arai et al. have in fact
studied in the late 1990s the stereoselective cyclopropanation reaction under phase-
transfer-catalyzed conditions of cyclic and acyclic α-haloenones. These compounds
are indeed quite reactive: the conjugated double bond works as suitable Michael
acceptor and the halogen atom as a good leaving group for a subsequent attack on
the α-carbon. There is then an intermolecular Michael addition followed by an in-
tramolecular cyclisation process. All of the above processes are indeed conducted
under phase transfer conditions, using K2CO3 and some quaternary ammonium
salts, or quinidine-derived quaternary ammonium salts for the asymmetric version
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SCHEME 1.22: Arai et al. PTC approach for the synthesis of the cyclopropane
ring via domino reaction.
of the approach.
Malonates, soft carbon nucleophiles, nitromethane with highly acid protons and
cyanoacetates bearing an active methylene and all their derivatives were screened
in the two studies. [52, 53]
Carlson et al. studied and exploited the same reaction in presence of ionic liquid,
1-butyl-3-methylimidazolium hexafluorophosphate ([BMIM]PF6) and were able to
direct the synthesis to dihydrofuran rings as well as bicyclo[3.1.0]hexanones. [54]
On the other side, tandem reactions have long been studied in the group where
part of this thesis work was researched in order to synthesise variously substituted
tetrahydrothiophenes, as it has been mentioned in 1.2 on page 12 and reported
in [34], where a tandem Michael-Henry reaction has been optimised to yield 3,4-
substituted tetrahydrothiphenes.
Starting from the dimer 46 of mercapto-acetaldehyde 47, the nucleophilic sulphur
atom was found able to undergo a Michael addition to the in situ generated ni-
troalkenes 48; these led to formation of intermediate compound 49 bearing an alde-
hyde group which in turn would undergo intramolecular Henry nitroaldol reac-
tion to finally build the thiophene ring 50, as reported in 1.2 on page 12 and shown
more in detail in Scheme 1.23. In a recent publication from the same group, com-
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SCHEME 1.23: Sequence of Michael-Henry tandem reaction for the synthesis of
variously substituted thiophenes.
pound 46 was reacted with α, β-unsaturated ketones in the tandem Michael-aldol
reaction process, resulting in the efficient preparation of monocyclic and bicyclic
3-hydroxythiophanes in good yields and high diastereoselectivity.
Dehydroalanine esters 51 were also considered as counterparts of compound 46
in the tandem sulfa-Michael/aldol reaction process. These compounds have been
used as Michael acceptors for conjugate addition reactions even though they are
typically considered poor electrophiles because of the electron-donating effects of
the lone pair of the nitrogen atom. Nonetheless, amidoacrilates were reacted with
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mercaptoacetaldehyde dimer in presence of potassium carbonate at room tempera-
ture in the same domino process to give the tetrahydrothiophane ring system. [55]
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SCHEME 1.24: Synthesis of variously substituted thiophenes.
1.3 The synthetic target – Project 2
1.3.1 MRI contrasting agents
Magnetic Resonance Imaging is a powerful technique which allows for the visuali-
sation of internal structures of the body in detail by imaging nuclei atoms inside the
body. This technique exploits the magnetic properties of atomic nuclei, in particular
the most abundant one in our bodies: 1H from the water molecule. Different tissues
will have different water concentration, hence the different response to the applied
magnetic field and the different grey gradient in the final picture. More in detail, an
MRI scanner is a device in which the patient lies within a large, powerful magnet
where the magnetic field is used to align the magnetization of some atomic nuclei
in the body, and radio frequency magnetic fields are applied to systematically alter
the alignment of this magnetization. [57] This causes the nuclei to produce a ro-
tating magnetic field detectable by the scanner and this information is recorded to
construct an image of the scanned area of the body. [58] Magnetic field gradients
cause nuclei at different locations to precess at different speeds, which allows spa-
tial information to be recovered using Fourier analysis of the measured signal. By
using gradients in different directions 2D images or 3D volumes can be obtained in
any arbitrary orientation.
MRI provides good contrast between the different soft tissues of the body, which
makes it especially useful in imaging the brain, muscles, the heart, and cancers
compared with other medical imaging techniques such as computed tomography
(CT) or X-rays, but it requires quite long scan times to acquire a proper image.
To enhance the visibility of internal body structures in MRI, different contrast
media can be used, and the most common compounds are gadolinium-based. These
type of agents works by altering the relaxation times of atoms within body tissues
after oral or intravenous administration.
In fact, MRI and NMR – which is the respective technique used routinely in
chemistry – is quite an insensitive technique: for example, it is quite astounding
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the difference in concentration in the preparation of the sample to be submitted to a
normal 1H−NMR experiment against the compound quantity submitted to an MS
analysis. Another example is the time and concentration requested to run a normal
13C−NMR experiment, because, as it is well known, the 13C is the least abundant
of all the isotopes of Carbon.
Several scans are also needed in order to achieve a good to optimal Signal-to-Noise
Ratio – at least 16 for normal 1H-NMR: δ, while thousands for 13C-NMR: δ. Finally,
reaction intermediates are not possible to detect.
FIGURE 1.3.1: Sagittal MRI
scan. [56]
The reason behind all of this is that the signal in-
tensity is related to relative populations of the mag-
netic levels probed during the experiment, a mech-
anism which is called polarization. At thermal equi-
librium the energy levels are close, or in other words
there is little energy needed to promote the transi-
tion from one level to the other one. Moreover, the
Boltzman distribution predicts that almost an equal
number of nuclei will be in the two different energy
levels, even in highest magnetic fields.
An altered distribution of the nuclei population in
the two levels would give raise to an increase in
NMR signal because more nuclei are subjected to
transition. This mechanism is called hyperpolariza-
tion.
1.3.2 para-Hydrogen Induced Polarisation
ParaHydrogen Induced Polarisation is a technique used extensively today to in-
duce polarisation into molecules, and this phenomenon has been exploited for the
generation of PHIP enhanced contrast agents for use in Magnetic Resonance Imag-
ing. [59]
In the H2 molecule the spins of the two hydrogen nuclei posses a spin =
1
2 and
is therefore NMR active, showing a singlet at around 4.55 ppm. In addition, this
two spins can couple to form a triply degenerate and symmetric with respect to
the exchange of nuclei state (orthohydrogen), while the remaining configuration is
antisymmetric with respect to exchange of nuclei and results in a singlet state, the
parahydrogen.
These spin configurations are extremely close together in energy, and therefore all
four are populated essentially equally at room temperature. But p-H2 is the most
stable isomer by quantum mechanics and it dominates at low temperatures. The
change from one isomer to the other is although symmetry forbidden: the spins can-
not simply flip from one state to another even if the thermodynamics are favourable
and suitable to drive the process forward. There is therefore need for a paramag-
netic catalyst like charcoal, Fe2O3 or Fe(OH)3.
When hydrogen reacts and its symmetry is broken in an oxidative addition reac-
tion to a metal centre, novel NMR effects can be seen provided the reaction proceeds
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in a spin correlated manner. Because hydrogen naturally contains approximately
equal numbers of molecules in each of its four spin configurations, the four possi-
ble configurations in the product are also populated approximately equally. Since
the intensity of an NMR signal is proportional to the population difference between
the energy levels, i.e., the number of nuclei capable of undergoing the transition
normally is very low, low intensity signals are detected, as depicted in figure Fig-
ure 1.3.2. On the other hand, if it is possible to use only one of the spin configura-
(A) Standard Boltzmann-derived
distribution of population and
resulting transitions and NMR
signals.
(B) p-H2 -derived distribution
of population and resulting
NMR signal.
FIGURE 1.3.2: Population of the energy levels of ortho- and para-hydrogen.
tions of the molecular hydrogen, the αβ− βα state, after the oxidative addition to
the metal centre only one of the spin states in the product would be selectively pop-
ulated, with a resulting hyperpolarisation. In this case, as it has already been said,
the populations of each energy level are greatly different to the usual Boltzmann
distribution and therefore the NMR signals of the product are greatly increased. It
is easy to see if the enhancement has worked since the resultant signals are now
antiphase, one set in absorption and the other in emission – Figure 1.3.2. Once the
enhancement has been observed by NMR, the sample relaxes back to thermal equi-
librium. As a result, it is often necessary to have the chemical system “refresh” itself
by reaction with more p-H2 throughout the experiment.
There are a few ways to exploit the p-H2 -induced polarisation: the two oldest
techniques are called ALTADENA, Adiabatic Longitudinal Transport After Dissoci-
ation Engenders Nuclear Alignment, and PASADENA, Parahydrogen And Synthe-
sis Allow Dramatically Enhanced Nuclear Alignment, and both requires that the
subjected molecules contain a suitable proton acceptor, be it a double or a triple
bond.
A newer approach to the generation of PHIP sensitised materials is SABRE -
signal amplification by reversible exchange - and is achieved without any chemi-
cal modification of the substrate. [60] [61] In this new approach, developed at the
University of York, UK, in the group of Professor Simon Duckett, there is no chem-
ical modification of the hyperpolarized material; it generate long lived spin states,
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FIGURE 1.3.3: SABRE mechanism for transfer of polarisation from p-H2 to the
substrate. [61]
i.e. longer lifetimes which render this approach suitable to develop an MRI appli-
cation. Finally, the polarization can be transferred to the heteronuclei through a
suitable NMR sequence. The only requirement is that the substrate needs to incor-
porate a pyridyl moiety that can obviously coordinate with the metal centre in the
catalyst. Hence, it seems that the metal centre serves as a template for allowing the
p-H2 and the substrate molecule to get close and participate in the magnetisation
exchange. Most unfortunately, the real mechanism by which the exchange takes
place is still unknown.
1.3.3 Arginine and NOS
Arginine, or 2-Amino-5-guanidinopentanoic acid, is a natural amino acid and one
of the 20 proteinogenic L-amino acids. Thanks to the guanidine end, it is one of the
most basic residues, with a pKa of 12.48.
Arginine is also the substrate for a class of enzymes called Nitric Oxide Syn-
thases (NOS). This class of enzymes accounts for three different isozyme forms that
catalyse the conversion of arginine to citrulline and nitric oxide: the Neuronal NOS,
the Endothelial NOS and the Inducible NOS. NO is produced in neuronal tissues to
be used as an intracellular second messenger for neurotransmission; NO is involved
in the regulation of smooth muscle relaxation and blood pressure in the endothelial
tissue; finally, in macrophage cells, NO is an answer to inflammatory stimuli. The
uncontrolled production of NO has been implicated in numerous disease states,
and it is outstanding the number of inhibitors that have been developed. The ac-
FIGURE 1.3.4: NOS catalytic cycle.
tion mechanism is shown in Figure 1.3.4: the guanidine moiety of the arginine is
oxidized into urea, the arginine becoming cytrulline upon nitric oxide release.
A lot of inhibitors structures are based on L-arginine, and changing motifs and
adding simple modification to the scaffold or capping an amine functionality could
target only one of the different isoforms of the NOS enzyme. [19]
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SCHEME 1.25: Some representative NOS inhibitors.
The classical NOS inhibitors, most significantly NG-nitroarginine (L-NNA, 52)
and NG-methylarginine (L-NMA, 53), are analogues of the NOS substrate, L-argi-
nine, but display low selectivity for inhibition of nNOS versus eNOS; therefore,
Cowart et al. described the synthesis and activity of a series of Nω-2-nitroaryl amino
acid analogues 54, where the R group is methyl or more methyl groups on the aro-
matic ring. A rationale for the preparation of this type of analogues was to create a
molecule combining features of the substrate amino acid arginine with an aromatic
moiety having the possibility of an interaction with one of the known NOS enzyme
cofactors such as flavin adenine dinucleotide (FAD), tetrahydrobiopterin, flavin
adenine mononucleotide (FMN), NADPH, or heme. Nitroarylated amino acids are
readily synthesized by N-alkylation of NR-Boc-protected amino acids with 2-fluoro
nitroaromatics, followed by removal of the protecting group. [62]
Lajoie et al. instead analysed the effect of structural constraints on the arginine
structure. The aim of their study was in fact to probe the active site of the three
NOS isoforms and retrieve informations about the enzyme binding and mecha-
nism, determining the conformational preference of each isoform and evaluating
the impact of the cyclopropyl moiety on isoform selectivity. They then developed
a simple procedure for the preparation of syn- and anti-trans-cyclopropyl arginine
55 and 56. [63, 64]
Finally, the conformational space was further probed by Silverman et al. by de-
signing and synthesising other conformationally-restricted arginine analogues like
57, 58, 59, 60, 61. [19]
1.4 The synthetic target – Project 3
2’,6’-Dimethyl-L-tyrosine 6 is an interesting target from a synthetic and pharmaco-
logical point of view. It is an analogue of the natural amino acid L-tyrosine with two
methyl groups on the phenyl ring in m position with respect to the oxydryl group
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of the parent compound. The presence of these two moieties renders the analogue’s
side chain more constrained as fewer conformations can be populated because of
the steric hindrance deriving from the two methyl groups.
It is well-known that secondary and tertiary structures of a peptide are crucial
for the biological activity, along with its sequence, i.e. the primary structure; and it
is also well established the relationship between the torsional angles φ,ψ and ω of
the amino acid residues and the secondary structure of peptides – helices, sheets,
turns. [65, 66] At the end of the 1990s an interest developed in studying the so-
FIGURE 1.4.1: Definition of the dihedral angles φ,ψ,ω and χ of a peptide. [67]
called χ-space, or the exploration of the possible conformers of the side chain of the
amino acids and how they influence the three-dimensional structure of peptides.
The χ angle, in fact, in conjunction with the backbone angles define the position of
side-chain functional groups in space: it is therefore a piece of great importance to
understand the mode of action of peptides – Figure 1.4.1. [67]
As reported by the Hruby group [68] and shown in Figure 1.4.2, a single residue
FIGURE 1.4.2: Up to 27 (3x3x3) different bioactive conformations are possible
for a single glutamic acid residue, based on the χ angle. [68]
of glutamic acid in a peptide could give rise to up to 27 possible biologically active
side-chain conformations as a result of three χ-angles determining the amino acid
3D structure.
On these bases, χ-constrained α-amino acids were designed alongside Dmt:
β,2’,6’-trimethyl-phenylalanine (β-TMP) 62, β,2’,6’-trimethyl-tyrosine (β-TMT) 63,
2’,6’-dimethylphenylalanine 64. [67, 68] Their incorporation in strategic positions
of peptides, giving raise to local side-chain constraints, has allowed for a reduction
of the corresponding side-chain conformers and for increased selectivity and/or
potency of several target peptides.
The focus of this project is on the development of an alternative synthetic route
to Dmt 6. In the following paragraph a short overview of all the synthetic routes
entertained so far, while in the following section there will space for presenting
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SCHEME 1.26: Some χ-constrained amino acids.
the pharmacological activity of this residue in some important target compounds.
Finally, there will be focus over the parent compound from which the target com-
pound is derived in the new devised plan.
1.4.1 Preceding enantioselective synthesis
Only three enantioselective synthesis of Dmt have been reported so far in the lit-
erature. Beside these, a chemoenzymatic approach have also been reported: the
enzymatic hydrolysis of α-N-acetyl-DL-2’,6’-dimethyltyrosine methyl ester in pres-
ence of α-chimotrypsin by Abrash et al. [69] allowed for the recovery of the single
L-isomer.
The first asymmetric synthesis is reported by Beck et al. [70] in 1992. Start-
ing from 3,5-dimethylphenol 65, iodophenol 66 is obtained and acetylated to pro-
vide a suitable substrate for the Heck coupling with 2-acetamidoacrylate. This last
step was repeated on a kilogram scale with an isolated yield of 85%. The desired
dehydroamino acid 67 was hydrogenated at 60°C under 60 psig of hydrogen in
ethyl acetate as solvent in the presence of 1.0 mole percent [Rh(1,5-COD)-(R,R)-
DIPAMP]BF4 in 12 to 24 hours. Protected-Dmt 68 was obtained under these con-
ditions in 87% yield with an enantiomer ratio of 96:4 (L:D). The reaction rate for
the hydrogenation reaction was expected to be slow because of the sterical conges-
tion of the olefinic bond in the dehydroamino acid. A final hydrolysis with 12 N
hydrochloric acid provided the expected compound in 97% yield with no loss of
optical purity in this final step. The drawback of this synthesis is the quite lengthy
hydrogenation step to be run under high pressure, which renders this route not ap-
proachable from a scale up point of view. Moreover, the the final ee is 92%. In fact,
this procedure was revised and scaled up by Praquin et al. recently, addressing the
aforementioned issues. [71]
A few years later, Soloshonok and Hruby [68, 72] reported the asymmetric syn-
thesis of Dmt via alkylation of a chiral equivalent of a nucleophilic glycine with a
suitable benzyl bromide. The chiral equivalent is based on a Ni(II) complex of the
chiral non-racemic Schiff base of glycine with (S)-o-[N-(N-benzylprolyl)amino]ben-
zophenone ([(S)-BPB]), introduced by Belokon’ et al. [73], compound 69 in Scheme 1.28
on page 27.
The synthesis started from commercially available bromodimethyl phenol 70
whose phenol moiety was protected as benzyl ether. The bromine atom was then
converted to aldehyde and then to benzyl alcohol, which was finally reacted with
PBr3 to give the benzyl bromide 71 – this final reaction is described by the authors
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SCHEME 1.27: Enantioselective synthesis reported by Beck. [70]
as rather difficult, most probably due to the steric hindrance on the benzyl position.
In general, benzyl bromides are more reactive than chlorides, and therefore more
suitable to sustain allylation from complex 69 at room temperature in presence of
KOH or NaOH.
The reaction between Ni(II)-complex 69 and benzyl bromide 71 was conducted at
room temperature in DMF using powdered NaOH as a base. The benzylation oc-
curred with an unexpectedly high reaction rate (5 min), furnishing two products 72
and 73 in a ratio of 8:1 and in 95% chemical yield. These two diastereomers were
separated via column chromatography and decampsed to afford the free amino
acids, with recovery of the chiral ligand 74.
Hydrogenation and hydrolysis of the obtained compounds lead to the obtainment
of both enantiomers of Dmt 6.
This short and rapid synthesis has a broader application [68] and is based on the
simple alkylation reaction of a chiral metal complex which can be easily recycled,
with high enantioselectivities from inexpensive and readily available reagents and
solvents.
Some years later, another short but enantiomerically pure synthesis was pub-
lished by Balducci et al. [74]. The key feature involves a kinetically controlled
reaction between lithium-derived enolates of a diketopiperazine – an asymmetric
glycine-moiety equivalent – and alkyl halides under very mild conditions at -78°C.
Once again the synthesis started from commercially available 65 which was pro-
tected with ethyl chloroformate to be chloroformylated to give benzyl chloride 75,
as already reported in [69]. This last compound was then converted into benzyl
iodide 76 via Finkelstein reaction over 50 hours.
This iodide compound would undergo alkylation from the lithium enolate formed
by diketopiperazine 77 and the lithium base LHMDS to yield compound 78. Upon
reflux with 57% iodidric acid and exchange resin, final Dmt 6 was obtained.
The chiral synthon 77 is easily obtained in two steps as reported in [75]. A promi-
nent feature of the method resides mostly in the stereocontrolled alkylation of the
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SCHEME 1.28: Enantioselective synthesis reported by Soloshonok et al. [72]
aforementioned synthon, which occurs with practically total diastereoselectivity to
furnish the cis-derivative (3S,6S)-78 A further interesting feature of this procedure
is the total conversion of (S)-phenylethylamine to (S)-Dmt: two units of the target
α-amino acid are obtained from one unit of the chiral synthon 77. [74]
1.4.2 Pharmacological activity
2’,6-Dimethyl-L-tyrosine is a widely used amino acids in the synthesis of opioid
peptides and pseudopeptides [76] and it was first introduced in this type of com-
pounds by Hansen et al. [77] The incorporation of this amino acid into simple pep-
tide sequence has lead to important alterations in activities through the elevation
of affinity, modification of receptor selectivity, and change in the spectrum of their
bioactivity profile. Although new analogues are always been sought by chemists
and pharmacologist, the use of Dmt in opioids still remains unsurpassed. [78]
Opioid receptors are a group of G protein-coupled receptors found widely in the
brain, spinal cord and digestive tract. The major types are called δ, κ and µ. With
their ligands they are involved in the path and mechanism of controlling pain with
exceptional efficacy. Efforts to understand and then avoid the causes of opioid-
related side effects such as physical dependence, tolerance, and respiratory depres-
sion, have generated a number of classes of opioid ligands ranging from derivatives
of the endogenous ligands (enkephalins, endorphins, endomorphins, dynorphins)
to frog skin peptides (deltorphins and dermorphins) and the alkaloids (morphine
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SCHEME 1.29: Enantioselective synthesis reported by Balducci et al. [74]
and naloxone). In addition, it has been found that opioid antagonists, originally de-
signed to reverse the adverse effects of opioid analgesics, are being useful in treat-
ments of a number of significant human illnesses like addictions from cocaine and
alcohol and autism. [79] Starting from investigating opioid analogues derived form
frog skin secretions, Salvadori et al. developed synthetic opioid agonists and antag-
onists containing Dmt; in particular, they were able to identify the H-2’,6’-dimethyl-
L-tyrosine-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (H-Dmt-Tic-OH) 79, as
a δ-opioid antagonist pharmacophore for the Dmt-Tic series of peptides. In fact,
incorporation of the Dmt amino acid into H-Tyr-Tic-OH peptide increased the δ-
receptor affinity 8500-fold. Moreover, it has been found that enclosure of Dmt in
place of Tyr at the N-terminus of diverse groups of opioid peptides produced a
broad range of activities, turning the respective peptide into an agonist or antago-
nist at time. [79]
This outstanding characteristics arises from the presence of the hydroxyl group on
the aromatic ring; the steric properties – on which we spent a few words on in the
introductory paragraph of this section – induced by the presence of the methyl moi-
ety in position 2’ and 6’ of the aromatic ring; aromatic ring which gives alignment
and stabilisation through ring stacking or pi − pi interactions between receptor and
ligand; finally, the presence of a N-terminal amine.
HO
H2N
O
N
COOH
79
FIGURE 1.4.3: Dmt-
Tic pharmacophore.
An example of potency of action is found in the
dermorphin-derived tetrapeptide [Dmt1]DALDA (H-Dmt-D-
Arg-Phe-Lys-NH2), where Dmt is incorporated in the first po-
sition of the sequence. This peptide is a highly potent µ opi-
oid agonist, characterised by a 7-fold higher binding affinity
with respect to morphine and a high µ receptor selectivity.
Moreover, pharmacokinetics studies found that the half-life
of this peptide is four times longer than that of morphine, and
recent studies indicates that it is also capable of crossing the
blood-brain barrier. Its analgesic mode of action is thought
to be triple: activation of the target opioid receptor, inhibition of norepinephrine
uptake and release of endogenous opioid peptides. [76]
More recently, Tourwé et al. reported the synthesis and pharmacological studies of a
novel dermorphin tetrapeptide in which Tyr1 has been replaced by Dmt1 because of
its enhancement of the µ and δ receptor interactions and significant increase in opi-
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oid agonist potency. Other modifications at other residues has been made, and this
lead to identification of the ligand H-Dmt-NMe-D-Ala-Aba-Gly-NH2 with mixed
µ/δ opioid agonist properties. This is part of an emerging approach because var-
ious studies proved the existence of physical and functional interactions between
the µ and δ receptors. [80]
1.4.3 Hagemann’s Ester as building block
Hagemann’s ester, or ethyl 2-methyl-4-oxocyclohex-2-enecarboxylate 80, its deriva-
tives and C-1 and C-6 alkylated analogues have long been used as a starting point
for modification and manipulation at their functional moieties in order to easily de-
liver interesting compounds
Its original synthesis has been improved over the years, but there are mainly four
different approaches, shown in Scheme 1.30: the original approach involves the
condensation of two equivalents of ethyl acetoacetate and methylene iodide in the
presence of sodium methoxide and subsequent cyclisation of the resulting diethyl
ester; Knoevenagel used a domino Knoevenagel-Michael-intramolecular aldol re-
action starting from two equivalents of acetoacetate and formaldehyde in the pres-
ence of basis; Newman and Lloyd exploited a Diels-Alder reaction and subsequent
hydrolysis to obtain the final compound; finally, Mannich and fourneau prepared
the ester by the action of sodium ethoxide on acetoacetic ester and a precursor of
methyl vinyl ketone. Hagemann’s ester finds useful application in the synthesis of
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SCHEME 1.30: A. Hagemann’s original approach. B. Knoevenagel’s approach.
C. Newman and Lloyd’s approach. D. Mannich and Fourneau approach. [81]
2-alkyl-3methyl-2-cyclohexen-1-ones 81, resulting from C-3 alkylation with suitable
halide followed by one-pot hydrolysis and decarboxylation. At the same time, it is
a convenient starting material to obtain differently decorated benzoates 82 by aro-
matisation with iodine in methanol at reflux.
On the former theme, an interesting study was published a few years ago on the
selectivity of C-3 versus C-1 alkylation products, and the ratio of the products was
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found to be more dependent on the electrophilic agent rather than on the basic
conditions of the reaction. At the same time, reaction of the title compound with
suitable Michael acceptor were screened and it was found that these conditions
are not selective, giving C-1 and C-3 adducts in almost comparable yields. [82] As
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SCHEME 1.31: Alkylation and aromatisation reaction of Hagemann’s ester . [81,
82]
already mentioned, Hagemann’s ester can be alkylated at different carbon atoms,
mainly C-3 and C-1, but also at C-5; its ester moiety can be removed, preserved or
elaborated; finally, its ring can be opened in order to deliver a more useful carbon
scaffold. [81] In the following paragraphs two selected examples of synthetic utility
of Hagemann’s ester are presented and discussed.
An example of the utility of Hagemann’s ester for the synthesis of natural prod-
ucts can be found in a recent synthesis of (+)-majuscolone 83which features a spiro-
fused six-membered ring at the C-3 position of original Hagemann’s ester . Starting
from trisubstituted 84 derived from previous alkylation with suitable derivative
and decarboxylation of Hagemann’s ester , ketalization with useful chiral auxiliary
allowed for the separation of the two epimers at C-3 – the undesired one is easily
recycled. 85 was easily obtained by intramolecular stereocontrolled insertion re-
action. After ozonolysis and aldol reaction, ring expansion was achieved to give
86. Chemoselective reduction and subsequent removal of the ketal group gave the
keto-alcohol. On this substrate, tertiary alcohol was generated alongside a new
ketone moiety. Final dehydration and allylic oxidation gave the spiro-compound
83. [83]
Hagemann’s ester 80 has been used in the past as a starting point for synthesis-
ing a steroid analog. [84] After ketalisation subsequent reduction and deprotection
of starting 80, derivative 87 is submitted to Michael reaction with dimethylmalonate
to yield 88. This latter is further manipulated to arrive phosphonium salt 89, which
is reacted with the appropriate aldehyde in a Wittig-Schlosser reaction to give the
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trans,trans-trienyne thioketal 90. After two more steps the final tettracycle 91 is ob-
tained from a stereocontrolled acid-promoted polyene cyclisation.
Part IFirst Project: Synthesis ofBicyclo[3.1.0]hexanes Amino Acids

2
Aim
The aim of this project is to develop an alternative and stereoselective route for the
synthesis of compound 7 and to find new ways of synthesising bicyclo[3.1.0]hexanes.
2.1 Studies Towards the Synthesis of Compound LY404039
The original synthesis of compound LY404039 7 has already been shown in Scheme 1.14
on page 13 and originally reported in [18, 27]. This synthesis is not stereoselective:
there is in fact need for a resolution step in order to differentiate and isolate the two
different enantiomers of the compound. Moreover, it is quite lengthy and the first
step is not at all efficient, as the best yield in target compound is 38%.
An alternative retrosynthetic analysis for synthesising the compound can be
found in Scheme 2.1. First disconnection on the cyclopropyl moiety could lead
to dihydrothiophene 92: by the experience matured in the group on synthesis of
this type of compounds, we disconnected further this ring and opened it into dehy-
droalanine 93 and mercaptoacetaldehyde 47. In fact, as shown in 1.2.2 on page 17
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SCHEME 2.1: Retrosynthetic analysis for the synthesis of compound 7.
and reported in [55], it is possible to construct the tetrahydrothiophene ring by a
tandem Michael-Aldol reaction of dithiane 46 – the dimer of 47 – onto a suitable
acceptor like an amino acrylate – structurally related to dehydroalanine 93.
To control the stereoselection and induce asymmetry in the tetrahydrothiophene
ring synthesis, it was thought to use a chiral auxiliary. (−)-Menthol esters had al-
ready found application in controlling the stereochemistry of in the literature in
the copper-promoted 1,4-conjugate addition of phenylmagnesium bromide to chi-
ral 2-acetamidoacrylates to produce N-acetylphenylalanine esters in high chemical
yields and good diastereoselectivity. [85]
2.1.1 Studies toward the Synthesis of Appropriate Amino Acrylate
The first step of the synthesis was then to investigate and tune the synthesis of (−)-
menthyl 2-acetamidoacrylate 94, which could be conveniently obtained through a
known two-step procedure. [86]
This preparation has been tested and standardised for the first time in our labs.
The starting materials are cheap and the obtained acrylate is optically active and
pure, making it a perfect substrate for reaction such as 1,4-conjugate addition. The
overall synthetic process is easy and do not require complex work-up procedures;
most important, it is scalable up to 10 grams of starting materials, with good yields
(41%) and easy work-up.
Esterification of pyruvic acid 95 with (−)-menthol 96 in refluxing benzene would
give ester 97. This intermediate is treated in a one-pot-reaction with acetamide 98
in refluxing benzene to finally yield the target chiral acetamidoacrylate 94.
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SCHEME 2.2: Preparation of the (−)-menthyl N-acetamido acrylate 94.
A series of experiments to study the best conditions for the two reactions, which
have been combineed together in a one-pot procedure, have been conducted.
For what is concerning the first step, several esterification reactions had been con-
ducted: the results are shown in Table 2.1.1. A few acid catalysts have been screened,
and the best ones are sulphuric acid and p-toluensulfonic acid. Acid catalysis by
pyridinium p-toluensulfonate and acidic Dowex resin were not successful attempts
in gaining more reaction yield or an easier work-up.
TABLE 2.1.1: Screening for best conditions to obtain ester 97.
Pyruvic Acid Menthol Other conditions and results
g mmol g mmol eq catalyst solvent ml T (°C) time (h) Y (%)
1 11.36 1.42 9.088 0.8 pTosOH 20 110 o.n. 62
1.5 17 2.12 13.6 0.8 PPTS 30 112 48 22
1.5 17 2.12 13.6 0.8 H2SO4 30 110 16 60
1.5 17 2.12 13.6 0.8 resin 30 110 48 NR
In this step, the formation of the by-product is observed as the reactive ketoester
reacts with itself to form the (−)-menthyl ester of the isotetronic acid; in the sec-
ond step, it is supposed to react with the acetamide to form the amidoester of the
isotetronic acid. Both compounds have been isolated and characterised.
For what is concerning the second step, changing the equivalents of acetamide
or using sulphuric acid as a catalyst is not suitable for the second reaction step, as
it can be seen in Table 2.1.2 on the facing page.
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TABLE 2.1.2: Screening for the best conditions to obtain (−)-menthyl N-
acetamido acrylate 94.
Ester Acetamide Other conditions and results
g mmol g mmol eq catalyst solvent ml T (°C) time (h) Y (%)
1.28 5.66 0.67 11.3 2 pTosOH 30 110 48 24
6.23 27.55 1.63 27.55 1 PPTS 60 112 24 22
3.12 13.8 1.63 27.6 2 H2SO4 60 110 48 42
In Table 2.1.3 on the next page all the different experiments for the one-pot re-
action are reported, alongside with the results and yields. In addition, scale-up
experiments for this synthesis are included, from 1,5 g up to 10 grams.
As it can be seen, catalysis by sulphuric acid was not used for the one-pot reac-
tion because it interferes in second step. Moreover, lower yields are obtained when
toluene is used as solvent or when longer reaction times are employed: this is prob-
ably due to high temperatures causing the reagents and the product to react and
give some other byproducts.
2.1.2 Reaction of the N-Acetamido acrylate of (−)-Menthol with Nu-cleophiles as Michael Acceptor
The double bond of the acrylate is conjugate and thus can undergo addition from a
nucleophile. We studied the reactivity of the double bond and the stereoselectivity
of the addition reaction led by the (-)-Menthol inserted in the molecule in presence
of different types of nucleophiles before turning the attention to the synthesis of the
tetrahydrothiophene ring.
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SCHEME 2.3: Reaction of (−)-menthyl N-acetamido acrylate 94 with Michael
acceptors.
Given the easy outcome of the reaction, reaction of compound 94with nitromethane
has been taken as a model reaction and therefore thoroughly investigated: different
types and kinds of bases have been used.
Only one product 99 is always formed. In Table 2.1.4 on page 39 all the carried out
experiments are reported. As it is also possible to notice, no reaction is reported for
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bases like L-proline or 2-hydroxy pyridine, probably due to the limited basicity of
these compounds and the scarce possible interactions.
TABLE 2.1.4
Base Eq. Y (%) Time
K2CO3/TEA 2 /0,1 86 6 days
TEA 0.1 NR 24 hrs
K2CO3 2 37 6 days
Cs2CO3 2 18 4 days
K3PO4 6 28 6 days
L-Proline 0.1 NR 6 days
2-Pyridone 0.1 NR 6 days
KF 1 11 12 days
Most unfortunately, the chiral HPLC analysis on the resulting compounds showed
that the only formed product is a racemic mixture, the (−)-menthol too far from the
reactive centre and hence not able to control the stereochemistry of the final step of
the Michael addition, where the negative charge is quenched with a proton.
Reaction with nitroethane to give 100 was then investigated: in this reaction
two new stereocenters are formed. As a result, two compounds which are diastere-
omeric are expected and in fact obtained, with different diastereomeric excess as it
is reported in Table 2.1.5. In this case, too, a few bases were assessed on the reaction.
TABLE 2.1.5
Base Eq. Y (%) d.e. (%) Time
K2CO3/TEA 2 /0,1 86 18 6 days
TMG 0.1 NR - 24 hrs
Cs2CO3 2 20.4 13 4 days
The previous studies and experiments conducted on the reactivity of the dou-
ble bond of the acrylate lead us to use the K2CO3/TEA base couple in the ratio
2:0,1 equivalents with respect to the acrylate protocol to generate the nucleophile in
Michael-type reaction.
This was in fact tested in the reaction with Ethyl Acetoacetate to give 101: two prod-
ucts are expected, but only one diastereomer is formed because of the keto-enolic
equilibrium, shown in Scheme 2.3 on page 37.
2.1.3 Synthesis of the Tetrahydrothiophene-compound
In the following Scheme 2.4 on the next page is reported the synthetic pathway for
the synthesis of the target bicyclo[3.1.0]hexane amino acid 7.
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SCHEME 2.4: Envisaged synthetic pathway to achieve formation of compound
102.
The first reaction is the Michael-Aldol tandem reaction previously studied in
our laboratories to form 103. It is the result of further improvements on the proto-
col developed and reported in the previous paragraph 2.1.2 on page 37.
Conditions were although altered: in particular, change of solvent was of great help
in improving the reaction yield. In fact, shift from DCM to DMF greatly improved
solubility of the dimer 46 of mercapto-acetaldehyde 47. Potassium carbonate was
still used as base, but a better phase transfer agent was chosen: tetrabutyl ammo-
nium bromide was indeed more efficient with respect to TEA to transfer the base
between the two phases. These two fact greatly improved reaction yield and time.
Moreover, some diastereoselectivity was observed in this reaction, as we were able
to obtain two different diastereomers in a 3:1 ratio. Most unfortunately, due to the
nature of the compounds, it has not been possible to perform a more in depth chiral
analysis via HPLC in order to discern and separate the diastereomeric mixture.
Compound 103 was then acetylated: in this way the alcohol functionality is pro-
tected from oxidation in the following step, but is also transformed in a good leav-
ing group for the subsequent elimination reaction. The sulphur atom of the acety-
lated compound 104 was oxidised with µ-chloroperbenzoicacid to sulphone 105.
The obtained compound was submitted to elimination reaction to achieve synthe-
sis of the double-bonded adduct 106. This is the final adduct before the construction
of the bicyclo[3.1.0]hexane scaffold and achieve synthesis of compound 102, to be
obtained via a suitable cyclopropanation reaction.
A few trials to obtain the cyclopropanated compound 102 were made with ethyl
diazoacetate and catalysts, but most unfortunately they did not result in isolable
quantities of the target compound.
Another strategy was then probed on the basis of MIRC reaction studies con-
ducted in the same lab and whose results are shown in 2.2 on the next page. A
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SCHEME 2.5: Alternative synthetic pathway to achieve formation of compound
102.
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bromine atom was successfully inserted on the α carbon of compound 106 by ordi-
nary bromination with molecular bromine to obtain bromodihydrothiophene 107.
This latter compound would then react in MIRC reaction with TMG-produced an-
ion of diethyl malonate to give the dicarboxylate compound 108.
Further studies have been conducted on a multicomponent Michael-Aldol-Wittig
tandem reaction, in order to add and generate more diversity in one place at one
time with the reaction of acrylate 109, mercaptoacetaldehyde dimer 46 and phos-
phorane 110. They were all added to the reaction vessel in a one-pot fashion. DCM
was chosen as a solvent even if dithiane has difficulties in being solved in it: in this
way, it reacts under basic conditions to give a Wittig adduct 111 that reacts with
acrylate upon formation in the tandem Michael-Aldol reaction to afford 112.
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SCHEME 2.6: Alternative synthetic pathway to achieve formation of compound
102.
Compound 111 was not isolated because of its high reactivity: it dimerises
rapidly. Screening of addition time for the reaction components lead to consider
a one-pot one-step reaction, or, in other words, the three components were added
altogether in pone place at one time. The choice of DCM as solvent rendered the dis-
solution of dithiane very slow, making it possible to react primarily with phospho-
rane and subsequently undergoing the Michael-Aldol reaction in order to achieve
the desired product 112.
This methodology was applied also on acrylate 94, but it proved less satisfactory.
2.2 Cyclic ketones and MIRC Reactions
2.2.1 Cyclopentenone
In the group where part of this thesis work was done, Michael reaction has been
throughly investigated as a mean for forming new C-C bonds. Efforts have there-
fore been turned towards using 1,4-conjugate addition reaction for synthesising bi-
cyclo[3.1.0]compounds, obviously exploiting and trying to develop a MIRC reac-
tion – see 1.2.1 on page 15.
The investigation started by exploring simple TMG-catalysed Michael addition
to cyclopentenone 113 of some nucleophiles. TEA was not found suitable for the
transformation because of the scarce conversion – isolation of unreacted starting
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material. In addition, the reaction was conducted in neat conditions. The conver-
sion is total with excellent yields in less than an hour’s time. The scope of the
reaction is shown in Scheme 2.7.
A particular mention is the last case, where nitromethane 119 was employed: the
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SCHEME 2.7: Michael-addition reaction of cyclopent-2-enone with different
enolates.
yields were scarce, possibly because of the high reactivity of the compound.
A MIRC reaction with molecular iodine was assessed on compounds 120 and 121,
under the conditions reported by [87]. This iodo-induced cyclization would allow
to achieve the bicyclo[3.1.0]hexanes structures 122 and 123 reported in Scheme 2.8
on the facing page. Most unfortunately this procedure proved unsatisfactory be-
cause of the very low yields. Moreover, decomposition of the starting material 120
was also observed, as it was possible to isolate the dimethyl malonate 115 which
was used in the preparation of the starting material.
Nonetheless, this failure prompted us to explore two different possibilities for
the MIRC reaction: 1. installation of the halogen atom onto the nucleophile and
2. the installation of an halogen atom onto the cyclopent-2-enone ring.
In the first case, reaction with bromonitromethane 124, bromo diethyl malonate
125 or bromoacetato 126 were unsuccessful. Both catalytic and equimolar ratios
of TMG and TEA were used in the reaction, but only the starting material were
recovered after appropriate work-up – Scheme 2.9 on the next page.
After this series of unsatisfying results, attention was then turned toward the
second option, i.e. insertion of the halogen atom onto the cyclopent-2-enone ring.
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SCHEME 2.8: Iodo-induced cyclization reaction.
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SCHEME 2.9: cyclopent-2-enone reaction with halogen-containing nucle-
ophiles.
Synthesis of 2-bromocyclopent-2-enone 127 was achieved following literature pro-
cedure with satisfying yields [88]. It was then reacted in different ways with nucle-
ophiles, i.e. the enolates of nitroacetate 114, of ethyl acetoacetate 116 and of diethyl
malonate 115 – see Scheme 2.10 on the following page. The method developed and
which lead to the synthesis of ethyl bicyclo[3.1.0]hexanonedicarboxylate 123 sees
the employment of equimolar ratios of the starting materials 127 and 115 and of the
base, TMG, in solvent-free conditions; the reaction time is less than an hour.
Most unfortunately, these conditions were successful only for the reaction of 127
with 115. No reaction took place, in fact, when the method was applied with other
different enolates. Outstanding is the reaction of 127 with 114: the expected com-
pound 122 was not produced in all the screened conditions. Neither ethyl acetoac-
etate 116 gave the expected bicyclo[3.1.0]hexanes structure 128. In these last two
cases, the starting materials were recovered.
2.2.2 Cyclohexenone
The Michael addition of suitable nucleophiles methodology which was studied on
the cyclopent-2-enone was then applied to it superior homologue, cyclohexen-1-
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SCHEME 2.10: 2-bromocyclopent-2-enone reaction with nucleophiles.
one 129, as reported in Scheme 2.11. It is possible to notice a few things from the
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SCHEME 2.11: Cyclohexen-1-one reaction with nucleophiles.
reported scheme: a. the reaction conversion is lower with respect to the previous
case, where cyclopentenone was used, as the starting ketone was isolated from re-
action medium; b. reaction time is also higher with respect to the previous case.
In this case too bromocyclopent-2-enone was synthesised and reacted with di-
ethyl malonate in order to synthesise a bicyclo[4.1.0]hexane dicarboxylate structure
in the conditions found suitable from the previous section. Most unfortunately, this
only lead to recovery of the starting materials.
3
Conclusions and Perspectives
3.1 On the synthesis of LY404039
A new synthetic pathway for the synthesis of compound LY404039 7 was devised.
The focal point of the synthesis is the use of a tandem Michael-Aldol reaction
to synthesise the tetrahydrothiophene ring. This is also the key stereochemical pas-
sage, because in just one step two new stereogenic centres are formed. Controlling
the stereochemistry of this passage is therefore central in planning an asymmetric
synthesis.
The envisioned method of using (−)-menthol as a chiral auxiliary inserted as
ester moiety most unfortunately resulted in very poor enantioselectivity, as demon-
strated by the chiral HPLC analysis performed on nitromethane and nitroethane
derivatives 99 and 100.
The reason behind this comes from the reaction mechanism, which can be seen
in Scheme 3.1. In fact, the esterificated menthol is too far away from the reactive
centre to control the stereoselectivity of the reaction: the key step that defines the
stereochemistry is the quenching of the negative charge by a proton – intermediate
130 in Scheme 3.1. Here the negative charge is in no way conditioned to attack the
the proton in a stereoselective way, because the far away methol cannot influence
this attack.
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SCHEME 3.1: Intramolecular cyclopropanation reaction.
Different is the case for the tandem Michael-Aldol reaction for the synthesis of
the tetrahydrothiophene ring, shown in Scheme 3.2 on the following page. For
instance, the quenching of the negative charge formed by Michael reaction and
which found itself “resting” at the branching of the amino acid moieties does not
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SCHEME 3.2: Intramolecular cyclopropanation reaction.
take place. After the first Michael attack by the mercaptoacetaòdehyde, which we
could argue occurs preferably at one side of the molecule because of the steric in-
cumbrance of menthol, the negative charge attacks the electrophilic centre on the
carbonyl moiety of the mercaptoacetaldehyde. In this way the subsequent aldol
reaction takes place, finally forming the tetrahydrothiophene ring. It is therefore
possible that in this case the esterificated (−)-menthol and its bulky presence could
in some way influence the stereochemistry of this second reaction. In fact, it is pos-
sible to separate by chromatographic column two compounds, with the same m/z
ratio and similar 1H-NMR signals, in a 3:1 ratio. Most unfortunately it was not pos-
sible to analyse and separate these compounds on a chiral HPLC column.
Some would argue that determination of the products configuration is futile at this
stage because in the following steps the alcohol is eliminated to yield a double bond.
Anyway, determining the configuration is vital to understand if the chosen chiral
auxiliary can or can not guide and control stereoselection in the reaction. Moreover,
since the double bond is to be cyclopropanated, the same stereoselection would be
expected.
It would be interesting to calculate the conformations and the energies for the
transition states, in order to see if and how the (−)-menthol influences the reaction
space.
A way to improve stereoselectivity in this step could be the employment of chi-
ral quaternary ammonium salts, derived from cinchona alkaloids, as phase transfer
catalysts. The Chiral Phase-Transfer Catalysis has in fact proven reliable and viable
for synthetic applications also on a large and even industrial scale, even in Michael
Reaction cases. [89]
A tandem Michael-Aldol reaction with simple quinine and K2CO3 was indeed tried,
but the resulting yields were not encouraging. This is possibly due to the fact that
the employed compound is not a real transfer agent – i.e. a quaternary ammonium
salt – and therefore its behaviour is like the one shown by the TEA/K2CO3 couple
at the beginning of the investigations on the Michael reaction on the selected com-
pounds, reported in 2.1.2 on page 37.
The other key step in the synthetic pathway is the final cyclopropanation reac-
tion. Decomposition of ethyl diazoacetate with catalysts to give suitable carbene to
react with double bond did not produced the expected cyclopropyl compounds. In-
stead, decomposition of the starting materials was observed. Rh2(OAc)4 and Cu(I)
trifluoromethane sulfonate were found inactive as catalysts, according to literature,
but also active Cu(II) acetylacetonate catalyst was found not reactive towards the
compound’s double bond.
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There is also to consider that, while metallic catalysts are at their best with active
double bonds, the considered double bond is in reality not so active because of the
conjugation with the sulphone moiety. It is possible that Pd-containing catalysts are
more efficient towards these type of bonds.
A trace of target compound was eventually isolated from the MIRC reaction be-
tween the brominated double bonded compound 107 and the diethyl malonate
ester. This is an application of the developed method for the synthesis of bicy-
clo[3.1.0]hexanes compounds with TMG and diethyl malonate, reported in 2.2.1 on
page 41. Most unfortunately, it was not possible to isolate it in reasonable yields to
get a full characterisation.
Finally, the multicomponent reaction resulted quite well by developing a one-
pot one-step Wittig-Michael-Aldol reaction. The slow dissolution of dithiane 46 in
DCM allowed it to react primarily with phosphorane 111. The so formed, very
reactive adduct was allowed to react with acrylate109 in order to give the desired
tetrahydrothiophene. In this way, in just one step more diversity was generated.
3.2 Cycloenones and Michael Reactions
Two cycloenones were chosen as the target for a simple Michael reaction and then
subsequent MIRC reaction was studied.
It is quite outstanding the difference in reaction times between cyclopenten-1-
one and cyclohexen-1-one in the studied Michael reaction conditions – a catalytic
amount of TMG and different enolates. This difference in reactivity is thought to
reside in the ring strain: the five-membered ring is more strained than the six-
membered, also because of the conjugated double bond. After the addition reaction
the double bond becomes a single bond and the strain is reduced.
Cyclohexen-1-one has more freedom of rotation in its ring and therefore is less re-
active.
Asymmetric addition was tried with α-phenylethylamine, but no reaction was
observed. The same result was found when APTC conditions were used, although
an asymmetric version of this MIRC reaction with PTC has been developed and
throughly studied and applied. [52, 53]
It is also quite outstanding that the methodology developed so-far was effective
only on the malonic ester derivative. It is although possible that the exothermicity
of the reaction and the higher reactivity of the other compounds used as nucle-
ophiles required different conditions which was not possible to study given the
short time this methodology has been studied.
The interest in researching how to construct this scaffolds arises from the fact
that these are intermediate in the synthesis of LY544344, as reported in [49] and
shown in Scheme 3.3 on the next page. The dicarboxylate compound 123 can in
fact be decarboxylated by basic hydrolysis followed by acidic treatment to yield
compound 131. This latter can be further manipulated to finally yield the target
compound.
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SCHEME 3.3: Manipulation of the dicarboxylic compound.
4
Experiments
The TLC layers are Macherey-Nagel Poligram SIL G/UV254 0.20 mm; a 1% solu-
tion of KMnO4, 2,4-dinitrophenylhydrazine in acidic solution were used to visu-
alise spots.
Chromatographic purifications were run over silica gel Macherey-Nagel 60M 230-
400 mesh.
1H-NMR and 13C-NMR were registered with Varian spectrometers at 300 MHz and
400 MHz at room temperature. Chemical shifts (δ) are reported with respect to
trimethylsilane in the following manner: chemical shift (multiplicity, coupling con-
stants, integer value). Signal multiplicity are shortened in the following manner:
s for singlet; d for doublet; t for triplet; q for quartet; br for broad signal; m for
multiplet; dd for double doublet.
Mass spectra were recorded on Mass spectra were recorded on Waters Micromass
ZMD 2000, ESI-Q-TOF 6520 Agilent Technologies, Agilent 6520 Q-TOF LC/MS Sys-
tem and LCQ Duo Finningan.
4.1 One pot preparation of (1S,2R,5S)-2-isopropyl-5-methylcyclohexyl2-acetamido-2-propenoate 504.1 One pot preparation of (1S,2R,5S)-2-isopropyl-5-meth-ylcyclohexyl 2-acetamido-2-propenoate
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In a round-bottomed-flask, 1,5 g (17 mmol) of pyruvic acid 95 were dissolved in
30 ml of benzene under vigorous stirring. Next, 0.8 eq. of (−)-Menthol 96 and 0.1
eq of p-toluensulfonic acid mono hydrate as catalyst were added.
The reaction was heated at reflux at about 106°C for at least 24 hours with a Dean-
Stark apparatus. The reaction was followed via TLC EtOAc:Cy 1/4. After depletion
of menthol, the reaction is considered finished and treated as following.
In the same reaction vessel from the previous reaction, 2 eq (with respect to men-
thol) of acetamide 98 were added, together with 0.05 eq (with respect to menthol)
of dihydroquinone. The reaction is stirred at reflux at around 105°C for about 24
hours. The reaction was monitored via TLC EtOAc:Cy 1/4. The final product has
an Rf=0.4.
After the reaction is complete, it is washed with a saturated solution of NaHCO3
3x100 ml, and the two layers are separated. The aqueous layer is extracted with
3x100 ml EtOAc (it is possible that the organic layers combined form a slightly
blurred solution). The combined organic layers are dried over anhydrous Na2SO4
and concentrated under vacuum, obtaining an oily and yellow compound which is
then purified via flash chromatography EtOAc/Cy 1:9 then 2:8.
Compound 94 is finally isolated as a yellow and dense oil. The overall yield for the
whole process is circa 50%.
1H-NMR (400 MHz, CDCl3): δ 7.76 (s, 1H), 6.56 (s, 1H), 5.85 (s, 1H), 4,79 (td, J = 10.9,
4.4, 1H), 2.12 (s, 3H), 2.02-1.97 (m, 1H), 1.83 (td, J = 7.0, 2.68, 1H), 1.73-1.42 (m, 5H),
1.13-1.02 (m, 2H), 0.93-0.85 (t, J =7.0, 8H), 0.77 (d, J = 7.0, 3H).
13C-NMR (100 MHz, CDCl3): δ 168.8, 163.3, 131.2, 108, 47.04, 40.57, 34.09, 31.39,
26.45, 23.55, 21.95, 20.61, 16.45.
4.2 Synthesis of (−)-Menthyl 2-acetamido-4-nitrobutan-oate
O
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94 99
Typical reaction conditions are as following.
The base or the base mixture is added to a round-bottomed-flask filled with 5 ml
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of nitromethane; then the acrylate 94 is included and the reaction is stirred at 25°C.
The reaction is followed by TLC EtOAc/Cy 1:1; upon formation of the product, a
white spot is seen after revelation of the TLC with KMnO4.
The starting material 94 does not disappear entirely during the reaction; mixing the
nitromethane with other solvents such as THF for improving the solubilisation of
the solid base does not result in change of the reaction rate, which is actually quite
slow.
When the reaction is finished, the organic layer is washed with 5 ml HCl 1N, and
the two phases are separated. The organic layer is dried over anhydrous sodium
sulphate and concentrated at reduced pressure. The product 99 is then purified via
flash chromatography EtOAc/Cy 7:3, then 1:1. In table Table 2.1.4 on page 39 all
the screened conditions and yields are reported.
1H-NMR (400 MHz, CDCl3): δ 6.27 (br s, 1H), 4.78-4.70 (m, 1H), 4.65 (ddd, J = 12.5,
8.0, 4.67, 1H), 4.51-4.44 (m, 1H), 4.44-4.37 (m, 1H), 2.67-2.59 (m, 1H), 2.31 (tq, J = 6.95,
6.55, 1H), 2.01 (s, 3H), 2.00-1.92 (m, 1H), 1.79 (ddd, J =10.4, 6.97, 3.45, 1H), 1.72-1.67
(m, 3H), 1.51-1.37 (m, 2H), 1.09-0.96 (m, 2H), 0.92-0.84 (m, 6H), 0,73 (d, 3H).
4.3 Synthesis of (−)-Menthyl 2-acetamido-4-nitropentan-oate
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Typical reaction conditions are as following. The base or the base mixture is
added to a round-bottomed-flask filled with 5 ml of nitromethane; then the acry-
late is included and the reaction is stirred at 25°C. The reaction is followed by TLC
EtOAc/Cy 1:1; upon formation of the products, two white spots can be seen after
revelation of the TLC with KMnO4. The starting material does not disappear en-
tirely during the reaction; mixing the nitromethane with other solvents such as THF
for improving the solubilisation of the solid base does not result in change of the
reaction rate, which is actually quite slow.
When the reaction is finished, the organic layer is washed with 5 ml HCl 1N, and
the two phases are separated. The organic layer is dried over anhydrous sodium
sulphate and concentrated at reduced pressure. The product 100 is then purified
via flash chromatography EtOAc/Cy 7:3, then 1:1. In table Table 2.1.4 on page 39
all the screened conditions and yields are reported.
1H-NMR (400 MHz, CDCl3): δ 8.38 (br dd, 1H), 4.72 (m, 1H), 4.61 (m, 1H), 4.58 (m,
1H), 4.24 (m, 1H), 2.39 (m. 1H), 1.99 (m, 1H), 1.82 (s, 4H), 1.68-1.58 (m, 2H), 1.52 (d,
J=7 3H), 1.50-1.32 (m, 2H), 1.12-0.98 (m, 2H), 0.90 (m, 7H), 0.78-0.75 (d, J = 7, 3H).
4.4 Synthesis of 1-ethyl 6-(−)-Menthyl 5-acetamido-3-acetyl-2-oxohexanedioate 524.4 Synthesis of 1-ethyl 6-(−)-Menthyl 5-acetamido-3-acet-yl-2-oxohexanedioate
O
O
N
H
O O
COOEt
K2CO3/TEA
DCM COO-(-)-MentAcHN
EtOOC O
O
*
* COO-(-)-MentAcHN
EtOOC O
O
*
H
94 101
0,9 mmol of acrylate 94 are reacted with one equivalent of ethyl acetoacetate
in DCM in presence of two equivalents of K2CO3 and 0,1 equivalents of TEA in a
round-bottomed flask for several days.
The reaction is followed via TLC EtOAc/Cy 1:1. The product’s spot – Rf=0,27 – is
white upon revelation with KMnO4, then it becomes yellow.
The reaction is washed with HCl 2N until acid pH; emulsion is formed, and the
solution is filtered over a celite pad. The two phases are then separated and th
organic layer is dried over anhydrous Na2SO4 and concentrated under reduced
pressure, obtaining 0,290 g of crude product. The crude product is purified via flash
chromatography EtOAc/Cy 1:2, then 1:1. The two starting materials, the acrylate
and the ethyl acetoacetate which did not react are recovered; at last, only 40 mg of
purified product 101 are recovered, with an overall yield of 13%.
1H-NMR (400 MHz, CDCl3): δ 8.28 (br s, 1H), 4.55 (m, 1H), 4.11 (br q, 3H), 3.68
(m, 1H), 2.23 (s, 1H), 2.19 (s, 1H), 2.09 (s, 6H), 1.86-1.79 (m, 3H), 1.68-1.49 (m, 2H),
1.48-1.2.29 (m, 2H), 1.25-1.16 (m, 3H), 0.91-0.81 (m, 10H), 0.69 (d, J = 7, 3H).
4.5 Synthesis of (−)-Menthyl 3-acetamido-4-hydroxythio-phene-3-carboxylate
O
O
N
H
O
S
S OH
HO
+
S
OH
AcHN
Ment-(-)-OOCConditions A. or B.
94 46 102
Condition A.
Acrylate 94 [1,38 g; 5,16mmol] is dissolved in DCM. To this solution, 393,1 mg of
1,4-dithiane-2,5-diol 46 [0,5 eq; 2,58 mmol], 1,4 g of K2CO3 [2 eq; 10,32 mmol] and 1
eq TEA are added. After a few minutes, the yellow solutions turns red. The reaction
is left under stirring for four days at r.t. TLC AcOEt/Cy 1:1 monitor shows that a
big part of acrylate did not react. The reaction is so worked-up to recover the start-
ing materials by washing the organic phase with HCL 1N and then NaHCO3 sat.
4.6 Synthesis of (−)-Menthyl 3-acetamido-4-acetoxythiophene-3-carboxylate 53
sol. The crude product is dried over sodium sulphate anhydrous and concentrated
under vacuum. A red solid is finally obtain.
Condition B.
Acrylate 94 [926,4 mg; 3,47mmol] is dissolved in DMF. Then, 263,9 mg of 1,4-dithiane-
2,5-diol 46 [ 0,5 eq; 1,73 mmol], 959mg of K2CO3 [ 2 eq; 6,94 mmol] and 1,119g of
tetrabutylammonium bromide (TBAB) [1 eq; 3,47mmol] are added, and the solu-
tion is stirred at room temperature for 24 hours. After a few minutes, the yellow
solutions turns red. The reaction is monitored via TLC AcOEt/Cy 1:1.
After reaction is complete, i.e. starting material 94 has been consumed, the solu-
tion is filtered to remove the undissolved K2CO3 and TBAB. Diethyl ether is added
and the organic phase is washed with distilled water and then with HCl 1N and
a saturated solution of NaHCO3. The organic solution is finally dried over anhy-
drous sodium sulphate. The crude reaction product is concentrated in vacuo to give
a brown solid which is run over a chromatographic column eluted with EtOAc/Cy
1:1 to afford 600 mg of 103, with a final yield of 62%.
1H-NMR (400 MHz, CDCl3): δ 6,4 (s, 1H); 4,75 (m, 1H); 4,50 (dt; 1H), 3,6 (dd, 1H);
3,1 (dd, 1H), 3,0 (d, 1H); 2,85 (m, 1H), 2,05 (s, 3H), da 1,95 a 0,95 (m, 9H), 0,9 (m,
6H), 0,75 (d, 3H).
M+= 343,9 m/z
4.6 Synthesis of (−)-Menthyl 3-acetamido-4-acetoxythio-phene-3-carboxylate
S
AcHN COO-(-)-Ment
OH S
AcHN COO-(-)-Ment
OAc
Conditions A. or B.
102 103
Condition A.
217 mg of compound 103 [0.63 mmol] are dissolved in circa 5 ml of DCM. At 0°C,
179 µl of acetyl chloride [4 eq; 2,52mmol] and 430 µl of DIPEA [4 eq; 2,52mmol]
are slowly added through a syringe. The reaction is then stirred at r.t. for 24 h and
monitored via TLC EtOAc/Cy 1:1.
Once the reaction is over, DCM is evaporated under reduced pressure and the crude
is redissolved in EtOAc. The organic phase is washed with HCl 1N and a saturated
solution of NaHCO3, dried over anhydrous sodium sulphate and concentrated in
vacuo. The crude product is purified over chromatographic column eluted with
EtOAc/Cy 1,5:1 to afford 37 mg of products, and a final yield of 15%.
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Condition B.
376 mg of compound 103 [1,098 mmol] are dissolved in circa 4 ml of pyridine. At
0°C circa 3 ml of acetic anhydride are added very carefully and very slowly. The
reaction is stirred for 24 h at room temperature and monitored via TLC EtOAc/Cy
2:1. AcOEt is then added, and the organic phase is washed with HCl 1N and a
saturated solution of NaHCO3, dried over anhydrous sodium sulphate and con-
centrated in vacuo.
The crude reaction product 104 is then used in the following step without further
purification.
1H-NMR (400 MHz, CDCl3): δ 6 (d, 1H); 5,6 (m, 1H); 4,75 (m, 1H); 3,6 (dd, 1H); 3,45
(dd, 1H); 3,25 (dd, 1H); 2,9 (m, 1H); 2,1 (s, 3H); 2,05 (s, 3H); 1,99 (m, 1H); 1,90-1,2
(m, 6H); 0,95 (m, 9H).
M+: 385,8 m/z
4.7 Synthesis of (−)-Menthyl -3-acetamido-4-acetoxysul-pholan-3-carboxylate
S
AcHN COO-(-)-Ment
OAc S
AcHN COO-(-)-Ment
OAc
O
O
m-CPBA
103 104
384 mg of compound 104 [0.998 mmol] are dissolved in circa 10 ml of DCM. 559
mg of m-chloro-perbenzoic acid 70% are added. The slightly yellowish solution
becomes blurry with the reaction proceeding. The reaction is stirred for 24 h at
room temperature and monitored via TLC EtOAc/Cy 1:1. The organic phase is
then washed with a saturated solution of NaHCO3 and brine. A white emulsion is
formed and removed with filtration over celite. The organic layer is then dried over
anhydrous sodium sulphate and concentrated under reduced pressure.
258 mg of crude product 105 are obtained. There was no need to further purify the
crude.
1H-NMR (400 MHz, CDCl3): δ 6,4 (d, 1H); 5,7 (m, 1H); 4,8 (m, 1H); 4 (m, 1H); 3,7
(m, 1H); 2,1- 1,8 (m, 7H); 1,2 (m, 9H).
M+ = 417,8 m/z
4.8 Synthesis of (−)-Menthyl -3-acetamido-2,3-disulpho-lan-3-carboxylate
220 mg of compound 105 [0,53 mmol] are dissolved in circa 10 ml of toluene, upon
which 158 µl of DBU [2 eq; 1,06 mmol] are added. The solution reaction is then
stirred at r.t. for 24 h and monitored via TLC AcOEt/Cy 2:1.
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S
AcHN COO-(-)-Ment
OAc
TMP4
S
AcHN COO-(-)-Ment
OAc
O
O
m-CPBA
104105
Once the reaction is deemed completed, toluene is evaporated under reduced pres-
sure, and the crude product is redissolved in EtOAc. The organic phase is washed
with HCl 1N and then with a saturated solution of NaHCO3, dried over anhydrous
sodium sulphate and concentrated in vacuo.
After purification over chromatographic column eluted with EtOAc/Cy 1:1, 58 mg
of compound 106 are obtained with a 31% yield.
1H-NMR (300 MHz, CDl3): δ 6,85 (d, 1H); 6,67 (d, 1H); 6,55 (d, 1H); 4,75 (m, 1H);
3,95 (dd, 1H); 3,5 (dd, 1H); 2,05 (s, 3H); 2,0- 1,2 (m, 7H); 0,95 ( m, 9H).
4.9 Synthesis of N-tert-butoxycarbonyl serine methyl es-ter
COOMeH2N
OH OO
O
O
O COOMeBocHN
OH
+
TEA
DCM
135 136 137
2 g [12,9 mmol] of serine methyl ester chlorohydrate 132 are treated with 4,224
g of Boc2O 133 [1,5 eq; 19,35 mmol] and 1,788 ml of trietilammina [1 eq; 12,9 mmol]
in DCM for 24 h at room temperature.
The reaction is monitored via TLC EtOAc/Cy 2:1. Upon completion, DCM is re-
moved under vacuum and the crude is redissolved in EtOAc, washed with HCl 2N
and then with a saturated solution of NaHCO3. The water phase are extracted with
EtOAc 1x5 ml. The organic phases are combined, dried over anhydrous sodium
sulphate and concentrated in vacuo.
The product is used as it is in following step, without further purification.
1H-NMR (300 MHz, CDCl3): δ 5,5 (s; 1H); 3,97 (dd, 1H); 3,86 (dd, 1H); 3,78 (s, 3H);
1.58 (s; 9H); 1,43 (s, 9H).
4.10 Synthesis of methyl 2-(bis(tert-butoxycarbonyl)ami-no)acrylate
COOMeBocHN
OH
OO
O
O
O
+
DMAP
ACN
COOMeBoc2N
109136137
4.11 Synthesis of methyl3-((di-Boc)amino)-4-(2-ethoxy-2-oxoethyl)tetrahydrothiophene-3-carboxylate 56
To a solution of compound 134 [2,67 g; 12.19mmol] in dry ACN, 147,8 mg of
DMAP [0,1 eq; 1,21 mmol] and 7g of Boc2O 133 [2,5 eq; 30,5 mmol] are added. The
reaction is then stirred at r. t. for 24 h and monitored via TLC Et2O/Cy 1:1. At the
end the reaction solution turns yellowish. The reaction solvent is evaporate under
reduced pressure and the crude is redissolved in Et2O.
The organic phase is washed with 100 ml of KHSO4 1M, then with a saturated solu-
tion of NaHCO3 and 3 x 50 ml of brine. The solution is finally dried over anhydrous
sodium sulphate and concentrated in vacuo.
The product 109 is used as it is, without further purification.
1H-NMR (300 MHz, CDCl3): δ 6,3 (s, 1H); 5,6 (s, 1H); 3,8 (s, 3H); 1,23 (s, 18H).
4.11 Synthesis of methyl 3-((di-Boc)amino)-4-(2-ethoxy-2-oxoethyl)tetrahydrothiophene-3-carboxylate
S
Boc2N
MeOOC COOEtCOOMeBoc2N
S
S
HO
OH
+ Ph3P COOEt TEA
DCM
+
109 46 110 112
In a round-bottomed flask 200 mg [0,66 mmol] of compound 109 are treated with
51 mg [0,5 eq; 0,33 mmol] of compound 46 and 290 mg [1eq; 0,66 mmol] of 110 in
DCM with a few drops of TEA, these last added when the reaction solution turns
clear. The eraction id stirred at r.t. for 24 h and monitored via TLC EtOAc/Cy 1:3.
Once the reaction is over, the organic phase is washed with HCl 1N and then with
a saturated solution of NaHCO3, dried over anhydrous sodium sulphate and con-
centrated under reduced pressure.
The crude compound is purified by chromatographic column eluted with EtOAc/Cy
1:5, then 1:3, to afford 98 mg of product 112 with a 32% yield.
1H-NMR (300 MHz, CDCl3): δ 4,2 (q, 2H); 3,4 (d, 1H); 3,3 (d; 1H); 3,1 (dd, 1H); 2,9
(dd, 1H); 2,7-2,2 (m, 3H); 2,2 (s, 3H); 1,4 (s, 18H); 1,1 (t; 3H).
[M− 202] = 247m/z, where 202 is the weight of the two tert-butoxycarbonyl moi-
eties lost in the mass analysis.
4.12 Synthesis of ethyl 2-nitro-2-(3-oxocyclopentyl)acetate
O
O2N
COOEt
TMG cat.
O
NO2
EtOOC
Y=97%
+
113 114 115
0.2 g [0,244 mmol] of compound 113 and 1 eq [0,27 ml] of ethyl nitroacetate 114
were reacted together in the same reaction vessel without any solvent in the pres-
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ence of 10 µl of TMG. The reaction was stirred for five hours and followed via TLC
EtOAc/Cy 1:1.
Upon completion of the reaction, diethyl ether is added; the organic phase is washed
with a few drops of HCl 2N and then with a few drops of a saturated solution of
NaHCO3. the aqueous phase was extracted with 4 x 5ml Et2O and then 3 x 5 ml
EtOAc. The crude is dried over anhydrous sodium sulphate and concentrated un-
der reduced pressure, affording 0,510 g of compound 120 which is not further puri-
fied. The yield is 97%.
1H-NMR (400 MHz, CDCl3): δ 5.07 (1 H, dd, J 9.3 and 4.0), 4.25-4.34 (2 H, m), 3.09-
3.19 (1 H, m), 2.50-2.60 (1 H, m), 2.04-2.45 (5 H, m), 1.69-1.89 (2 H, m), 1.26-1.35 (3
H, m).
13C-NMR (100 MHz, CDl3): δ 90.60 (CH), 62.71 (CH2), 41.47 (CH2), 37.49 (CH2),
36.82 (CH), 26.20 (CH2), 13.58 (CH3).
4.13 Synthesis of diethyl 2-(3-oxocyclopentyl)malonate
O
EtOOC
EtOOC
TMG cat.
O
COOEt
EtOOC
quant.
+
113 116
117
0.2 g [0,244 mmol] of compound 113 and 1 eq [0,37 ml] of ethyl nitroacetate 115
were reacted together in the same reaction vessel without any solvent in the pres-
ence of 10 µl of TMG. The reaction was stirred for five hours and followed via TLC
EtOAc/Cy 1:1.
Upon completion of the reaction, diethyl ether is added; the organic phase is washed
with a few drops of HCl 2N and then with a few drops of a saturated solution of
NaHCO3. the aqueous phase was extracted with 4 x 5ml Et2O and then 3 x 5 ml
EtOAc. The crude is dried over anhydrous sodium sulphate and concentrated un-
der reduced pressure, affording 0,598 g of compound 121 which is not further puri-
fied. The yield is quantitative.
1H-NMR (400 MHz, CDCl3): δ 4.24-4.16 (m, 4H), 3.32 (d, J = 9.5 Hz, 1H), 2.83 (s, 1H),
2.50 (dd, J = 18.4, 7.5 Hz, 1H), 2.33-2.19 (m, 3H), 2.01 (ddd, J = 18.4, 11.1, 1.4 Hz, 1H),
1.68-1.63 (m, 1H), 1.29-1.24 (m, 6H).
4.14 Synthesis of ethyl 3-oxo-2-(3-oxocyclopentyl)butanoate
0.2 g [0,244 mmol] of compound 113 and 1 eq [0,37 ml] of ethyl acetoacetate 116
were reacted together in the same reaction vessel without any solvent in the pres-
ence of 10 µl of TMG. The reaction was stirred for three hours and followed via TLC
EtOAc/Cy 1:2.
Upon completion of the reaction, diethyl ether is added; the organic phase is washed
4.15 Synthesis of 3-(nitromethyl)cyclopentanone 58
O
EtOOC
TMG cat.
O
EtOOC
quant.
+
O
O
113 118 119
with a few drops of HCl 2N and then with a few drops of a saturated solution of
NaHCO3. the aqueous phase was extracted with 3 x 5ml Et2O and then 3 x 5 ml
EtOAc. The crude is dried over anhydrous sodium sulphate and concentrated un-
der reduced pressure, affording 0,544 g of crude that is purified over chromato-
graphic column eluted with EtOAc/Cy 1:2 to afford 0.433 g of compound 117 as a
mixture of diastereomers. The yield is 84%.
1H-NMR (400 MHz, CDCl3): δ 4.25-4.17 (m, 2H), 3.42 (dd, J = 9.8, 6.4 Hz, 1H), 2.91-
2.82 (m, 1H), 2.50-2.43 (m, 1H), 2.35-2.13 (m, 6H), 1.95 (ddd, J = 18.4, 11.1, 1.4 Hz,
1H), 1.81 (ddd, J = 18.3, 11.0, 1.4 Hz, 1H), 1.65-1.47 (m, 1H), 1.31-1.24 (m, 3H).
13C-NMR (100 MHz, CDCl3): δ 217.077, 217.019, 201.563, 168.295, 64.823, 64.606,
61.697, 42.955, 42.700, 38.163, 38.016, 35.836, 35.744, 29.458, 29.220, 27.615, 27.331,
14.105, 14.069.
4.15 Synthesis of 3-(nitromethyl)cyclopentanone
O
TMG cat.
O
NO2Y=20%
+ CH3NO2
113 120 121
0.2 g [0,244 mmol] of compound 113 and 1 eq [132 µl] of nitromethane 119 were
reacted together in the same reaction vessel without any solvent in the presence of
10 µl of TMG. The reaction was stirred o.n. hours and followed via TLC EtOAc/Cy
1:2.
Upon completion of the reaction, which is turned orange, 2 ml EtOAc is added; the
organic phase is washed with a few drops of HCl 2N and then with a few drops
of a saturated solution of NaHCO3. The aqueous phase was extracted with 2 x 5
ml EtOAc. The crude is dried over anhydrous sodium sulphate and concentrated
under reduced pressure, affording 0,384 g of crude yellow oil that is purified over
chromatographic column eluted with EtOAc/Cy 1:1 to afford 0.072 g of compound
118. The yield is 20%.
1H-NMR (400 MHz, CDCL3): δ missing!!!
4.16 Synthesis of 2-bromocyclopent-2-enone 59
O
Br2 / TEA
CCl4
O
Br
113 127
4.16 Synthesis of 2-bromocyclopent-2-enone
In a round-bottomed flask 1 g of cyclopenten-1-one 113 [12.2 mmol] is dissolved in
100 ml CCl4. After cooling at 0°C the reaction vessel, molecular bromine [1.1 eq,
13.4 mmol, 0,70 ml] in 10 ml of solvent is added dropwise in an hour.
After this, and under much vigorous stirring, TEA [1.5 eq, 2,34 ml] is added drop-
wise in an hour at 0°C. Upon addition, the clear yellowish solution becomes blurry
and then brown. The reaction is left stirring at room temperature for another 2
hours.
The slurry is then filtered over celite, washed twice with 25 ml HCl 2N, once with
25 ml saturated solution of sodium carbonate and finally with 25 ml of brine. The
crude is dried over anhydrous sodium sulphate and concentrated under reduced
pressure, affording 1,727 g of oily compound 127 which solidifies upon standing at
r.t. The final yield is 86%.
1H-NMR (400 MHz, CDCl3): δ 7.78 (t, J = 3.0 Hz, 1H), 2.72-2.68 (m, 2H), 2.55-2.52
(m, 2H).
4.17 Synthesis of diethyl 2-oxobicyclo[3.1.0]hexane-6,6-di-carboxylate
EtOOC
EtOOC
+
O
COOEt
COOEtTMG
O
Br
127 116 123
In a round-bottomed flask 0.2 g of 2-bromocyclopent-2-enone are reacted with 1
eq [0.186 ml] of diethyl malonate 115 with 1 eq [0.15 ml] of TMG in 2 ml of chloro-
form. The reaction is left stirring at 30°C and monitored via TLC EtOAc/Cy 1:2.
Upon completion after a few hours, the reaction is washed with HCl 2N and a
saturated solution of NaHCO3, dried over anhydrous sodium sulphate and con-
centrated under reduced pressure, affording 0,232 g of crude compound which is
purified via chromatographic column eluted with EtOAc/Cy 1:4 to afford 0,206 g
of 123 as a yellow oil. The final Yield is 78%.
1H-NMR (400 MHz, CDCl3): δ 4.23-4.17 (m, 4H), 2.74 (td, J = 5.7, 0.6 Hz, 1H), 2.52
(d, J = 5.8 Hz, 1H), 2.36-2.17 (m, 3H), 1.87-1.78 (m, 1H), 1.30-1.24 (m, 9H).
13C-NMR (100 MHz, CDCl3): δ 209.77, 166.595, 165.603, 62.469, 61.479, 61.464, 40.744,
39.738, 35.014, 33.970, 20.655, 14.017, 13.812.
4.18 Synthesis of ethyl 2-nitro-2-(3-oxocyclohexyl)acetate 604.18 Synthesis of ethyl 2-nitro-2-(3-oxocyclohexyl)acetate
NO2
COOEt
TMG cat., 24h
Y=60%
+
O O
COOEt
NO2 +
O
129129 114 130
0.23 g [0,244 mmol] of compound 129 and 1 eq [0.27 ml] of ethyl nitroacetate
135 were reacted together in the same reaction vessel without any solvent in the
presence of 10 µl of TMG. The reaction was stirred o.n. hours and followed via TLC
EtOAc/Cy 1:2.
Upon completion of the reaction, which is turned orange, 2 ml EtOAc are added;
the organic phase is washed with a few drops of HCl 2N and then with a few drops
of a saturated solution of NaHCO3. The aqueous phase was extracted with 2 x 5
ml EtOAc. The crude is dried over anhydrous sodium sulphate and concentrated
under reduced pressure, affording 0,66 g of crude yellow oil that is purified over
chromatographic column eluted with EtOAc/Cy 1:1 to afford 0.561 g of compound
136 as a diastereomeric mixture. The yield is 57%.
1H-NMR (400 MHz, CDCL3): δ5.03 (dd, J = 18.3, 7.3 Hz, 1H), 4.36-4.26 (m, 2H), 2.86-
2.72 (m, 1H), 2.50-2.40 (m, 3H), 2.37-2.24 (m, 2H), 2.13 (dtt, J = 13.3, 6.6, 3.3 Hz, 1H),
2.06-1.93 (m, 2H), 1.78-1.65 (m, 2H), 1.65-1.50 (m, 1H), 1.34-1.28 (m, 3H).
4.19 Synthesis of diethyl 2-(3-oxocyclohexyl)malonate
EtOOC
EtOOC
TMG cat., 24h
Y=83%
+
O O
COOEt
COOEt
+
O
129129 116 131
0.23 g [0,244 mmol] of compound 113 and 1 eq [0,37 ml] of diethyl malonate
115 were reacted together in the same reaction vessel without any solvent in the
presence of 10 µl of TMG. The reaction was stirred o.n. hours and followed via TLC
EtOAc/Cy 1:2.
Upon completion of the reaction, which becomes brown, 2 ml EtOAc is added; the
organic phase is washed with a few drops of HCl 2N and then with a few drops of a
saturated solution of NaHCO3 and brine. The aqueous phase was extracted with 2 x
5 ml EtOAc. The crude is dried over anhydrous sodium sulphate and concentrated
under reduced pressure, affording 0,65 g of crude yellow oil that is purified over
chromatographic column eluted with EtOAc/Cy 1:3 to afford 0.522 g of compound
137. The yield is 83%.
1H-NMR (400 MHz, CDCl3): δ 4.23-4.16 (m, 4H), 3.28 (d, J = 7.9 Hz, 1H), 2.57-2.48
(m, 1H), 2.46-2.32 (m, 3H), 2.30-2.20 (m, 2H), 2.10-2.00 (m, 2H), 1.95 (dddt, J = 13.0,
5.3, 3.6, 1.8 Hz, 1H), 1.73-1.62 (m, 1H), 1.55-1.45 (m, 1H), 1.29-1.24 (m, 6H).
4.20 Synthesis of ethyl 3-oxo-2-(3-oxocyclohexyl)butanoate 614.20 Synthesis of ethyl 3-oxo-2-(3-oxocyclohexyl)butanoate
EtOOC
TMG cat., 24h
Y=91%
+
O
O O
COOEt
O +
O
129129 118 132
0.23 g [0,244 mmol] of compound 113 and 1 eq [0.31 µl] of ethyl acetoacetate
138 were reacted together in the same reaction vessel without any solvent in the
presence of 10 µl of TMG. The reaction was stirred o.n. hours and followed via TLC
EtOAc/Cy 1:2.
Upon completion of the reaction, which becomes brown, 2 ml EtOAc is added; the
organic phase is washed with a few drops of HCl 2N and then with a few drops of a
saturated solution of NaHCO3 and finally brine. The aqueous phase was extracted
with 2 x 5 ml EtOAc. The crude is dried over anhydrous sodium sulphate and
concentrated under reduced pressure, affording 0,612 g of crude yellow oil that is
purified over chromatographic column eluted with EtOAc/Cy 1:3 and then 1:1 to
afford 0.504 g of compound 139. The yield is 91%.
1H-NMR (400 MHz, CDCL3): δ 4.23-4.15 (m, 2H), 3.37 (dd, J = 8.7, 7.7 Hz, 1H), 2.62-
2.54 (m, 1H), 2.42-2.32 (m, 2H), 2.30-2.19 (m, 4H), 2.14 (dt, J = 13.7, 1.6 Hz, 1H),
2.07-2.00 (m, 1H), 1.92-1.82 (m, 1H), 1.73-1.63 (m, 1H), 1.50-1.37 (m, 1H), 1.29-1.24
(m, 3H).
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Part IISecond Project: Synthesis of l-arginineanalogues as potential MRI contrastagents

5
Aim
The second project is focused on the synthesis of arginine analogues that could be
potential substrate for eNOS enzyme and also could be easily polarised by either
the PHIP or the SABRE techniques reported in the introduction.
The structural modifications devised are based on two different scaffolds: a. an
arginine residue coupled with different picolyl bases and b. an α-methyl arginine
or α-trifluoromethyl arginine structure incorporating a double or triple bond. This
project has been developed in collaboration with the group of Professor Matteo
Zanda at the University of Aberdeen, UK. This project was developed between the
group of Professor Zanda, the group of Professor Michael Frenneaux and doctor
Dana Dawson at the University of Ferrara and the group of Professor Simon B.
Duckett at the University of York.
Part of the project was funded under the program “Bando Rivolto a Giovani Ricer-
catori Non Strutturati dell’Università degli Studi di Ferrara per il Finanziamento di
Progetti di Ricerca e Mobilità Internazionale – Fondi 5x1000 Anno 2009”.
The practical application of this project resides on the fact that peculiar ana-
logues and peptides involved in the catalytic process of the synthesis of the Nitric
Oxide could be detected through Magnetic Resonance Imaging if these compounds
could be source of their NMR signal. In other words, there is interest in developing
arginine analogues that could work as MRI contrasting agents which are target-
specific because they would be located only into the NOS enzymes. This could
result in the MRI technique being turned into a more sensitive and faster technique.
5.1 Arginine coupled with picolyl moieties
The aim of this work is to synthesise arginine analogues which can be hyperpo-
larised through the SABRE technique. A series of analogues will therefore incor-
porate a pyridyl/pycolyl moiety. A biological assay will be performed to test the
affinity with the eNOS enzyme.
This type of compounds are in fact suitable substrates for the transfer of polar-
ization by p-H2 molecules through the SABRE technique.[61] A synthetic route for
these analogues and small dipeptides coupled with an arginine residue has been
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devised: the question for these compounds is whether they could be substrates for
these enzymes and could be polarised with p-H2 .
5.1.1 First Generation
Four analogues 140, 141, 142, 143, were synthesised in good yield exploiting the
Boc-Cbz chemistry. They are shown in scheme Scheme 5.1; they had been submitted
for biological test and their correspondent protected precursors had been polarised
with good results by the group of professor Simon B. Duckett at the Univesrity of
York, UK. As it is possible to notice, these little dipeptides contains a picolyl moiety,
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SCHEME 5.1: Analogues synthesised in 2011.
each one bearing a substituent place in a different position of the moiety, in order
to change their : 144, 145, 146 and 147.
These four analogues were synthesised starting from Boc-Arg(Cbz)-OH 148 us-
ing a standard peptide coupling method with EDC.HCl and Oxyma Pure in DCM
with TEA.
The four deprotected amino acids 140, 141, 142, 143, have been obtained by
treating the protected precursors with a solution of trifluoroacetic acid and trifluo-
romethanesulfonic acid.
The usual deprotection chemistry, involving treatment with TFA to release the Boc-
protected amine and then subsequent hydrogenation with hydrogen on Pd/C in
order to remove the Cbz group, lead to hydrogenation at the pyridine ring and was
therefore discarded. It has also been found that the use of the scavengers thioanisole
and m-cresol was not necessary for the triflic and trifluoroacetic deprotection pro-
tocol, but instead counterproductive as it was almost impossible to fully remove
them from the resulting mixture..
Another deprotection method was tried with trimethylsilyl iodide in acetonitrile: a
total of 7.2 equivalents of deblocking agent were needed in order to achieve com-
plete deprotection of the peptide, and this method was therefore discarded.
After deprotection reaction, most unfortunately, it was not possible to the com-
plete remove TFA and triflic acid from the reaction mixture; nonetheless, the re-
sulting oily and difficult to handle residue was submitted for biological tests and
polarisation studies.
It has been thought of using a cationic exchange resin to exchange the counterions
with the more common chloride anion, but most unfortunately all the deprotected
compounds were lost once put on the resin.
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SCHEME 5.2: Synthetic route to the analogues.
Despite all, the biological tests gave good results, as it is shown in Table 5.1.1 on
the following page, but the polarisation did not work on the submitted compounds.
5.1.2 Polarisation Tests
The samples that were tested using the SABRE technique were compounds 149,
150, 151, 152. The preparation of the NMR tube for the first compound 144 is re-
ported as following: 19 mg of sample were dissolved in 0.6 ml CD3OD with catalyst
[Ir(IMes)(COD)Cl]. The Acquisition parameters were modified to single scan acqui-
sition with receiver gain= 1.
Factors like shaking time, temperature and magnetic field at which the magnetic ex-
change would take place were changed in order to find the best condition to obtain
the best enhancement for each compound. In the end, a shaking time of 8 seconds
at Earth’s magnetic field and 40°C were found to be the best conditions for the ex-
change to occur.
All the tables summarising the performed experiments and the proton NMRs of
the enhanced molecules are reported in the appendix A on page 113. In the follow-
ing Figure 5.1.1 on the following page is reported a superimposition of the aromatic
portion of the 1H-NMR spectra for the most enhanced experiments of all the tested
compounds, where it is possible to make comparisons between the different en-
hanced molecules.
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FIGURE 5.1.1: Expansion of the aromatic region of the 1 H-NMR for the com-
pounds.
5.1.3 Biological Tests
The deprotected compounds 141, 143, 142 and 140 were finally tested with the
eNOS enzyme according to a protocol based on a standard Nitrate-Nitrite colori-
metric assay protocol; the full protocol is reported in the appendix B.1 on page 121.
In the following Table 5.1.1 the results of the tested compounds are reported in
comparison with L-arginine, the substrate of the enzyme. As it is possible to notice,
the synthesised compounds can be considered analogues to the enzyme substrate.
TABLE 5.1.1: Biological tests.
Sample eNOS unit Average O.D. Final Nitrate
Concentration
(µM)
L-arginine 1 0.192 12.93
141 1 0.186 12.43
143 1 0.219 14.95
142 1 0.199 13.42
140 1 0.170 11.28
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5.1.4 Second Generation
A different approach to the synthesis was planned, involving the use of a Boc- and
Pbf-protected arginine 153 as a starting material, using the conventional coupling
method with EDC and Oxyma Pure with TEA in DCM.
In this way, a first synthesis on a mg-scale was attempted to obtain compound
154, as shown in Scheme 5.3.
Compound 154 is interesting in the fact that it is formed by an arginine, substrate
for the eNOS enzyme, coupled with amine 155 bearing a triple bond, which can be
easily hydrogenated with para-hydrogen and a suitable catalyst. The carbon adja-
cent to the triple bond is instead bonded to two methyl groups, making it a quater-
nary carbon: for this reason, its T1 is higher and the the half-life of the enhanced,
polarised 1 H-NMR signal should be extended.
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SCHEME 5.3: Synthetic route to the analogue.
Upon synthesising compound 156 in moderate yield, it was successfully depro-
tected with TFA – proving the new strategy works – to give 154. The compound
was precipitated in diethyl ether and recovered as a white powder. The product
was then freeze-dried and the excess TFA removed at the same time.
Studying more carefully the 1H-NMR spectrum for compound 154, it was found
that other protons signals were present alongside the expected signals for the prod-
uct. Moreover, the MS spectra for the aforementioned deprotected compound didn’t
show any remaining peak for the starting material 156.
It was therefore thought that these signals could be coming from a remaining byprod-
uct encaged in some manner in the mixture deriving from the deprotection with
TFA of 156. Most unfortunately, a complete removal of the remaining byproduct
was not possible with the usual mean of washing and stripping the precipitate with
Et2O.
This byproduct was finally removed using C-18 cartridges.
Finally, a sixth analogue was thought to be of spectroscopic interest: compound
157, shown in Scheme 5.4 on the following page, bearing the pyridyl moiety directly
attached to the amide bond – coupling with 158. There is hope that in this way the
para-hydrogen induced polarisation could spread over the entire dipeptide skele-
ton, and eventually a polarised 13C-NMR for the molecule could be recorded.
In the end, then, the five analogues were re-synthesised starting from Boc-Arg(Pbf)-
OH 153 initially using the standard peptide coupling method with EDC.HCl and
Oxyma Pure in DCM with TEA. Most unfortunately, this protocol was found not
suitable for the new starting material, as moderate yields of protected peptides were
recovered.
The synthetic procedure was therefore changed to the coupling method with
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HATU and TEA in DCM and is reported in the following Scheme 5.5.
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SCHEME 5.5: Synthetic route to the analogues.
All the final compounds 140, 142, 143, 141 and 157 were analysed via HPLC-MS
in order to assess their purity.
5.1.5 Determination of the Molecular Weight: accounting for the amountof TFA counterion
The synthesised molecules contain more than one possible protonation site: it is
therefore our aim to determine the concentration of the TFA in the samples by
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TABLE 5.1.2: Correlation Compounds-Yields.
Compound Yield Deprotected compound
159 97.7% 140
160 76.5% 142
161 88.4% 143
162 82,8% 141
163 40% 157
means of ERETIC-2 experiments in MeOH−d6 or D2O and Elemental Analysis.
In this way, we would be able to finally assess the molecular weight of our com-
pounds, and offer a more reliable estimation of the millimoles in the samples we
are going to submit to biological tests and the NMR polarisation experiments.
It is known that the deprotected compounds are precipitated from diethyl ether
as trifluoroacetic salts. This fact and their structure, altogether with the impossibil-
ity of eluting the free compounds on an ion-exchange resin has lead to think that
these compounds are strongly basic.
The question which arises is then how many protonatoin sites there are on the
synthesised molecules, and therefore how many counter-ions – the trifluoroacetic
anions – there are. This simple and trivial question is nonetheless a very important
one, because only accounting for the actual number of counter-ions is possible to
state the exact molecular weight of the molecule, given the molecular weight of TFA
of 114 g/mol.
The amount of TFA trapped as a counterion may be predicted based on the pKa(s)
of the considered molecule; however, this is not always straightforward with com-
plex structures containing multiple ionizable functional groups. Additionally, the
method of compound isolation and purification plays a role in the final amount of
counterion present.[90]
Two techniques were taken into account to determine the amount of counter-
ions: the Elemental Analysis and the 19F-NMR.
The first technique is widely used and renown and it allows the determination of
the composition of any submitted compound. Also NMR is a primary method for
Quantitation, for the NMR-signal (integral) is directly proportional to the number
of atoms (nuclei) and molecules present in the sample. It is therefore an analytical
technique with which it is possible to analyse mixtures of compounds directly. It is
possible to achieve qNMR in at least two ways: by setting up an ERETIC-2 experi-
ment or by interpolation on a calibration curve.
This last method consists of a calibration curve developed using least square linear
regression, and the NMR integral area is obtained from serial dilutions of stock so-
lution of the reference compound. Analyte test samples are then recorded using the
same experimental parameters and the integral area is compared with the calibra-
tion curve to calculate the concentration. [91]
The ERETIC-2 type of experiment implemented in Bruker’s TOPSpin is basically
quantification via an external reference sample of the same nucleus. If the spectra
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are acquired in a properly quantitative way, it is possible to really determine ab-
solute concentrations by reference to an external standard, to quite high accuracy.
This method is based on the PULCON sequence.
Most unfortunately, EA was conducted only on sample from compounds 157
since it was the only ones which, upon freeze-drying, exhibited a powdery struc-
ture. Moreover, the detector used in the analyser from the Department of Chemistry
at the University of Ferrara is not able to detect and reveal fluorine atoms: there-
fore, the analyses were carried out anyway and the data collected only for C, N, H
and S atoms.
In the following paragraph the determination of the amount of TFA and therefore
the final weight for compound 157 is accounted for.
Determination of the weight of compound N-(pyridin-4-yl)arginine amide
In the following table Table 5.1.3 it is possible to view the data from the Elemental
Analysis of compound 157. The sample was analysed twice.
TABLE 5.1.3: Elemental Analysis results for the elected compound.
Sample name Element %Nitrogen Carbon Hydrogen Sulfur
157-1 17,65 35,54 6,18 5,45
157-2 16,04 32,98 5,97 4,93
As it is possible to notice, elemental sulphur has been unexpectedly found in the
sample. Moreover, it is not in small quantity, nor it was found in the blank: there-
fore, the detection of the element is not a mistake and it belongs in some manner
to the analysed sample. This led to think that the deprotection process was incom-
plete, but, revising the data from the HPLC-MS analyses run on the final, purified
reaction product, this possibility was discarded: only one peak for the deprotected
compound can be observed.
A few simulations of possible structures of the final product were then envisaged
and their elemental analysis calculated with ChemDraw, accounting for a remain-
ing SO2 from the protecting group. It came out that a deprotected 157 with two
trifluoroacetic counterions and an SO2 group attached in some manner to the struc-
ture has a calculated Elemental analysis accounting for the following quantities:
Elemental Analysis: C, 33.28; H, 3.54; F, 21.05; N, 15.52; O, 20.69; S, 5.92. As it is pos-
sible to notice, the calculated formula is quite close to what was found experimen-
tally. The final Chemical Formula of compound would then be C15H19F6N6O7S,
with a molecular weight of 541,40 g/mol.
It was then possible to “infuse” a 10 ppm sample in ACN aliquot of the sample
into an ESI-MS system equipped with linear ion trap MS analyser. The base-peak
was at 126.08 m/z – [M + 2 H]2+ – , and the molecular peak is at 251.12 m/z, ie. the
[M + H]+. The [M + H]+ was then isolated and fragmented: the two major transi-
tions were 251.12 m/z −→ 157.00 m/z and 251.12 m/z −→ 94.92 m/z. Then, m/z
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540.00, the expected molecular weight for the compound under study, was identi-
fied as a tiny peak among the noise and fragmented, giving the following main m/z:
251.08, 256.17, 257.25, 283.25, 284.25, 311.25, 312.25 and 415.17. It is not possible to
see it in great abundance because of the ion pairing effect from TFA. [92] The first
m/z fragment was therefore isolated and fragmented once more, showing the same
fragmentation pattern of 251.12.
This was the final proof we needed to state that the molecular weight of 157 is
really 541.40 g/mol.
With this knowledge, 4.9 mg of the freeze-dried compound were dissolved in 1
ml D2O and a
19F-ERETIC-2-NMR experiment was run. The automatic calculation
gave a concentration of TFA 24.1 mM. Assuming a MW = 541.40 g/mol, then 4.9
mg = 0,009 mmol. This quantity dissolved in 1 ml deuterated water accounts for a
concentration 0,009 M, i.e. 9 mM. Doubling this, that is acknowledging the presence
of two TFA counterions, we obtain 18 mM, which is roughly in the same order of
quantitation.
5.2 α-Methyl- and α-trifluoromethyl arginine
The aim of this part of the second project is to synthesise arginine analogues which
can be hyperpolarised through the PHIP technique, i.e. containing a double or triple
bond to be hydrogenated in the presence of p-H2 . A biological assay will be per-
formed to test the affinity with the eNOS enzyme.
The presence of a methyl or a trifluoromethyl group on the α carbon of the amino
acid is relevant because in this way the T1 of the adjacent protons is raised. More-
over, the presence of a alpha-trifluoromethylic moiety on the α carbon would to
only result in higher T1 time for the adjacent hydrogens, but also the fluorine atom
could be used as a spectroscopic probe in MRI: it is in fact known that 19F is magnet-
ically active and not abundant in our body, hence its incorporation in our studies.
In addition, analogues of the Arginine with a double bond are known and work
effectively on the eNOS enzymes: not so much is known of α-methyl arginine
derivatives. [19] It is therefore one aim of this second project to devise a synthe-
sis for these analogues.
Two double-bonded α-substituted arginine analogues synthetic pathways were
devised, and three triple-bonded α-substituted arginine analogues synthetic path-
ways were envisaged.
The retrosynthetic pathway for a double-bonded α-methyl arginine, or (E)-2-a-
mino-5-guanidino-2-methylpent-3-enoic acid 164 can be seen in Scheme 5.6 on the
next page. Guanidine moiety can be introduced on the double-bonded α-mehyl
ornithine 165 via coupling reaction with protected isothiourea 166. Adduct 165 is
obtained by a Wittig-Horner-Emmons reaction between phosphonate 167 and alde-
hyde 168. This latter is obtained by oxidation of opportunely protected α-methyl
serine, easily obtainable from commercial sources.
The α-trifluoromethyl homologue 169 of the previously described compound
164 can be obtained in a similar way, as shown in Scheme 5.7 on the following page.
Guanidine moiety can be in fact introduced on the double-bonded α-trifluoromehyl
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SCHEME 5.7: Synthetic route to the analogues.
ornithine 170 via coupling reaction with protected isothiourea 166. Adduct 170 is
obtained by a Wittig-Horner-Emmons reaction between phosphonate 167 and alde-
hyde 171. This latter is obtained by oxidation of opportunely protected α-methyl
serine 172, which can be synthesised as reported in [93].
Two different routes were devised for the triple-bonded α-trifluoromethyl argi-
nine 173: route A. is inspired from [94], while route B. has been inspired form a re-
cent work by Zhang et al. [95]. Compound 174 can be in fact obtained by coupling
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SCHEME 5.8: Synthetic route to the analogues.
of imine 175 with adduct 176 formed from propargyl bromide 177 and LHMDS.
For what is concerning the second route, 174 is obtained by dimethyl zinc-mediated
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coupling between 178 and STABASE adduct 179, which is in turn obtained from its
precursors 180 and 181.
In the following paragraphs the synthesis of the aforementioned analogues is
explained.
5.2.1 α-Methyl doublebonded arginine
Commercially available α-methyl serine 182 was protected as methyl ester and Boc-
anhydride to give compound 183. This adduct was then oxidised with Dess-Martin
periodinane to give (R)-methyl 2-((tert-butoxycarbonyl)amino)-2-methyl-3-oxopro-
panoate 168. This was reacted under Wittig-Horner-Emmons conditions with phos-
phonate 167. This latter compound was obtained by refluxing bromoethyl phtalim-
ide 184 in triethylphosphite. Most unfortunately, in the used conditions the Wittig
reaction did not work.
The Wittig adduct would have then undergone deprotection on the phtalimide moi-
ety and subsequent coupling with an opportunely protected thioisourea in order to
put in place the guanidine moiety. Final deprotection of compound 185 would have
lead to compound 164.
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SCHEME 5.9: Synthetic route to the analogues.
5.2.2 α-trifluoromethyl arginine
A first attempt to synthesise 169 started from aza-phosphorane 186, easily obtained
through a Staudinger reaction between azide 187 and triphenyl phosphine. It is
then reacted with ethyl 3,3,3-trifluoro-pyruvate 188 to yield imine 175, which is
treated with methyl-tolylsulfoxide and LDA to give an intermediate which is read-
ily treated under so-called Non-oxidative Pummerer Reaction conditions [93] to
give protected α-trifluoromethyl serine 172. Most unfortunately, Swern oxidation of
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this compound to aldehyde 171 was unsuccessful, and therefore the devised route
to the final compound 169, similar if not equal to the one just described for the α-
methyl aldehyde, was not undertaken, but it is nonetheless shown in Scheme 5.10.
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SCHEME 5.10: Synthetic route to the analogues.
It seemed easier incorporation of a triple bond into the arginine skeleton: at-
tention was therefore turned to method A. reported in a previous publication [94],
where the adduct 176 between propargyl bromide and LHMDS is reacted in situ
with 175 – synthesised as previously shown in Scheme 5.10 – to give an intermedi-
ate that, upon further manipulations, would finally result in 173. This route, shown
in Scheme 5.11, most unfortunately failed to react at the beginning as it was not
possible to isolate a product from the coupling reaction.
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SCHEME 5.11: Synthetic route to the analogues.
Therefore, route B. was undertaken: dimethyl propargyl amine was reacted with
1,2-bis(chlorodimethylsilyl)ethane to give the STABASE adduct 189 as reported in
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the literature. [96] Imine 178 was then prepared according to literature procedure
and coupling in the presence of dimethyl zinc in toluene was tried, but most unfor-
tunately it was not possible to isolate the expected product in reasonable yield. The
plan did not proceed further and was therefore abandoned.
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SCHEME 5.12: Synthetic route to the analogues.
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6
Conclusions and Perspectives
It can be said that from the positive results obtained fro the first generation of
picolyl-coupled arginine analogues on the spectroscopic and biological side, the
results presented here take us a step further toward the goal of responsive high-
sensitivity MR-based methods for the diagnosis of disease.
Most unfortunately, there is still a lot of work to be done in order to achieve a
full understanding and comprehension of the mechanism for the transfer of polari-
sation, but the results are very promising.
Moreover, this is one of the first deployment of such a method on organic molecules
other than normal SABRE substrates, i.e. pyridine. It was also demonstrated that
these compounds are substrates for the target enzyme.
In the following paragraphs the different generations of analogues, the problems
encountered, the possible solutions and perspectives will be analysed.
6.1 On the picolyl-coupled arginines
For what is concerning the first generation of the picolyl-coupled arginine ana-
logues, the protected analogues polarised quite well and it was demonstrated that
they can be considered arginine analogues.
Most unfortunately the complete removal from the reaction mixture of TFA and
triflic acid was not possible for these compounds, although the resulting oily and
difficult to handle residue was submitted anyway for biological tests and polarisa-
tion studies.
Despite all, the biological tests gave good results, as it is shown in Table 5.1.1 on
page 68, but the polarisation did not work on the submitted compounds.
A possible explanation for this might be that the guanidine moiety is interacting
with the catalyst’s metal centre instead of the pyridyl moiety, hence impeding or
altering the transfer of polarisation – which could transferred, in this case, onto the
nitrogen atoms.
A second synthetic generation was then developed: it was interesting to no-
tice how the change of just one protecting group to another one affected the whole
synthetic pathway. Indeed, the previous developed coupling method needed to be
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changed: the standard EDC.HCl and Oxyma Pure in DCM with TEA was changed
to HATU and TEA in DCM. Deprotection and isolation of compound were finally
accomplished in an easy way.
6.2 On the double- and triple bond-containing α-methyl-and α-trifluoromethyl arginines
Synthesis of double- and triple bonded arginine with an α-methyl or α-trifluoromethyl
moiety was not easy if not impossible to achieve.
The Wittig methodology failed, most probably because of elimination reactions
taking place at the phthalimide moiety instead of the proper Wittig reaction for the
construction of the double bond.
Not so much can be said about the reason for the failure of the installation of the
triple bond on the skeleton of the arginine. While some methods need to be more
thoroughly investigated, other gave inexplicable results.
6.3 Perspectives
A common trait for all of the synthesised compounds is the determination of the
molecular weight: in fact, it has been said that it is a central and focal point the de-
termination of such an entity in order to offer a sure amount of the millimoles in the
samples that are going to be submitted to biological tests and the NMR polarisation
experiments.
While for the first analogues’ generation an estimation based on the protonation
sites was made – accounting for four possible protonation site –, for what is con-
cerning the second generation a more precise and accurate method was devised. In
fact, EA and qNMR were employed with good accordance on compound 157.
Elemental Analysis on the remaining compounds and respective ERETIC-2 NMR
experiments are on going for the determination of the MW of the remaining sam-
ples.
Finally, it can be said that with this type of compounds it would be possible to
address problems like sensitivity and functionality in the MRI spectroscopy.
Indeed, with PHIP the sensitivity of the NMR technique can be raised. In addition,
target-oriented development of organic tracers could and should open the door,
in the future, to a possible easy detection, in this case, of heart-stroke and related
diseases by a simple MRI scan with great improvement in the patients’ health. In
other words, another step will be made in the direction of turning the MRI from an
insensitive technique into a functional and rather fast one.
7
Experiments
Commercially available reagents were purchased from Sigma-Aldrich, Fisher, Acros
Organic, Merck and VWR Prolabo. All of these chemicals were the highest grade
and used without further purification.
TLCs were performed on Merck silica gel glass plates (60 F254). Visualisation was
accomplished by irradiation with a UV lamp and/or staining with a ceric ammo-
nium molybdate or KMnO4 solution. Flash chromatography was performed on
Silica gel Si 60 (40-63 µm).
NMR data were recorded on Bruker ADVANCE III for 1H at 400 MHz, for 13C at
100 MHz and for 19F at 376 MHz, or on Varian VNMRS-400 spectrometer. All chem-
ical shifts (δ) are expressed in ppm and coupling constant (J) are given in Hertz. The
following abbreviations are used for spin multiplicity: s = singlet, d = doublet, t =
triplet, q = quartet, dd = doublet-doublet, dt = doublet-triplet, m = multiplet, br =
broad.
LC-MS experiments were perfomed on an Agilent Technologies 1200 Series HPLC
system equipped with a DAD and a 6120 MS detector composed by a ESI ioniza-
tion source and a Single Quadrupole mass selective detector using a Analytical C18
RP column (Phenomenex Luna, C18(2) 250x4.60 mm, 5 µ, 100 ). HPLC purifica-
tions were performed on the Agilent 1200 system using a Semipreparative C18 RP
column (Phenomenex Luna, 250x10.00 mm, 5µ, 100 ).
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7.1.1 Synthesis
The four analogues were synthesised starting from Boc-Arg(Cbz)-OH 148 using a
standard peptide coupling method with EDC.HCl and Oxyma Pure in DCM with
TEA.
A typical procedure can be found in the following lines: The protected amino
acid is dissolved in DCM and then 1.2 equivalents of coupling agent are added
followed by 2 equivalents of TEA, and finally by 1.2 equivalents of Oxyma Pure.
The mixture is lightly yellow and, upon completion of the coupling reaction, be-
comes orange, if not red. The reaction is then worked up by washing it with
3x10 ml KHSO4 1M – this gives raise to an emulsion –, then the organic phase is
washed with 2x20 ml NaHCO3 saturated solution and finally with 2x10 ml of brine.
After drying over sodium sulphate anhydrous, the crude material is purified with
a chromatographic column.
Compound Boc-Arg(Cbz)-N-(pyridin-4-ylmethyl)amide
Compound 149 was obtained in 54% yield.
1H-NMR (400 MHz, CDCl3): δ 9.36-9.27 (m, 2H), 8.36 (d, J = 5.2 Hz, 2H), 7.35-7.13
(m, 10H), 7.10-7.01 (m, 1H), 6.87 (d, J = 5.7 Hz, 2H), 5.82 (d, J = 8.3 Hz, 1H), 5.22-5.15
(m, 3H), 4.98 (d, J = 12.4 Hz, 1H), 4.88-4.85 (m, 1H), 4.29-4.22 (m, 1H), 4.01-3.90 (m,
2H), 3.78-3.70 (m, 1H), 1.75-1.48 (m, 5H), 1.43-1.32 (m, 9H).
Compound Boc-Arg(Cbz)-N-methyl-N-(pyridin-4-ylmethyl)amide
Compound 150 was obtained in 71% yield.
1H-NMR (400 MHz, CDCl3): δ 8.45 (dd, J = 4.4, 1.5 Hz, 2H), 7.35-7.20 (m, 9H), 6.98-
6.97 (m, 1H), 6.94 (dd, J = 5.4, 2.4 Hz, ), 5.23-5.22 (m, 2H), 5.16 (q, J = 5.4 Hz, 2H),
5.04 (t, J = 3.9 Hz, 2H), 4.59-4.48 (m, 2H), 4.25 (d, J = 15.6 Hz, 1H), 3.96-3.90 (m, 1H),
2.85-2.83 (m, 2H), 2.76 (s, 1H), 1.68-1.44 (m, 6H), 1.35-1.33 (m, 6H).
13C-NMR (101 MHz, CDCl3): δ 160.5, 150.0, 136.7, 128.8, 128.38, 128.31, 128.1, 127.9,
122.3, 68.1, 67.0, 50.5, 50.1, 49.2, 44.3, 35.3, 29.9, 28.3, 24.7.
Compound Boc-Arg(Cbz)-N-(1-(pyridin-4-yl)ethyl)amide
Compound 151 was obtained in 88% yield.
1H-NMR (400 MHz, CDCl3): δ 8.35 (dd, J = 18.1, 5.5 Hz, 2H), 7.35-7.14 (m, 9H), 6.96
(dd, J = 7.9, 5.9 Hz, 3H), 5.80 (dd, J = 8.7, 3.0 Hz, 1H), 5.18-5.16 (m, 1H), 5.14-5.11
(m, 2H), 5.03 (dq, J = 23.1, 11.2 Hz, 2H), 4.91-4.81 (m, 2H), 4.20 (s, 1H), 3.95-3.84 (m,
1H), 3.80-3.69 (m, 1H), 1.71-1.47 (m, 4H), 1.33-1.28 (m, 8H), 1.14-1.05 (m, 3H).
13C-NMR (101 MHz, CDCl3): δ 160.5, 149.5, 136.7, 128.8, 128.38, 128.3, 128.1, 127.8,
120.6, 67.08, 53.80, 47.55, 43.65, 28.03, 24.51, 20.60
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Compound (R)-methyl 2-Boc-Arg(Cbz)-2-(pyridin-4-yl)acetate
Compound 152 was obtained in 72% yield.
1H-NMR (400 MHz, CDCl3): δ 9.47-9.25 (m, 3H), 8.46-8.38 (m, 2H), 7.46-7.26 (m,
11H), 6.95-6.92 (m, 2H), 5.29-5.04 (m, 5H), 4.78-4.73 (m, 1H), 4.25-4.18 (m, 1H), 3.91-
3.73 (m, 3H), 3.67-3.63 (m, 3H), 3.00-2.95 (m, 1H), 2.68 (dt, J = 13.2, 8.1 Hz, 1H),
1.77-1.49 (m, 6H), 1.44-1.38 (m, 9H).
13C-NMR (101 MHz, CDCl3): δ 160.5, 150.0, 136.7, 128.8, 128.38, 128.31, 128.1, 127.9,
124.17, 68.31, 67.92, 66.75, 53.86, 51.91, 43.71, 36.68, 29.9, 28.3, 24.7.
7.1.2 Deprotection reaction
A typical procedure is reported as follows.
To a stirring solution of protected compound in 3 ml of trifluoroacetic acid, 6 eq. of
trifluoromethanesulfonic acid are added. the reaction is followed via NMR and MS.
Upon completion, the acidic mixture is evaporated under a nitrogen flux. A few
millilitres of HCl 1 N are added and the aqueous phase is extracted with EtOAc.
The aqueous phase is then concentrated under high-vacuum to yield the final de-
protected amino acid as a clear oil.
Compound (R)-2-Arginine-3-(pyridin-4-yl)propanoic acid
Compound 141 was isolated as a clear oil in the amount of 0.280 g.
1H-NMR (400 MHz, CD3OD): δ 8.61 (d, J = 6.8 Hz, 2H), 7.92 (t, J = 5.7 Hz, 2H), 4.94
(dt, J = 9.1, 4.4 Hz, 1H), 3.83 (dt, J = 5.7, 3.1 Hz, 1H), 3.55-3.50 (m, 1H), 3.30-3.23 (m,
3H), 3.16-3.10 (m, 2H), 1.90-1.54 (m, 6H).
13C-NMR (101 MHz, D2O): δ 172.7, 169.3, 158.7, 156.6, 140.7, 127.7, 117.9, 52.5, 52.2,
40.2, 36.4, 27.9, 23.2.
Compound N-(1-(pyridin-4-yl)ethyl)arginine amide
Compound 143 was isolated as a clear oil in the amount of 0.198 g.
1H-NMR (400 MHz, CD3OD): δ 8.73-8.70 (m, 1H), 8.00-7.97 (m, 1H), 5.14-5.09 (m,
1H), 3.93-3.87 (m, 1H), 3.22 (d, J = 1.6 Hz, 11H), 3.20-3.14 (m, 1H), 1.93-1.55 (m, 5H),
1.51-1.48 (m, 2H).
13C-NMR (101 MHz, D2O): δ 169.14, 163.86, 156.63, 141.20, 124.46, 52.56, 49.7, 40.15,
27.92, 23.70, 19.75.
Compound N-methyl-N-(pyridin-4-ylmethyl)argininamide
Compound 142 was isolated as a clear oil in the amount of 0.114 g.
1H-NMR (400 MHz, CD3OD): δ 8.72-8.70 (m, 2H), 7.89 (d, J = 6.8 Hz, 2H), 4.50 (dd,
J = 7.9, 4.4 Hz, 1H), 3.13 (d, J = 1.7 Hz, 3H), 2.00-1.91 (m, 2H), 1.88-1.79 (m, 2H),
1.71-1.62 (m, 3H).
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Compound N-(pyridin-4-ylmethyl)argininamide
Compound 140 was isolated as a clear oil in the amount of 0.222 g.
1H-NMR (400 MHz, D2O): δ 8.57 (d, J = 6.4 Hz, 2H), 7.81 (d, J = 6.3 Hz, 2H), 4.64-
4.54 (m, 2H), 4.01 (t, J = 6.6 Hz, 1H), 3.10 (t, J = 6.9 Hz, 2H), 1.90-1.79 (m, 2H), 1.54
(quintet, J = 7.7 Hz, 2H).
13C-NMR (101 MHz, D2O): δ 170.1, 159.3, 141.0, 125.1, 52.8, 42.5, 40.2, 27.9, 23.6.
7.2 Second generation picolyl-coupled arginine analogues
7.2.1 Synthesis of the protected derivatives
The protected amino acid 153 is dissolved in DCM and then 1.4 equivalents of cou-
pling agent HATU are added, followed by 2.9 equivalents of TEA, and finally by
1.1 equivalents of the desired pycolyl-amine. The resulting mixture is lightly yel-
low and, upon completion of the coupling reaction, becomes dark orange. The
reaction is then worked up by washing with HCl 1N and a saturated solution of
sodium bicarbonate. After drying over sodium sulphate anhydrous, the mixture is
concentrated in vacuo and the crude material is purified with a chromatographic
column (DCM/MeOH 95:5).
All the reactions were first tried on a 50 mg scale and then scaled up to 0.5 g of
starting material 153.
Compound Boc-Arg(Pbf)-N-(pyridin-4-ylmethyl)amide
Compound 159 was isolated as a yellowish transparent solid in the amount of 0.572
g with a final yield of 97%.
1H-NMR (400 MHz, D2O): δ 8.52-8.50 (m, 2H), 7.24-7.22 (m, 2H), 5.64-5.61 (m, 1H),
4.50-4.36 (m, 2H), 4.36-4.28 (m, 1H), 3.34-3.27 (m, 2H), 2.96 (d, J = 5.1 Hz, 2H), 2.56-
2.55 (m, 3H), 2.48-2.46 (m, 3H), 2.14-2.08 (m, 4H), 1.89-1.83 (m, 1H), 1.71-1.58 (m,
3H), 1.48-1.38 (m, 12H).
Compound Boc-Arg(Pbf)-N-(pyridin-4-yl)amide
Compound 157 was isolated as white solid in the amount of 0.602 g. with a final
yield of 40%.
1H-NMR (400 MHz, D2O): δ 8.43 (d, J = 6.3 Hz, 2H), 7.62 (td, J = 1.7, 0.3 Hz, 2H),
6.30 (d, J = 0.2 Hz, 2H), 5.72-5.70 (m, 1H), 3.32-3.28 (m, 2H), 2.97 (s, 2H), 2.61 (s, 3H),
2.53 (s, 3H), 2.11 (s, 3H), 1.95-1.82 (m, 3H), 1.71-1.64 (m, 3H), 1.47-1.40 (m, 15H).
Compound Boc-Arg(Pbf)-N-(1-(pyridin-4-yl)ethyl)amide
Compound 160 was isolated as a whitish solid, with a final yield of 76.5%.
1H-NMR (400 MHz, CDCl3): δ 8.61-8.57 (m, 2H), 7.15-7.12 (m, 2H), 5.71-5.68 (m,
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1H), 4.70-4.53 (m, 3H), 3.43-3.41 (m, 1H), 3.23-3.19 (m, 1H), 3.02-2.90 (m, 6H), 2.59
(d, J = 7.3 Hz, 3H), 2.53 (s, 3H), 2.10 (s, 3H), 1.75-1.60 (m, 5H), 1.43-1.42 (m, 13H).
Compound (R)-methyl 2-Boc-Arg(Pbf)-2-(pyridin-4-yl)acetate
Compound 162 was isolated as a solid in the amount of 0.552 g and a yield of 83%.
1H-NMR (400 MHz, CDCl3): δ 8.53 (s, 2H), 7.20 (s, 2H), 4.88 (s, 1H), 4.15 (s, 1H),
3.77-3.74 (m, 3H), 3.36 (m, 1H), 3.23 (m, 2H), 3.15 (m, 1H), 2.98 (s, 2H), 2.62 (s, 3H),
2.55 (s, 3H), 2.13 (s, 3H), 1.81 (m, 1H), 1.64 (m, 9H), 1.46 (d, J = 18.1 Hz, 13H).
Compound Boc-Arg(Pbf)-N-(1-(pyridin-4-yl)ethyl)amide
Compound 151 was obtained in 88% yield.
Compound 161 was isolated as a transparent solid in the amount of 0.530 g with a
yield of 88.4%. 1H-NMR (400 MHz, CDCl3): δ 8.49 (dd, J = 11.5, 5.2 Hz, 2H), 7.28 (d,
J = 7.8 Hz, 2H), 5.02-4.96 (m, 1H), 4.26-4.23 (m, 1H), 2.96 (s, 2H), 2.58 (d, J = 12.1 Hz,
3H), 2.51 (s, 3H), 2.10 (s, 3H), 1.81-1.75 (m, 1H), 1.57-1.50 (m, 2H), 1.46-1.44 (m, 8H),
1.42 (d, J = 14.7 Hz, 10H).
Compound Boc-Arg(Pbf)-N-(2-methylbut-3-yn-2-yl)amide
Compound 156was synthesised according to the procedure reported in section 7.1.1
on page 82. It was isolated as a yellowish solid in the amount of 0.344 g with a yield
of 50%. 1H-NMR (400 MHz, CDCl3): δ 4.10-4.05 (m, 2H), 3.49 (s, 1H), 3.22-3.21 (m,
2H), 2.95 (s, 2H), 2.59 (d, J = 5.0 Hz, 3H), 2.53 (s, 3H), 2.33-2.32 (m, 1H), 2.09 (s, 3H),
1.85-1.80 (m, 2H), 1.64-1.61 (m, 8H), 1.48-1.44 (m, 6H), 1.43 (d, J = 9.1 Hz, 9H).
7.2.2 Deprotection Reaction
The protected compounds were then deprotected with neat TFA (2-5 ml). After the
evaporation of the acid under a nitrogen stream, the product was precipitated by
help of a few millilitres of diethyl ether. After stripping several times with diethyl
ether and centrifuging the recovered solid, it was dissolved in water and eluted
through the C-18 cartridge; the water fractions were collected. The collected water
fractions were united and freeze-dried to give the pure product of interest. Under
the freeze-drying conditions the excess of TFA was removed as well.
All the reactions were first tried on a 50 mg scale and then scaled up to 0.5 g of
starting material 153.
All the final compounds 140, 142, 143, 141 and 157 were analysed via HPLC-MS in
order to assess their purity.
Compound N-(pyridin-4-ylmethyl)argininamide
Compound 140 was isolated as a solid in the amount of 0.24 g.
1H-NMR (400 MHz, D2O): δ 8.67 (d, J = 6.6 Hz, 2H), 7.91-7.89 (m, 2H), 4.13-4.10 (m,
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1H), 3.49 (q, J = 7.1 Hz, 1H), 3.20-3.16 (m, 2H), 1.97-1.90 (m, 2H), 1.66-1.58 (m, 2H),
1.10 (dd, J = 8.4, 5.8 Hz, 2H).
Compound N-(pyridin-4-yl)arginineamide
Compound 157 was isolated as a solid in the amount of 0.119 g.
1H-NMR (400 MHz, CDCl3): δ 8.58 (m, 2H), 8.0 (m, 2H), 4.3 (m, 1H), 3.17 (m, 1H),
2.00 (m, 2H), 1.67 (m, 2H).
Compound N-(pyridin-4-ylmethyl)argininamide
Compound 142 was isolated as a clear solid in the amount of 0.289 g.
1H-NMR (400 MHz, D2O): δ 8.77-8.63 (m, 2H), 7.92-7.75 (m, 2H), 5.01-4.88 (m, 1H),
3.52-3.47 (m, 1H), 3.24-3.18 (m, 4H), 3.00 (d, J = 5.0 Hz, 1H), 1.98-1.78 (m, 2H), 1.72-
1.55 (m, 2H).
Compound (R)-2-Arginine-3-(pyridin-4-yl)propanoic acid
Compound 152 was isolated as a solid in the amount of 0.240 g.
1H-NMR (400 MHz, D2O): δ 8.65-8.62 (m, 2H), 7.93-7.89 (m, 2H), 5.01-4.97 (m, 1H),
3.96-3.92 (m, 1H), 3.59-3.47 (m, 2H), 3.35-3.28 (m, 1H), 3.19-3.14 (m, 2H), 1.89-1.83
(m, 2H), 1.66-1.54 (m, 2H), 1.11 (tt, J = 7.1, 0.8 Hz, 1H).
Compound N-(1-(pyridin-4-yl)ethyl)arginine amide
Compound 143 was isolated as a clear oil in the amount of 0.336 g.
1H-NMR (400 MHz, D2O): δ 8.70-8.68 (m, 1H), 7.90-7.85 (m, 1H), 5.10-5.06 (m, 1H),
3.93-3.87 (m, 1H), 3.16 (d, J = 1.6 Hz, 11H), 3.20-3.14 (m, 1H), 1.93-1.55 (m, 5H), 1.51-
1.48 (m, 2H).
Compound N-(2-methylbut-3-yn-2-yl)arginineamide
Compound 154 was isolated as a white solid in the amount of 71.2 mg.
1H-NMR (400 MHz, CD3OD): δ 3.88-3.84 (m, 1H), 3.28-3.22 (m, 2H), 2.74-2.72 (m,
1H), 1.99-1.90 (m, 2H), 1.76-1.67 (m, 2H), 1.66-1.63 (m, 3H), 1.63 (dd, J = 8.6, 0.4 Hz,
2H), 1.46-1.44 (m, 2H).
7.3 Synthesis of (R)-methyl 2-amino-3-hydroxy-2-methyl-propanoate
HOOC NH2 OH
SOCl2
MeOH, 0°C -> r.t.
Y = 95%
MeOOC NH2 OH
182 190
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In a round-bottomed flask, 0.64 ml [2.1 eq.] of thionyl chloride were added
to a cooled solution of 15 ml of MeOH under stirring. After this, 0.5 g of start-
ing material 182 were added. The readtioin is allowed to stir and monitored via
TLC DCM/MeOH 4:1 for two days, and additional 2.1 eq. of thionyl chloride were
added.
After evaporation of the solvent under reduced pressure, 0.734 g of crude com-
pound 190 were obtained and used as is in the following reaction.
1H-NMR (400 MHz, CDCl3): δ 8.45 (d, J = 10.0 Hz, 2H), 4.00 (d, J = 12.2 Hz, 1H), 3.93
(d, J = 12.1 Hz, 1H), 3.80 (s, 2H), 3.42-3.42 (m, 3H), 1.61 (d, J = 6.0 Hz, 2H).
7.4 Synthesis of (R)-methyl 2-((tert-butoxycarbonyl)ami-no)-3-hydroxy-2-methylpropanoate
MeOOC NH2 OH
(Boc)2O,TEA 
DCM
Y = 43%
MeOOC NH OH
Boc
183190
In a round-bottomed flask, crude 190 was dissolved in DCM; 0.76 ml [1 eq] of
TEA were then added, followed by 1.19 g [1 eq.] of Boc anhydride. The reaction
was left stirring at r.t. for 24 h, then additional 0.5 eq. of TEA and 0.5 eq. of Boc
anhydride were added. The reaction was followed via TLC DCM/meOH 4:1. The
reaction is then refused o.n.
It was then worked-up by washing with HCl until acidic pH, then washed with
a few portions of a saturated solution of sodium bicarbonate. The aqueous phase
was extracted with EtOAc, dried over anhydrous sodium sulfate and concentrated
in vacuo, obtaining 0.95 g of crude product. This latter was purified with a chro-
matographic column eluted with DCM/MeOH 4:1, affording 0.544 g of product
with a yield of 43%.
1H-NMR (400 MHz, CDCl3): δ 6.70 (s, 1H), 4.89 (t, J = 6.2 Hz, 1H), 3.55 (d, J = 8.3 Hz,
3H), 3.48 (tt, J = 10.5, 5.2 Hz, 2H), 1.30 (d, J = 39.1 Hz, 11H).
7.5 Synthesis of (R)-methyl 2-((tert-butoxycarbonyl)ami-no)-2-methyl-3-oxopropanoate
MeOOC NH OH
Boc 1. DMP
2. DCM water sat., MTBE
3. Na2S2O3 in NaHCO3 sat.
MeOOC NH
O
Boc
168183
In a round-bottomed flask 0.291 starting material 183 was dissolved in DCM wet
and 1.06 g [2 eq.] of DMP were added under stirring at r.t. The reaction becomes
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opalescent and is followed via TLC EtOAc/Cy 1:1. After six hours from an addi-
tional 1 eq. of DMP were added, MTBE and a saturated solution of NaHCO3 and
Na2S2O3 were added under stirring.
The two phases are separated. The aqueous phase is extracted with 2 x 20 ml DCM.
The collected organic phases are washed with 50 ml of NaHCO3 saturated solution;
2 x 50 ml of distilled water and 2 x 50 ml of brine – inversion of phase can be noticed
at this point.
After drying over anhydrous sodium sulfate and concentration in vacuo, obtaining
0.225 g of crude product purification over chromatographic column eluted with
EtOAc/Hex 3:7 is accomplished, affording 0.158 g of product with a yield of 60%.
1H-NMR (400 MHz, CDCl3): δ 9.56 (s, 1H), 3.80-3.79 (m, 3H), 1.63-1.60 (m, 3H), 1.41
(s, 9H).
13C-NMR (101 MHz, CDCl3): δ 193.8, 169.3, 53.3, 28.2, 19.2.
7.6 Synthesis of diethyl (2-(1,3-dioxoisoindolin-2-yl)ethyl)-phosphonate
N
O
O
Br
N
O
O
P
O
OO
P(OEt)3
rflx, 12h
184 167
In a round-bottomed flask, to a solution of 6.74 ml [5 eq.] of triethyl phosphite
phthalimide 184 was added. The resulting mixture id refluxed for 12 h. The excess
triethylphosphite was removed under vacuum distillation.
After addition of EtOH and further stripping, 2.85 g of oily 167 were recovered and
used as is.
1H-NMR (400 MHz, CDCl3): δ 7.80-7.77 (m, 2H), 7.67-7.64 (m, 2H), 4.10-3.99 (m,
5H), 3.93-3.86 (m, 2H), 2.19-2.11 (m, 2H), 1.27-1.21 (m, 7H).
7.7 Synthesis of (Benzyloxycarbonyl)amino triphenylphos-phorane
Si N3 Cl O
O
N3 O
O
Ph3P
N
O
O+ Pyrbenzene
rflx, 30'
PPh3
0°C -> r.t.
Y = 50%
191 192 187187186
To a solution of 1.0g trimethylsilylazide 191 [8.7 mmol] and 0.48 mL benzyl chlo-
roformate 192 [6.2 mmol] in 10 ml of dry benzene under nitrogen atmosphere, were
added three drops of pyridine, and the solution was heated for 30 min. at reflux
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temperature, then diluted with further 10 ml of benzene and cooled to 0°C. This
solution, containing intermediate 187, was slowly added to a solution of 1.6 g of
triphenyl phosphine [1 eq.] in 15 ml of benzene at 0°C. When nitrogen evolution
ceased, the mixture was stirred for 30 min. at rt., then the solvent was removed
under reduced pressure. Crystallisation of the residue from AcOEt afforded the re-
quired iminophosphorane 186 as white crystals (2.5g, 98%).
1H-NMR (400 MHz, CDCl3): δ 5.05 (s, 2H).
7.8 Synthesis of Sulfinylamine
F3C
O
O
O
F3C COOEt
NCbz S
O
Tol
SO CF3
COOEt
HN Cbz
+
THF
+
LDA
THF
Y = 75%
Ph3P
N Cbz
186 188 175
193 194
Under an inert atmosphere, to a solution of 0.5 g of 186 in dry THF, 0.17 ml [1.05
eq.] of trifluoroethyl pyruvate 188 were added. The reaction was stirred at r.t. and
monitored via TLC EtOAc/Hex 1:1.
After this reaction is complete, it is added via cannula to a cooled (-78°C) solution
of 0.19 g [1 eq.] of methyl tolyl sulfoxide 193 in the presence of 0.66 ml [1.1 eq.] of
LDA.
After 20 minutes, reaction is then quenched with a saturated solution of NH4Cl.
The crude amount of 1.05 g is purified over a chromatographic column, affording
0.420 g of a diastreomeric mixture of the desired product 194, and a yield of 65%
1H-NMR (400 MHz, CDCl3): δ 7.44 (d, J = 8.1 Hz, 2H), 7.34-7.25 (m, 7H), 6.53 (s, 1H),
5.09 (dt, J = 18.4, 9.0 Hz, 2H), 4.35 (qd, J = 7.2, 4.3 Hz, 2H), 4.12 (d, J = 13.0 Hz, 1H),
3.50 (d, J = 13.0 Hz, 1H), 2.35 (s, 3H), 1.31 (t, J = 7.1 Hz, 3H).
7.9 Synthesis of α-trifluoromethyl serine
CF3
COOEt
HN Cbz
HO
Tol
SO CF3
COOEt
HN Cbz
N
TFAA, ACN1.
2. NaBH4, H2O
Y = 56%
194 172
To a cooled (0 °C) and stirred solution of 0.187 g of 194 [0.435 mmol] in 4 ml of
acetonitrile, under nitrogen, was added 0.170 ml of sym-collidine [3 eq.], followed
by 0.30 ml of trifluoroacetic acid [5 eq.]. After 2 min at room temperature, TLC
analysis EtOAc/Hex 3:7 showed the disappearance of the starting material. To the
reaction mixture, cooled longer at 0 °C, was added one drop of water, and portion-
wise one drop of water was added at 0 °C, followed by an excess of NaBH4 [about 3
eq.]. After 2 min, the reaction was warmed at r.t. and stirred for 1.5 h. The mixture
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was quenched, at 0 °C with a saturated aqueous solution of NH4Cl and extracted
with 3 x 5 ml EtOAc. The collected organic layers were washed twice with a 1 N
HCl solution to remove sym- collidine and then with aqueous NaHCO3. After rou-
tine workup, the crude was purified by FC EtOAc/Hex 3:7 affording 93 mg of 172
with a 60% yield.
1H-NMR (400 MHz, CDCl3): δ 7.32-7.25 (m, 4H), 5.89 (s, 1H), 5.08-5.04 (m, 2H), 4.55-
4.52 (m, 1H), 4.26 (dq, J = 13.7, 6.6 Hz, 2H), 4.14 (d, J = 12.1 Hz, 1H), 4.04 (qd, J = 7.2,
1.0 Hz, 1H), 1.26-1.22 (m, 3H).
Part IIIThird Project: Studies toward theSynthesis of 2’,6’-dimethyl-l-tyrosine
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Aim
The aim of this third and last project is to find a new synthetic pathway to 2’,6’-
dimethyl-L-tyrosine, a potent and well-known substitute for L-tyrosine in opioid
peptides.
OH
H3C CH3
COOH
NH2
O
COOEt
+
COOH
NH2
6 195 196
SCHEME 8.1: Disconnection for the synthetic plan for Dmt.
As it is shown in Scheme 8.1, disconnection of the amino acidic residue on C1 of
the phenyl ring of Dmt 6 leads to a 4-hydroxy-2,6-dimethylphenyl residue whose
skeleton resembles the Hagemann’s ester ’s derivative 196. This residue would then
be coupled with a surrogate of the amino acid moiety 195.
In this way, three different routes were designed to achieve the final product 6, all
of them starting from compound 196, which is easily obtained by tandem Michael
addition-aldol condensation reaction of two equivalents of acetoacetate 197 with
acetaldehyde 198 in good yield. [97] This method is an improvement of the orig-
inal Knoevenagel approach, and Chong et al. report that the annulation reaction
proceeds smoothly using potassium tert-butoxide in tert-butanol at refluxing tem-
perature, as shown in Scheme 8.2.
O
OEt
O
O2 +
tBuOK/tBuOH
rflx, 48h
O
COOEt
118 198 195
SCHEME 8.2: Synthesis of Hagemann’s ester ’s derivative 196. [97]
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The three different investigated routes for the synthesis of 6 are shown in the fol-
lowing Scheme 8.3. First of all, suitable Michael addition of acrolein 199, tert-butyl
OH
H3C CH3
COOH
NH2
H3C CH3
O
COOEt
+
O
O
OtBu
I
H3C CH3
O
NO2
COOEt
O
H3C CH3
H3C
I
N
N
O O
O
H3C CH3
H3C
OH
+
+
A.
B.
C.
6 195
199
200
201
202 203
77
87 114
SCHEME 8.3: Synthetic routes for Dmt.
acrylate 200 and iodoethane 201 on Hagemann’s ester ’s C1 position was envisaged
– route A. This C1 alkylation would have led to compounds whose alkyl chain
could have been manipulated and turned into the amino acid moiety. After alky-
lation, aromatisation reaction of the obtained product would have been required in
order to build the Dmt skeleton.
On the other hand, Dmt can be obtained by alkylation of benzyl iodide 202 with
diketopiperazine 77; the former can be afforded by opportune transformation of
benzyl alcohol 203, which in turn is derived from Hagemann’s ester as a starting
material – route B. This route can be considered an evolution or improvement of
what has been previously reported in [74].
Finally, aromatisation of the Michael adduct between the Hagemann’s ester -derived
dienone 87 and nitroacetate 114 can yield racemic Dmt – route C. As it is possible
to notice, Hagemann’s ester is very versatile and quite a useful compound!
8.1 Route A. 958.1 Route A.
For what is concerning investigations on the first route, Hagemann’s ester 196 was
reacted in the presence of TMG or Yb(OTf)3 in different solvents with the afore-
mentioned electrophiles 199, 200 and 201: as previously reported in the literature,
these approach was not satisfying because of the presence of compounds alkylated
in other positions.
An alternative was then alkylation with tert-butyl acrylate 200 of compound 204 in
the presence of LDA, where the former was obtained from O-pivaloyl protected Ha-
gemann’s ester : unfortunately also this last reaction did not result in the expected
alkylated product, as it is possible to see in the following Scheme 8.4.
O
COOEt COOEt
OCOtBu
Cl
O
DIMAP LDA
COOEt
OCOtBu
O
O
COOtBu
195 204
SCHEME 8.4: Synthesis of Hagemann’s ester ’s derivatives.
In the mean time, attempts at aromatisation of the ester was attempted. The
whole process started with elimination of the ester moiety by basic hydrolysis fol-
lowed by decarboxylation in acidic medium. Promising results were achieved in
the presence of Ba(OH)2, while also KOH in ethanol gave good results; decompo-
sition of the starting material was observed under the Krapko conditions.
Unfortunately, aromatisation of compound 205 with Pd/C in ethylene glycol in or-
der to study the feasibility of the procedure to arrive to the 3,5-dimethylphenol 206
was unsuccessful.
O
COOEt
KOH/EtOH
O
or Ba(OH)2/EtOH
Pd/C
Ethylene glycole, rflx
OH
195 205 206
SCHEME 8.5: Studies towards aromatisation.
The failure of all the experiments for the envisaged route A., the synthetic ap-
proach was changed in favour of route B.
8.2 Route B.
Route B. sees the inversion of the synthetic “logic” shown in path A.: in fact, aro-
matisation reaction in this case occurs as the first step. Following Kotnis findings,
Hagemann’s ester was aromatised in refluxing methanol in the presence of molec-
ular iodine. [98] A mechanism is not certain for this transformation, nor it has been
8.2 Route B. 96
proposed, but most likely oxidation of the ring occurs by mean of one molecule of
iodine. At the same time, oxidation produces hydrogen iodide in situ which proto-
nates the methanol: this latter can act as electrophile or form iodomethane, finally
leading to p-methoxybenzoate 207. Finally, the benzoate was reduced to benzylic
alcohol 203 easily in the presence of LiAlH4 – Scheme 8.6.
O
COOEt
I2
MeOH
Y = 66%
O
COOEt
LiAlH4
O
OH
Et2O
Y = 54%
195 207 203
SCHEME 8.6: Studies towards aromatisation.
At this point, investigations began on how it could be possible to transform the
benzylic alcohol into a better leaving group. This might seem a trivial problem, but
the two methyl groups in the o position to the benzylic alcohol hinder greatly this
position, actually blocking and impeding the reactivity. It is therefore important to
transform this moiety in a more reactive centre, for example into an halide. In fact,
attempts to synthesise a mesyl- or tosyl derivative of 203 failed.
A few halogen derivatives were then synthesised with different methodologies.
Firstly, benzyl chloride 208: reaction with thionyl chloride was unsuccessful, but
simple Appel reaction with CCl4 and triphenyl phosphine in DCM or DMF gave the
expected product in moderate yield. This approach required although removal of
unwanted triphenyl phosphoxide by means of a chromatographic column, leading
to loss of product during the purification process. The obtained chloride was then
subjected to Finkelstein retain with NaI in acetone, in order to exchange the chlo-
ride with the iodide atom. It is in fact well-known that generally iodide-containing
compounds are better substrates and reactive towards alkylating agents. Unfortu-
nately, this exchange reaction did not work.
In the meantime, synthesis of the benzylic bromide was accomplished, always un-
der Appel reaction conditions with CBr4 and triphenyl phosphine in DMF. The C-Br
bond is more reactive, and even though the crude was purified, compound 209 was
obtained in better yields than its chloride homologue.
O
OH
O
X
CX4/PPh3
DMF
NaI
Acetone
O
I
X = Cl:
X = Br:
203 202208
209
SCHEME 8.7: Studies towards formation of benzylic halide – part 1.
Nonetheless, the real goal was obtainment of iodide 202 in good yields and
quantities. Under specific Appel conditions for the synthesis of iodides, i.e. with
triphenyl phosphine and imidazole, in the presence of molecular iodide in DMF at
8.3 Route C. 97
r.t., the expected product was not formed. [99]
It turned out that a modification of a literature procedure was found working on
the substrate: KI and BF3 ·OEt2 were employed in anhydrous conditions in diethyl
ether and a few drops of DMF. [100] The reaction in this case was successful, but
unreacted starting material was found from the crude 1H-NMR spectrum. Unfor-
tunately, purification of compound did not lead to isolation of significant amount
of desired product, nor its 1H-NMR purity was deemed sufficient for using it in the
following step. This is a confirmation of the fact that the iodide is the sought for,
reactive compound for the alkylation reaction.
An improvement in the synthesis of 202 was achieved by reacting benzylic alcohol
203 with NaI in the presence of trimethyl chlorosilane in dry ACN: in this case the
yield was finally quantitative and the product could be used in the following step
without any further purification.
O
OH
O
I
KI/BF3.OEt2
DMF, r.t.
or
NaI/(CH3)3SiCl
ACN, rt.
203 202
SCHEME 8.8: Studies towards formation of benzylic halide – part 2: synthesis
of the benzylic iodide.
The finally obtained compound 202 was alkylated by 2,5-diketopiperazine 77
in the presence of LHMDS in anhydrous THF, as reported in [74]. The alkylated
adduct 210 was then hydrolysed in refluxing hydrogen iodide to finally afford the
amino acid L-Dmt with good stereoselectivity, thanks to the chiral synthon 77.
O
I
N
N
O
O
+
LiHMDS
THF, -78°C
O
N
N
O
O
O
HI
NH2
O
OH
*HO
202 77 210 6
SCHEME 8.9: Alkylation reaction and release of the amino acid.
8.3 Route C.
Racemic Dmt can be also obtained by means of Michael addition of ethyl nitroac-
etate on dienone 87. This latter is obtained starting from Hagemann’s ester 211:
8.3 Route C. 98
protection of the ketone as dioxolane 212 is followed by selective reduction of the
ester moiety in the presence of LiAlH4. Stirring the obtained alcohol 213 in acidic
medium for a few hours easily led to stable compound 87. [101]
O
COOEt
OH
OH
OO
COOEt
pTosOH, 
benzene
LiAlH4
Et2O
OO
HO
H+
O
211 212 213 87
SCHEME 8.10: Synthesis of the dienone.
Construction of the Dmt skeleton was then accomplished by simple Michael
addition of ethyl nitroacetate on dienone 87 followed by iodine-mediated aromati-
sation, as shown in the following Scheme 8.11. The nitrate group was eventually
reduced to amine by Sn/HCl, leading to the racemic ethyl ester of Dmt 214.
O
O2N COOEt
TMG, DCM
O
COOEt
NO2
I2
EtOH
OEt
COOEt
NO2
Sn/HCl
OEt
COOEt
NH2
87 214
SCHEME 8.11: Alkylation reaction and release of the amino acid.
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Conclusions and Perspectives
Hagemann’s ester is a very useful and versatile building block: it has been shown
before in the introduction and from th recent publication [81], but also in this last
project.
It is in fact very easy to synthesise and purify and can be manipulated in quite
a few different manners to achieve the most varied structures. We chose Hage-
mann’s ester because of its substituents position resemblance to the Dmt aromatic
skeleton. Moreover, it is well known that the ester moiety can be easily transformed.
A stereoselective synthesis, based on previous work [74], was accomplished.
The crucial step is the alkylation on the part of the chiral synthon 2,5-diketopiper-
azine on the benzylic iodide: all of the compounds can be easily synthesised and
do not require chiral catalysts. Moreover, the aforementioned diketopiperazine and
its employment fall under the auspices of the atom economy: in fact, all of its atoms
concur and are in the end part of the amino acid.
It was also possible to develop an easy route to benzyl iodide 202.
One aim of the following work is to study the feasibility of the employment of
the 2,5-diketopiperazine chiral synthon in the Michael addition to dienone 87.
100
10
Experiments
The TLC layers are Macherey-Nagel Poligram SIL G/UV254 0.20 mm; a 1% solu-
tion of KMnO4, 2,4-dinitrophenylhydrazine in acidic solution were used to visu-
alise spots.
Chromatographic purifications were run over silica gel Macherey-Nagel 60M 230-
400 mesh.
1H-NMR and 13C-NMR were registered with Varian spectrometers at 300 MHz and
400 MHz at room temperature. Chemical shifts (δ) are reported with respect to
trimethylsilane in the following manner: chemical shift (multiplicity, coupling con-
stants, integer value). Signal multiplicity are shortened in the following manner:
s for singlet; d for doublet; t for triplet; q for quartet; br for broad signal; m for
multiplet; dd for double doublet.
Mass spectra were recorded on Waters Micromass ZMD 2000, ESI-Q-TOF 6520 Ag-
ilent Technologies, Agilent 6520 Q-TOF LC/MS System and LCQ Duo Finningan.
10.1 Synthesis of ethyl 2,6-dimethyl-4-oxocyclohexen-2-encarboxylate 10210.1 Synthesis of ethyl 2,6-dimethyl-4-oxocyclohexen-2-encarboxylate
O
OEt
O
O2 +
tBuOK/tBuOH
rflx, 48h
O
COOEt
118 198 195
In a round-bottomed flask, 5.2 g of ethyl acetate 116 [39,96 mmol, 2eq], 1,11 ml
of acetaldehyde 215 and 40 ml of tert-butanol were stirred together. At 0°C, 0,16 g
of tert-butanol [0,1 eq] were added, and the mixture was stirred at the same temper-
ature for about one hour. After this, additional 0.4 g [0.25 eq] of tert-butanol were
added, and the reaction was heated under reflux for about 48 hours and followed
via TLC EtOAc/Cy 1:2.
After this time, the reaction was cooled to room temperature, washed with HCl 1N
followed by a saturated solution of sodium bicarbonate, NaOH 1N, distilled water
and brine. The aqueous phases were extracted with EtOAc. The combined organic
layers are dried over anhydrous Na2SO4 and concentrated under vacuum, obtain-
ing an oily and yellow compound which is then purified via flash chromatography
EtOAc/Cy 1:4, affording 2.57 g of product 196 with a final yield of 65%.
MS [ESI] = 197.1 m/z [MH+]
1H-NMR (400 MHz, CDCl3): δ 5,9 (s, 1H), 4,15 (m, 2H), 3,10 (m, 1H), 3 (m, 1H), 2,85
(m, 1H), 2,6 (m, 1H), 1,95 (s, 3H), 1,3 (m, 3H), 1,1 (m, 3H).
10.2 Synthesis of 3,5-dimethylcyclohexen-2-one
O
COOEt
KOH/EtOH
O
or Ba(OH)2/EtOH
195 205
10.2.1 Procedure A.
500 mg of 196 [2.55 mmol] were dissolved in 13 ml of ethanol and added to a
EtOH/water mixture containing 1 g of KOH [7 eq.]. The mixture was heated under
refluxing conditions over night.
The solution was dissolved in 10 ml of water and the ethanol was evaporated un-
der reduced pressure. HCl 6N was added and the mixture refluxed for additional 2
hours.
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The aqueous phase was then cooled and extracted thrice with diethyl ether and
washed with brine. The combined organic layers are dried over anhydrous Na2SO4
and concentrated under vacuum, obtaining 118.6 mg of crude compound 205which
is then filtered over a silica pad, affording 52 mg of product with a final yield of 16%.
10.2.2 Procedure B.
396 mg of 196 [2.02 mmol] were dissolved in 8 ml of ethanol; 2.83 g of Ba(OH)2
[8.86 mmol] were added to the mixture, which was then was heated at reflux tem-
perature over night.
The solution was the cooled and acidified and extracted thrice with diethyl ether.
The organic layer was dried over anhydrous Na2SO4 and concentrated under vac-
uum, obtaining 281 mg of crude compound 205 which is then purified via chro-
matographic column EtOAc/Cy 1:3, affording 109 mg of product with a final yield
of 44%.
1H-NMR (400 MHz, CDCl3): δ 5,9 (s, 1H); 2,4 (m, 2H); 2,2 (m, 1H); 2 (m, 2H) 1,9 (s,
3H); 1,05 (d, 3H, J= 12 Hz).
10.3 Synthesis of 2,6-dimethyl-4-(pivaloxy)cyclohexen-2-encarboxylate
O
COOEt COOEt
OCOtBu
Cl
O
DIMAP
195 204
10.3.1 Procedure A.
In a round-bottomed flask, 204 mg [1.04 mmol] of compound 196 were dissolved in
THF. Then, 2 eq. [0.25 ml] of pivaloyl chloride and 2.5 eq. [0.39 ml] of TMEDA were
added, and the reaction was stirred at room temperature o.n.; a white precipitate
started to form.
After TLC analysis the following day, starting material was still present: additional
2.5 eq. of base were added. Following further monitoring of the reaction, additional
pivaloyl chloride was added too, but the reaction was not proceeding anymore.
The reaction was then worked-up: the organic phase was washed with HCl 1N,
and the aqueous phase was extracted with diethyl ether. The organic layer was
dried over anhydrous Na2SO4 and concentrated in vacuo, obtaining 318 mg of crude
compound 204 which is then purified via chromatographic column EtOAc/Cy 1:4,
affording 74 mg of product and 107 mg of starting material 196, with a final yield
of 44%.
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10.3.2 Procedure B.
In a round-bottomed flask, 507 mg of compound 196 were dissolved in THF. Then, 2
eq. of pivaloyl chloride and 2.5 eq. [0.39 ml] of DMAP were added, and the reaction
was stirred at room temperature o.n.; a white precipitate started to form.
The reaction was then worked-up: the organic phase was washed with HCl 1N
and the aqueous phase was extracted with diethyl ether. The organic layer was
dried over anhydrous Na2SO4 and concentrated in vacuo, obtaining 700 mg of crude
compound 204 which is then purified via chromatographic column EtOAc/Cy 1:4,
finally affording 349 mg of product and 272 mg of starting material 196, with a final
yield of 44%.
1H-NMR (400 MHz, CDCl3): δ 5,6 (s, 1H); 4,20 (m, 2H); 3 (m, 1H); 2,8 (m, 1H); 2,2 (s,
3H), 2 (m, 2H); 1,3 (t, 2H, J=7 Hz) 1,2 (m, 9H); 1,1( d, 3H J= 6,9 Hz).
13C-NMR (100 MHz, CDCl3): δ 176,489; 167,838; 152,492; 141,496; 124,424; 116,056;
59,919; 39,008; 33,332; 29,850; 26,980; 21,076; 18,348; 14,330.
10.4 Synthesis of 4-methoxy-2,6-dimethylbenzene
O
COOEt
I2
MeOH
Y = 66%
O
COOEt
195 207
3 g of ester 196 [67.6 mmol] and 7.7 g [2.2 eq] of molecular iodine were dissolved
in 20 ml of methanol and refluxed for a few hours.
After reaction completion, methanol was evaporated under reduced pressure and
the crude was taken up in EtOAc. The organic phase was washed with a saturated
solution of sodium bicarbonate and with a saturated solution of sodium thiosulfate,
followed by water and brine. The organic layer was dried over anhydrous Na2SO4
and concentrated in vacuo, obtaining 2.7 g of crude compound 207 which is then
purified via chromatographic column EtOAc/Cy 5:95, finally affording 2.11 g of
final product 216, with a final yield of 66%.
1H-NMR (400 MHz, CDCl3): δ 6,559 (s, 2H); 4,369 (q, 2H, J= 7 Hz); 3,779 (s, 3H);
2,320(s, 6H), 1,372 (t, 3H, J= 7 Hz).
13C-NMR (101 MHz, CDCl3): δ 169.8, 159.9, 137.4, 126.4, 113.1, 60.7, 55.1, 20.3, 14.3.
10.5 Synthesis of (4-methoxy-2,6-dimethyl)methanol
Under nitrogen atmosphere, 1 g of starting material 216 was added drowse to a
suspension of 68 mg [0.75 eq] of LiAlH4 in 10 ml of diethyl ether.
After two hours of reaction, total conversion to product 203 was accomplished.
Reaction was then treated with NaOH 2N to destroy the excess of reducing agent
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O
COOEt
LiAlH4
O
OH
Et2O
Y = 54%
207 203
and filtered over a celite pad. The organic layer was dried over anhydrous Na2SO4
and concentrated in vacuo, obtaining 0.24 g of crude compound 203 which is then
purified via chromatographic column EtOAc/Cy 1:2, finally affording 0.21 g of final
product 203, with a final yield of 54%.
1H-NMR (400 MHz, CDCl3): δ 6,6 (s, 2H), 4,7 (s, 2H), 3,8 (s, 3H), 2,4 (s, 6H).
13C-NMR (101 MHz, CDCl3): δ 158.9, 139.0, 113.6, 66.1, 59.0, 55.1, 41.5, 19.7.
10.6 Synthesis of 2-(chloromethyl)-5-methoxy-1,3-dimethyl-benzene
O
OH
O
Cl
CCl4/PPh3
DMF
203 208
To a solution of 201 mg of 203 in 5 ml of DMF, 0.12 ml [1 eq.] of CCl4 and 317
mg [1 eq.] of triphenyl phosphine were added. The reaction mixture was allowed
to stir at r.t.
After 30 minutes, TLC-monitoring did not show anymore the presence of the start-
ing material. Water was added and the solution was extracted in η-hexane. The
organic phase was dried over anhydrous sodium sulphate and concentrated under
reduce pressure to give 174 mg of crude, which was purified on silica gel eluted
with EtOAc/Cy 1:8, affording 34 mg of desired product 208 as a white solid, with a
final yield of 15%.
1H-NMR (400 MHz, CDCl3): δ 6,554 (s, 2H); 4,513 (s, 2H); 3,752 (s, 3H); 2,358 (s,
6H).
13C-NMR (101 MHz, CDCl3): δ 158,779; 139,482; 126,925; 113,365; 66,102; 55,074;
19,830.
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O
OH
O
Br
CCl4/PPh3
DMF
203 20910.7 Synthesis of 2-(bromomethyl)-5-methoxy-1,3-dimethyl-benzene
To a solution of 200 mg of 203 in 3 ml of DMF, 0.4 g [1 eq.] of CBr4 and 315 mg [1
eq.] of triphenyl phosphine were added. The reaction mixture was allowed to stir
at r.t. for three days.
After completion of the reaction, water was added and the solution was extracted
in η-hexane. The organic phase was dried over anhydrous sodium sulphate and
concentrated under reduce pressure to give 762 mg of crude product, which was
purified on silica gel eluted with EtOAc/Cy 1:6, affording 136 mg of desired prod-
uct 209 as a white solid, with a final yield of 49%.
1H-NMR (400 MHz, CDCl3): δ 6,55 (s, 2H); 4,5 (s, 2H), 3,78 (s, 3H), 2,4 (s, 6H).
13C-NMR (101 MHz, CDCl3): δ 158.8, 139.5, 126.9, 113.4, 66.1, 55.1, 19.8.
10.8 Synthesis of 2-(iodomethyl)-5-methoxy-1,3-dimethyl-benzene
O
OH
O
I
KI/BF3.OEt2
DMF, r.t.
or
NaI/(CH3)3SiCl
ACN, rt.
203 202
10.8.1 Procedure A.
Under an inert atmosphere, 200 mg [1.2 mmol] of compound 203 was dissolved in
5 ml of dry diethyl ether. To this, 200 mg [1 eq.] of KI dissolved in anhydrous DMF
and 0.15 ml [1 eq.] of BF3 ·OEt2 were added under stirring, and the reaction was
left at r.t. for one day.
Upon reacting, a change of colour can be observed: complete reaction is in fact dark
orange.
The reaction solution was washed with cooled water, extracted thrice with diethyl
ether, dried over anhydrous sodium sulphate and concentrated under reduce pres-
sure to give 257 mg of crude product 202. Purification with Isolera automatic col-
umn yielded not quantifiable and extremely impure final product.
10.9 Synthesis of (3S,6S)-3,6-bis(4-methoxy-2,6-dimethylbenzyl)-1,4-bis(§-1-phenyl-ethyl)piperazyn-2,5-dione10710.8.2 Procedure B.
Under an inert atmosphere, 1,5 g [9.04 mmol] of compound 203, 1.35 g [1 eq.] of
NaI, 1.35 ml [1 eq.] of chloro trimethylsilane were dissolved in 10 ml ACN. A white
precipitate is formed and reaction colour becomes dark red. After 30 minutes and
TLC monitoring, reaction is complete.
The reaction solution was washed with water, and a saturated solution of sodium
thiosulfate, extracted thrice with diethyl ether, dried over anhydrous sodium sul-
phate and concentrated in vacuo to give 2,36 g of crude product 202 which was not
further purified.
1H-NMR (400 MHz, CDCl3): δ 6,56 (s, 2H); 4,47 (s, 2H); 3,765 (s, 3H); 2,33 (s, 6H).
13C-NMR (101 MHz, CDCl3): δ 159,108; 138,694; 127,001; 113,931; 55,100; 19,710;
5,101.
10.9 Synthesis of (3S,6S)-3,6-bis(4-methoxy-2,6-dimethyl-benzyl)-1,4-bis((S)-1-phenylethyl)piperazyn-2,5-dione
O
I
N
N
O
O
+
LiHMDS
THF, -78°C
O
N
N
O
O
O
202 77 210
Under an inert atmosphere in a round-bottomed flask, 875 mg [0.5 eq] of 77 are
dissolved in 5 ml of freshly distilled THF. At -10°C, 3 ml of LHMDS 1M in THF [0.5
eq.] are added. After circa 30-40 minutes, 750 mg [0.5 eq] of benzyl iodide 202 are
added at -78°C. The reaction is stirred at -78°C for an hour and followed via TLC.
after depletion of starting material 202, another 3 ml of LHMDS 1M in THF [0.5 eq.]
are added at -10°C, and after 40 minutes 750 mg [0.5 eq] of benzyl iodide 202 are
added at -78°C. the reaction is then allowed to reach r.t. and is stirred for circa 5
hours.
The reaction was then worked-up by washing with HCl 1N; the aqueous phase is
extracted with EtOAc and dried over anhydrous sodium sulphate and concentrated
in vacuo to afford 2.5 g of crude product 210.
The crude compound was purified over chromatographic column eluted with EtOAc/Cy
1:3, obtaining 0.8 g of pure compound 217, with a yield of 47 %.
MS (ESI) = [MH+]: 619,7 m/z
1H-NMR (400 MHz, CDCl3): δ 7,289 (m, 6H); 7,004 (m, 4H); 6,608 (s, 4H); 5,718 (q,
2H, J=7); 4,046 (t, 2H, J=8); 3,782 (s, 6H); 3,43 (m, 4H), 2,322 (s, 12H); 1,33 (d, 2H,
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J=7).
13C-NMR (101 MHz, CDCl3): δ 167,89; 158,02; 138,28; 128,69; 128,01; 127,25; 113,95;
58,1; 55,04; 35,56; 26,90; 21,61.
10.10 Synthesis of 2,6-dimethyl-l-tyrosine
O
N
N
O
O
O
HI
NH2
O
OH
*HO
210 6
0.8 g of alkylated diketopiperazine 210 are reacted with 10 ml of HI 57% con-
centrated at refluxing temperature for about three hours. After this time, the acidic
solution was concentrated in vacuo, diluted with water and extracted with EtOAc.
It was then purified over ion-exchenge resin Dowex 50 WX 8 (50-100 mesh), eluted
with a solution of ammonium hydroxide 5M. After evaporation of the ammonia
solution, 100 mg of final S-Dmt is isolated aswhite powder, with an overall yield of
74%.
1H-NMR (400 MHz, D2O): δ 6,43 (s, 2H); 3,6 (t, 1H, JAX =8); 3,06 (dd, 1H, JBX =8,
JAB = 14); 2,8 (dd, 1H, JAX = 8, JAB = 14), 2,1 (s, 6H).
10.11 Synthesis of ethyl 7,9-dimethyl-1,4-dioxaspiro[4.5]-dec-7-ene-8-carboxylate
O
COOEt
OH
OH
OO
COOEt
pTosOH, 
benzene
211 212
2.87 g [14.62 mmol] of Hagemann’s ester 211 were refluxed under Dean-Stark
apparatus in 100 ml of benzene in the presence of 2.86 ml [51.17 mmol 3.5 eq.] of
ethylene glycol and a catalytic amount of p-TosOH over night.
After complete conversion in product 212, the reaction mixture is cooled at r.t.,
washed with a saturated solution of NAHCO3 and brine, dried over anhydrous
sodium sulphate and concentrated in vacuo to afford 3.22 g of crude product 212.
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This latter was purified over chromatographic column eluted with EtOAc/Cy 1:3,
obtaining 2.21 g of pure compound and a finale yield of 63%.
1H-NMR (400 MHz, CDCl3): δ 4,2 (m, 6H), 2,9 (m, 1H), 2,4 (m, 2H), 2 (m, 2H), 1,9 (s,
3H), 1,3 (t, 3H, J=7 Hz), 1,1 (d, 3H, J= 6,5 Hz).
10.12 Synthesis of 3,5-dimethyl-4-methylenecyclohex-2-en-one
OO
COOEt
LiAlH4
Et2O
OO
HO
H+
O
212 213 87
Compound 212 [5,42 g] was added in a single portion to a suspension of 1 g of
LiAlH4 in 20 ml of diethyl ether and 20 ml of freshly distilled THF at 0°C. After stir-
ring at this temperature for additional 20 minutes, the reaction vessel was allowed
to reach room temperature.
After elimination of excess of reducing agent by carefully adding water and EtOAc
to the reaction flask, the organic phase is decanted and concentrated under reduced
pressure. It is then taken up with chloroform and stirred for 5 hours in the presence
of 20 ml of HCl 2N.
The organic phase is the separated and dried over anhydrous sodium sulphate; fi-
nally, the organic solvent was evaporated, affording 2.9 g of target compound 87.
1H-NMR (400 MHz, CDCl3): δ 5,9 (s, 1H), 5,4 (d, 1H, J= 4 Hz), 5,3 (d, 1H, J= 4 Hz), 2,9
(m, 1H), 2,6 (m, 1H), 2,2 (m, 1H), 2 (s, 3H), 1,2 (d, 3H, J= 6,5). 13C-NMR (101 MHz,
CDCl3): δ 199.4, 154.1, 147.6, 127.2, 114.8, 45.4, 35.9, 20.5, 19.9.
10.13 Synthesis of ethyl 3-(2,6-dimethyl-4-oxocyclohex-2-en-1-yl)-2-nitropropanoate
O
O2N COOEt
TMG, DCM
O
COOEt
NO2
87 218
In a round bottomed-flask, 1,4 g of compound 87 is dissolved in 5 ml DCM; to
this solution, 1.15 ml [1 eq.] of ethyl nitroacetate is added in the presence of 4-5
drops of TMG. The reaction is stirred at r.t. until completion over one day.
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The reaction mixture is washed with HCl 1N and extracted with diethyl ether. Af-
ter drying over anhydrous sodium sulphate, the organic solvent was evaporated,
affording 0.9 g of target compound 218.
1H-NMR (400 MHz, CDCl3): δ 5,9 (s, 1H), 5,3 (m, 3H), 4,3 (m, 3H), 2,4 (m, 6H), 2 (s,
3H), 1,3 (m, 6H), 1 (m, 3H).
10.14 Synthesis of ethyl 3-(4-ethoxy-2,6-dimethylphenyl)--2-nitropropanoate
O
COOEt
NO2
I2
EtOH
OEt
COOEt
NO2
218 219
In a round-bottomed flask, 0.9 g [3.34 mmol] of compound 218 are dissolved in
10 ml of ethanol in the presence of 1.7 g [2 eq.] of molecular iodine. The reaction is
then heated at refluxing conditions for 24 hours and is monitored via TLC.
After completion of the reaction, the organic phase is washed with a saturated so-
lution of sodium thiosulfate, then a saturated solution of sodium bicarbonate and
finally with brine. After drying over anhydrous sodium sulphate, the organic sol-
vent was evaporated and the crude purified over chromatographic column eluted
with EtOAc/Cy 1:3, affording the target compound 219 with a 70% yield.
1H-NMR (400 MHz, CDCl3): δ 6,6 (s, 2H), 4,2 (q, 2H, J= 7 Hz), 4 (q, 2H, J=6,9 Hz),
3,5 (m, 3H), 2,3 (s, 6H), 1,3 (t, 3H, J= 6,9 Hz), 1,2 (t, 3H, J= 7 Hz).
10.15 Synthesis of ethyl 2-amino-3-(4-ethoxy-2,6-dimethyl-phenyl)propanoate
O
COOEt
NO2
I2
EtOH
OEt
COOEt
NO2
219 214
Previously isolated 0.27g [2.34 mmol] of compound 219were dissolved in ethanol;
then, 0.3g of powdered tin and 1 ml of concentrated HCl were added. The reaction
was stirred at room temperature for a few hours and monitored via TLC.
Upon completion, the organic phase is washed with NaOH 1M and the aqueous
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phase is extracted with DCM, dried over anhydrous sodium sulphate and concen-
trated in vacuo to afford 0.2 g of 214 as a pure product.
1H-NMR (400 MHz, CDCl3): δ 6,6 (s, 2H), 4,2 (q, 2H, J= 7 Hz), 4,1 (m, 1H), 4 (q, 2H,
J=6,9 Hz), 3 (m, 2H), 2,3 (s, 6H), 1,3 (t, 3H, J= 6,9 Hz), 1,2 (t, 3H, J= 7 Hz).
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A
Polarization experiments
A.1 Compound Boc-Arg(Cbz)-N-(pyridin-4-ylmethyl)amide
Adduct 149 was polarised as previously described.
The reference peak for calculating the enhancements was set at 8.38 ppm.
TABLE A.1.1: Polarisation test for compound Boc-Arg(Cbz)-N-(pyridin-4-
ylmethyl)amide.
1 3 4 6 10 11 13 14 23 24
Enhancement 1.00 0.72−1.72−1.58−0.58−3.23−0.33−8.77−7.75−17.59
T (°C) r.t. r.t. r.t. r.t. r.t. r.t. r.t. 40 r.t. 60
B (G) 0 0 0 0 0 68 0 0 0 0
Shake time (sec) 8 8 8 8 8 8 8 8 20 8
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(A) Superimposition of all the protonic NMR spectra
for the compound.
(B) Thermal proton NMR superimposed to the one
with the higher enhancement.
FIGURE A.1.1
A.2 Compound Boc-Arg(Cbz)-N-methyl-N-(pyridin-4-ylmethyl)amide 115A.2 Compound Boc-Arg(Cbz)-N-methyl-N-(pyridin-4-ylmethyl)amide
Adduct 150 was polarised as previously described.
The reference peak for calculating the enhancements was set at 8.43 ppm. The shake
time was set being 8 sec.
TABLE A.2.1: Polarisation test for Boc-Arg(Cbz)-N-methyl-N-(pyridin-4-yl-
methyl)amide.
27 29 30 31 35 39
Enhancement 1.00 0.587 −2.306 −3.933 −8.013 −11.568
T (°C) r.t. r.t. r.t. r.t.. 40 60
(A) Superimposition of all the protonic
NMR spectra for the compound.
(B) Thermal proton NMR superimposed
to the one with the higher enhancement.
FIGURE A.2.1
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Adduct 151 was polarised as previously described.
The reference peak for calculating the enhancements was set at 8.41 ppm. The shake
time was set being 8 sec.
TABLE A.3.1: Polarisation test for compound Boc-Arg(Cbz)-N-(1-(pyridin-4-
yl)ethyl)amide.
43 45 46 47 51
Enhancement 1.00 0.629 −5.981 −8.992 −8.358
T (°C) r.t. r.t. r.t. r.t. 40
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(A) Thermal proton NMR superimposed to the one
with the higher enhancement.
(B) Superimposition of all the protonic NMR spectra
for the compound.
FIGURE A.3.1
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Adduct 152 was polarised as previously described.
The reference peak for calculating the enhancements was set at 8.38 ppm. The shake
time was set being 8 sec.
TABLE A.4.1: Polarisation test for compound (R)-methyl 2-Boc-Arg(Cbz)-2-
(pyridin-4-yl)acetate.
54 56 57 58 61
Enhancement 1.00 0.494 −4.480 −1.58 −3.375 −6.049
T (°C) r.t. r.t. r.t. r.t. r.t. 40
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(A) Thermal proton NMR superimposed to the one
with the higher enhancement.
(B) Superimposition of all the protonic NMR spectra
for the compound.
FIGURE A.4.1
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B
Biological Assay
B.1 Protocol for testing L-arginine analogues
B.1.1 Ingredients for the NOS reaction
The ingredients for the NOS reaction were found to be from the Cayman eNOS
product info sheet, cat no 60880:
1 unit eNOS (eNOS supplied in 50 mM HEPES, pH 7.4, with 10% glycerol, 5mM
CHAPS and 100µM DTT);
50 mM HEPES, pH 7.4;
1mM CaCl2;
20 µg/ml calmodulin;
0.1 mM NADPH;
50 µM L-arginine or L-arginine analogue;
12 µM BH4 (tetrahydrobiopterin).
Prepare the above for a 200µl amount for each time point below (5 time points).
One Unit of eNOS produces 1 nM NO/minute at 37°C. Follow all instructions re-
garding storage and lab use from the eNOS data sheet, especially with regards to
temperature. The assay should be performed first with L-arginine in order to draw
a response curve (incubation times of 5 min, 10 min, 20 min, 40 min and 1 hour). The
assay should be performed afterwards with each L-arginine analogue, also with all
the incubation times above.
After incubation for x min at 37°C, the reaction is terminated by the addition of 3 ml
of ice-cold stop buffer (20 mM HEPES pH: 5.5, 2 mM EDTA, 2 mM EGTA as Ca2+
chelators).
For all not mentioned in the following lines please refers to the Nitrate-Nitrite
colorimetric assay protocol. Follow the instructions of the standard wells (A-F).
Follow all the instructions of the rest of the reaction for each analogue and for each
analogue concentration to test.
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B.1.2 Stock solutions preparation
The stock solutions are prepared 10 times of above concentrations, so that 10 µl of
each component below is used for a 100 µl reaction:
HEPES (Sigma, H3375, 25g, £22.9), Mol weight=238.3. Make stock solution 500
mM (0.5M): 11.9 g HEPES in 100 mls water Make it in 90 mls water first and pH
with NaOH to 7.4, then dilute to a total of 100 mls.
CaCl2 (VWR, 250g, £35), Mol weight=147.01. Make stock solution10 mM: 147
mg CaCl2 dihydrate in 100 mls water.
Calmodulin (Millipore, 14-368A, 100µg, £76) Make stock solution of 200µg/ml,
so 100µg into 0.5 ml water. Check the size of the bottle in which it comes as 100
µg powder, dilute with 500 µl water and aliquote to freeze at -20°C. Keep on ice at
all times, whilst preparation in the lab, waiting times. From the amount calculated
there will be 200 µl left over to freeze.
L-arginine (Sigma, 11009, 25g, £18), Mol weight = 174.2. Make stock solution
500 µM (0.5 mM). 1M=174.2 g/L, so 0.5M=87.1g/L, so 0.5mM=0.0871 g/L = 87.1mg
in 1000 mls, therefore equivalent to adding 8.71 mg to 100 mls water. Make fresh
every time it is used.
NADPH (Sigma, N1630, 25 mg, £45.8) Mol weight = 833.35. Make stock solu-
tion 1mM. Add 8.33 mg to 10 mls water. Use fresh every time, make new if more
needed.
BH4 (Sigma, T4425, 5 mg, £32.2), Mol weight=314.2. Make 120 mM stock solu-
tion (this is 1000x of the reaction concentration, due to small amount of BH4 pro-
vided, so will need further dilution, see below).
Add 5 mg BH4 to 132 µl water; aliquot and freeze in 5 µl aliquots. On the day of the
experiment dilute the 5 µl aliquot in 5000 µl water to get the 120 µM stock. From
this, use the 10 µl for the 100 µl reaction.
For each 100 µl reaction use the following dose from the 10x concentrated stocks
above:
10 µl (0.5M) HEPES
10 µl (10 mM) CaCl2
10 µl (200 µg/ml) CaM
10 µl (500 µM) L-arginine
10 µl (1 mM) NADPH
10 µl (120 µM) BH4
Add them in the reaction in exact the above order. BH4 needs to be added after
NADPH to prevent its oxidation.
Then add the following amounts of water/eNOS, to vary the concentration of
eNOS in the reaction:
The eNOS needs to be added last and the timing of the reaction is calculated
from this moment onwards.
So in total, for each reaction to happen in duplicate, at 5 time points and with 5
different concentrations of enzyme, 50 wells are needed.
At this point stop the reaction and then go onto point 2 from the first page and
follow the instructions from the colorimetric assay.
B.1 Protocol for testing L-arginine analogues 123
eNOS quantity (U) eNOS µl Water (µl)
0 0 40
0.25 1.375 38.625
0.5 2.75 37.25
1 5.5 34.5
2 11 29
B.1.3 Preparation of the Analogues solutions
L-Arginine analogues: assigned molecular weights are the following.
Compound 141 : 921.19 mol;
Compound 143 : 878.19 mol;
Compound 142 : 878.19 mol;
Compound 140 : 864.17 mol.
We need 0.5 mM concentration for all of these, as with L-arginine, which are calcu-
lated as following:
Compound 141: MW = 921.19 g/mol.
Furnished 22.8 mg. Dilute in 49.4 mls water to make stock solution 0.5 mM.
mol =
g
MW
=
0.0228
921.19
= 0, 0000247 mol
M =
mol
Vol (l)
=
0, 0000247 mol
0, 0494 l
= 0, 0005 mol/l = 0.5 mM = 500µM
Compound 143: MW = 878.19 g/mol.
Furnished 23.1 mg. Dilute in 52.6 mls water to make stock solution 0.5 mM.
mol =
g
MW
=
0.0231
878, 19
= 0, 0000263 mol
M =
mol
Vol (l)
=
0, 0000263 mol
0, 0526 l
= 0, 00050 mol/l = 0.50 mM = 500µM
Compound 142: MW = 878.19 g/mol.
Furnished 23 mg. Dilute in 52.2 mls water to make stock solution 0.5 mM.
mol =
g
MW
=
0.023
878, 19
= 0, 0000261 mol
M =
mol
Vol (l)
=
0, 0000261 mol
0, 0522 l
= 0, 00050 mol/l = 0.50 mM = 500µM
Compound 140: MW = 864.17 g/mol.
Furnished 21.9 mg. Dilute in 50.7 mls water to make stock solution 0.5 mM.
mol =
g
MW
=
0.0219
864, 17
= 0, 0000253 mol
M =
mol
Vol (l)
=
0, 0000253 mol
0, 0507 l
= 0, 0005 mol/l = 0.50 mM = 500µM
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B.1.4 Preparation of the Stop solution
Quantity to prepare: 100 mls.
20 mM HEPES pH = 5.5, 2 mM EDTA, 2 mM EGTA as Ca2+ chelators. Make
stock solutions 10x more concentrated so that 10 mls of each stock solution below
can be used for a total of 100 mls stop solution:
1. HEPES (Sigma, H3375, 25g, £22.9), Mol weight=238.3. Make stock 200 mM:
1M concentration is 238.3 g/L, so 200 mM=47.66 g/L or 4.76 g in 100 mls. Put 4.76
g in 90 mls water, pH with HCl to 5.5 and then add water to 100 mls.
2. EDTA, mol mass = 372.24. Make stock 20 mM: 1M concentration is 372.24
g/L, so 20 mM = 740 mg in 100 mls.
3. EGTA, mol mass=380.35. Make stock 20 mM: 1M concentration =380.35 g/L,
so 20 mM = 760 mg in 100 mls.
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a b s t r a c t
‘One-pot’ tandem reactions of commercially available 1,4-dithiane-2,5-diol (the dimer of mercaptoace-
taldehyde) with electrophilic alkenes resulted in the facile formation of substituted tetrahydrothiophene
derivatives. Thus, sulfa-Michael/Henry and sulfa-Michael/aldol sequences provided polysubstituted
tetrahydrothiophenes using in situ generated nitroalkenes and a,b-unsaturated carbonyl compounds as
the electrophilic partners of mercaptoacetaldehyde dimer, respectively.
 2011 Elsevier Ltd. All rights reserved.
1. Introduction
The tetrahydrothiophene moiety is the core structural compo-
nent of many natural products, bioactive compounds, and synthetic
intermediates. Tetrahydrothiophene-based compounds include the
essential coenzyme biotin 1, a water-soluble vitamin involved in
important biological functions,1 the cholecystokinin type-B re-
ceptor antagonist tetronothiodin 2,2 the nucleoside 3 showing
potent activity against human cytomegalovirus,3 and glucosidase
inhibitors, such as kotalanol 44 and salacinol 55 (Fig. 1).
Furthermore, tetrahydrothiophene derivatives have been used
in a range of chemical transformations, including asymmetric hy-
drogenation,6 catalytic asymmetric epoxidation,7 and catalytic
intramolecular cyclopropanation.8 The synthetic usefulness and the
wide range of biological activities give tetrahydrothiophenes
a privileged role in organic chemistry. Accordingly, various ap-
proaches to these interesting scaffolds have been developed,
the earliest and present most common ones being listed in our
recent paper dealing with the synthesis of nitrohydroxylated
tetrahydrothiophenes by ‘one-pot’ tandem sulfa-Michael/Henry
reactions.9 2. Results and discussion
Our studies entailed the use of 1,4-dithiane-2,5-diol 6, the
mercaptoacetaldehyde dimer, as a convenient and efﬁcient synthon
incorporating a thiol group able to add to in situ generated
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Fig. 1. Structure of bioactive tetrahydrothiophenes 1e5.
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nitroalkenes. The derived nitroalkane adducts provided 4-nitro-
tetrahydrothiophen-3-ol scaffolds through a subsequent intra-
molecular nitroaldol reaction (Scheme 1).
Thus, tandem sulfa-Michael/Henry sequences smoothly took
place by reaction of 2-nitroethylacetates 7e9, used as stable
precursors for the corresponding nitroalkenes, with dimer 6 in
dichloromethane containing triethylamine providing good yields
of the expected 4-nitro-tetrahydrothiophen-3-ols 10e12 as 1.5:1
mixtures of diastereomers (Table 1).9,10 The ratio was de-
termined by integration of characteristic signals in their 1H NMR
spectra.
Quite surprisingly, the simple two-carbon atom unit in-
corporating a thiol group and an additional electrophilic func-
tionality, such as the aldehydic group, has been only occasionally
used in domino reactions with a,b-unsaturated carbonyl
compounds.11
We envisioned the reaction of 1,4-dithiane-2,5-diol 6 with
cyclohexenone as a straightforward route to the hexahydro-ben-
zothiophen-4-one nucleus, the scaffold of a diterpenoid isolated
from the seeds of Japanese Morning Glory (Ipomoea violacea),12
which seems to regulate the activity of gibberellin A3. Indeed, the
reaction, performed in dichloromethane containing catalytic trie-
thylamine (5 mol %), proceeded smoothly via a sulfa-Michael/aldol
reaction sequence leading to the formation in good yield (75%) of
a 3:1 mixture of the diastereomeric hexahydro-benzothiophen-4-
ones 13 and 14, easily separated by column chromatography
(Scheme 2).
The structure of the prevalent compound 13 has been un-
equivocally assigned through single-crystal X-ray analysis (Fig. 2).13
Analogously, use of different a,b-unsaturated ketones as part-
ners of mercaptoacetaldehyde dimer in the tandem Michael-aldol
reaction process resulted in the efﬁcient preparation of mono-
cyclic and bicyclic 3-hydroxythiophanes in good yields and high
diastereoselectivity.
As shown in Scheme 3, treatment of 6 with cyclopentenone
under the same conditions as above gave rise to an inseparable
diastereomeric mixture of bicyclic derivatives 15 (3:1 ratio from 1H
NMR, 65% yield), while single stereoisomers 18 and 19 could be
obtained in 45% yield through reaction of 6with (S)-carvone 16 and
b-ionone 17, respectively.
The stereochemistry of compound 18 was tentatively assigned
by NOE experiments, while X-ray crystallographic analysis allowed
us to assign the structure of tetrahydrothiophene 19 (Fig. 3).13
In the context of our studies, we considered also dehydroalanine
esters as counterparts of mercaptoacetaldehyde dimer in the tan-
dem sulfa-Michael/aldol reaction process. These compounds have
been largely utilized as Michael acceptors for conjugate addition
reactions14 even though typically considered poor electrophiles
due to the electron-donating effects of the nitrogen lone pair.
However, to the best of our knowledge, dehydroalanine esters have
not been hitherto employed in tandem reaction processes. There-
fore, we were intrigued to test the reactivity of differently N-
Table 1
Synthesis of tetrahydrothiophene compounds 10e12
S
S OH
HO
R NO2
OAc
6
7-9
Et3N, CH2Cl2
12 h, r.t.
S
HO NO2
R
10-12
Nitroacetate R Product (dr) Yielda (%)
7 H 10 (1.5:1) 65
8 CH2OH 11 (1.5:1) 70
9 (CH2)2OCH2OMe 12 (1.5:1) 80
a Isolated yield after puriﬁcation by column chromatography.
Fig. 2. ORTEP view of compound 13 displaying the thermal ellipsoids at 30%
probability.
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Scheme 1. General approach to the synthesis of 4-nitro-tetrahydrothiophen-3-ol de-
rivatives via tandem reactions.
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Scheme 2. Synthesis of tetrahydrothiophenes 13 and 14.
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Scheme 3. Synthesis of tetrahydrothiophenes 15, 18, and 19.
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protected dehydroalanine esters in cascade reactions with a simple
bifunctional reagent, such as mercaptoacetaldehyde dimer.
Thus, the reaction between 6 and methyl 2-formamidoacrylate
20, in turn easily obtained from serine methyl ester hydrochlo-
ride and methyl formate as described in the literature,15 performed
in dichloromethane at room temperature in the presence of po-
tassium carbonate gave the interesting 3,4-trisubstituted tetrahy-
drothiophene 21 in satisfactory yield (50%) as an inseparable 1.5:1
mixture of diastereomers (Scheme 4). The ratio was determined by
integration of characteristic signals in their 1H NMR spectra.
Unsuccessful attempts to induce asymmetry in this domino
process using conventional organocatalysts (e.g., quinine and some
derived thioureas, proline and (S)-diphenylprolinol TMS ether) led
us to turn our attention to a chiral auxiliary-assisted approach using
()-menthyl 2-acetamidoacrylate 22, which could be conveniently
obtained through a known two-step procedure.16
Menthyl esters have been conveniently applied in the copper-
promoted 1,4-conjugate addition of phenylmagnesium bromide
to chiral 2-acetamidoacrylates to produce N-acetylphenylalanine
esters in high chemical yields and good diastereoselectivity.17
Based on these ﬁndings, we were conﬁdent that the domino
reaction betweenmercaptoacetaldehyde dimer and ()-menthyl 2-
acetamidoacrylate 22 could be stereocontrolled by the bulky chiral
auxiliary group.
Treatment of 22 with 6 in THF at room temperature in the
presence of potassium carbonate provided tetrahydrothiophene 23
in disappointing low yield (30%) and diastereoselectivity (dr 1.5:1
from 1H NMR) (Scheme 5). All attempts to improve the reaction
outcome proved unsuccessful.
Notwithstanding, compound 23 could be considered a very in-
teresting intermediate to accomplish a new synthetic approach to
()-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate 24, or
its S-oxidized variants 25 and 26 (Fig. 4), which have been shown to
be highly potent and selective agonists of metabotropic glutamate
receptors 2 (mGlu2) and 3 (mGlu3).18
As shown in Scheme 6, tetrahydrothiophene 23 has been readily
converted into the dihydrothiophene compound 29, which repre-
sents an advanced intermediate toward 26.
Thus, m-chloroperbenzoic acid (m-CPBA) oxidation of 23 pro-
duced the intermediate sulfone 27 (50% yield), which took part in
a subsequent acylation step providing the acetoxy derivative 28 in
93% yield. The latter has been eventually taken to the target com-
pound29 throughaquantitativeDBU-promotedeliminationreaction.
3. Conclusion
In summary, we have developed highly efﬁcient tandem re-
actions to form tetrahydrothiophene ring systems using the mer-
captoacetaldehyde dimer as a common and convenient starting
material. Thediverse functional groups in theproducts obtainedwill
permit furthermanipulation for synthesizing bioactive compounds.
4. Experimental
4.1. General methods
Melting points were determined on a B€uchi-Tottoli apparatus.
IR spectrawere recorded using a PerkineElmer FT-IR SPECTRUM100
spectrophotometer equippedwith ATR (diamond/ZnSe serial No.14031),
and only themore representative frequencies (cm1) are reported.
1H and 13C NMR spectra were recorded on a Varian Gemini 300
spectrometer. Chemical shifts (d) are given in parts per million and
coupling constants (J) in Hertz. Data are reported as follows: s,
singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad.
Solvents were distilled prior to use and reactions were per-
formed under nitrogen or argon atmosphere. Organic solutions
were dried over anhydrous magnesium sulfate and evaporated
Fig. 3. ORTEP view of compound 19 displaying the thermal ellipsoids at 30%
probability.
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with a rotary evaporator. Chromatographic puriﬁcations were car-
ried out using 70e230 mesh silica gel.
Nitroacetates 7 and 8 were prepared from commercially avail-
able 2-nitroethanol and acetyl chloride by adopting the same
procedure used for the synthesis of the corresponding nitro-
benzoates,19 while nitroacetate 12 was obtained through already
reported directions.20
4.2. General procedure for the preparation of compounds
10e12
A solution of nitroacetate (1.5 mmol) in CH2Cl2 (2 mL) was
added to a stirred suspension of 1,4-dithiane-2,5-diol 6
(0.75 mmol) in CH2Cl2 (2 mL) containing triethylamine
(1.65 mmol). The reaction mixture was stirred at room temper-
ature for 12 h, then the solvent was evaporated. The residual oil
was puriﬁed by ﬂash chromatography (silica gel, EtOAc/cyclo-
hexane 1:4).
4.2.1. 4-Nitro-tetrahydrothiophen-3-ol (10). Oil (0.14 g, 65%). Data
for the major isomer: IR (neat) 3410,1545 cm1; 1H NMR (300MHz,
DMSO-d6) d 2.81 (dd, J¼7.0, 14.0 Hz, 1H), 3.07 (dd, J¼7.0, 14.0 Hz,
1H), 3.34 (dd, J¼7.0, 14.0 Hz, 1H), 3.38 (dd, J¼7.0, 14.0 Hz, 1H), 4.80
(q, J¼7.0 Hz, 1H), 5.06 (q, J¼7.0 Hz, 1H), 5.90 (br s, 1H); 13C NMR
(75MHz, DMSO-d6) d 31.9, 37.3, 72.7, 93.9; C4H7NO3S (149.17): calcd
C 32.21, H 4.73, N 9.39; found C 32.23, H 4.70, N 9.35. Selected data
for the minor isomer: 1H NMR (300 MHz, DMSO-d6) d 2.78 (dd,
J¼7.0, 14.0 Hz, 1H), 3.03 (dd, J¼6.8, 13.6 Hz, 1H), 3.30 (dd, J¼7.0,
13.0 Hz, 1H), 3.35 (dd, J¼7.0, 13.0 Hz, 1H), 4.71e4.82 (m, 2H), 5.60
(br s, 1H); 13C NMR (75 MHz, DMSO-d6) d 31.9, 37.2, 73.0, 94.0.
4.2.2. 4-Hydroxymethyl-4-nitro-tetrahydrothiophen-3-ol (11). Oil
(0.19 g, 70%). Data for the major isomer: IR (neat) 3400, 1540 cm1;
1H NMR (300 MHz, CDCl3) d 2.87 (dd, J¼7.2, 14.6 Hz, 1H), 3.10 (d,
J¼8.2 Hz, 1H), 3.35 (dd, J¼7.2, 14.6 Hz, 1H), 3.57 (d, J¼8.2 Hz, 1H),
3.90 (d, J¼14.0 Hz, 1H), 4.30 (d, J¼14.0 Hz, 1H), 4.72 (br s, 1H), 5.60
(m, 1H); 13C NMR (75 MHz, CDCl3) d 36.3, 37.6, 60.5, 71.8, 94.7;
C5H9NO4S (179.20): calcd C 33.51, H 5.06, N 7.82; found C 33.55, H
5.08, N 7.84. Selected data for the minor isomer: 1H NMR (300MHz,
CDCl3) d 3.10 (dd, J¼4.0, 13.5 Hz,1H), 3.15 (d, J¼8.0 Hz,1H), 3.20 (dd,
J¼6.8, 13.5 Hz, 1H), 3.61 (d, J¼8.0 Hz, 1H), 3.80 (dd, J¼15.0, 5.0 Hz,
1H), 3.95 (dd, J¼4.5, 15.0 Hz, 1H), 4.18 (s, 2H), 5.10 (m, 1H); 13C NMR
(75 MHz, CDCl3) d 35.8, 38.6, 72.0, 96.0.
4.2.3. 4-(2-Methoxymethoxy-ethyl)-4-nitro-tetrahydrothiophen-3-ol
(12). Oil (0.28 g, 80%). Data for the major isomer: IR (neat) 3460,
1545 cm1; 1H NMR (300MHz, DMSO-d6,160 C) d 2.25 (t, J¼6.0 Hz,
1H), 2.46 (t, J¼6.0 Hz, 1H), 2.85 (dd, J¼6.0, 15.0 Hz, 1H), 3.20 (d,
J¼14.0 Hz, 1H), 3.30 (dd, J¼6.0, 15.0 Hz, 1H), 3.38 (s, 3H), 3.60 (m,
3H), 3.65 (d, J¼14.0 Hz, 1H), 4.58 (s, 2H), 5.20 (br s, 1H); 13C NMR
(75 MHz, CDCl3) d 31.3, 36.4, 37.6, 55.5, 64.5, 71.3, 94.0, 97.3;
C8H15NO5S (237.27): calcd C 40.50, H 6.37, N 5.90; found C 40.53, H
6.33, N 5.88. Selected data for the minor isomer: 1H NMR (300MHz,
DMSO-d6, 160 C) d 2.35 (t, J¼6.0 Hz, 1H), 2.39 (t, J¼6.0 Hz, 1H), 3.05
(dd, J¼3.0, 15.0 Hz, 1H), 3.30 (dd, J¼5.0, 15.0 Hz, 1H), 3.35 (s, 3H),
3.65 (m, 3H), 4.62 (s, 2H), 5.30 (br s, 1H); 13C NMR (75 MHz, CDCl3)
d 32.2, 36.0, 55.7, 63.4, 76.0, 98.5.
4.3. General procedure for the preparation of compounds 13,
14, 15, 18, and 19
A suspension of dithiane 6 (1.30 mmol), enone (2.60 mmol),
and triethylamine (0.13 mmol) in CH2Cl2 (8 mL) was stirred at
room temperature for 16 h. After this time, the reaction mixture
was concentrated under reduced pressure and the residue
obtained was puriﬁed by column chromatography (silica gel,
EtOAc/cyclohexane 1:4).
4.3.1. 3-Hydroxy-hexahydro-benzo[b]thiophen-4-one (13). White
solid (0.25 g, 57%); mp 68e70 C. IR (neat) 3500, 1715 cm1; 1H
NMR (300MHz, CDCl3) d 1.80e1.90 (m, 2H), 2.20e2.55 (m, 6H), 3.10
(m,1H), 3.80 (m,1H), 4.35 (m,1H); 13C NMR (75MHz, CDCl3) d 23.8,
30.3, 38.1, 39.6, 47.0, 59.9, 76.9, 207.9; C8H12O2S (172.25): calcd C
55.78, H 7.02; found C 55.71, H 7.10.
4.3.2. 3-Hydroxy-hexahydro-benzo[b]thiophen-4-one (14). White
solid (0.08 g, 18%); mp 78e79 C. IR (neat) 3500, 1715 cm1; 1H
NMR (300MHz, CDCl3) d 1.80e1.90 (m, 2H), 1.95e2.60 (m, 6H), 2.87
(m, 1H), 3.20 (m, 1H), 4.20 (m, 1H), 5.00 (m, 1H); 13C NMR (75 MHz,
CDCl3) d 21.6, 28.2, 35.3, 42.1, 44.5, 56.0, 77.7, 214.5; C8H12O2S
(172.25): calcd C 55.78, H 7.02; found C 55.71, H 7.10.
4.3.3. 3-Hydroxy-hexahydro-cyclopenta[b]thiophen-4-one
(15). White solid (0.27 g, 65%). Data for the major isomer: IR
(neat) 3600, 1745 cm1; 1H NMR (300 MHz, CDCl3) d 2.10e2.40 (m,
4H), 2.70 (m, 1H), 2.85 (m, 1H), 3.15 (m, 1H), 3.90e4.10 (br s, 1H),
4.02 (m, 1H), 4.60 (m, 1H); 13C NMR (75 MHz, CDCl3) d 23.8, 36.8,
38.1, 58.2, 58.3, 75.3, 218.1; C7H10O2S (158.22): calcd C 53.14, H
6.37; found C 53.20, H 6.28. Selected data for the minor isomer: 1H
NMR (300 MHz, CDCl3) d 2.09e2.38 (m, 2H), 2.60 (m, 1H), 2.80 (m,
1H), 3.21 (m, 1H), 3.80e4.00 (br s, 1H), 4.30 (m, 1H), 4.80 (m, 1H);
13C NMR (75 MHz, CDCl3) d 30.5, 36.2, 39.7, 58.2, 58.4, 55.8, 75.4,
220.5.
4.3.4. (3R,3aR,6S,7aS)-3-Hydroxy-6-isopropenyl-3a-methyl-hexahy-
dro-benzo[b]thiophen-4-one (18). Oil (0.26 g, 45%). IR (neat) 3300,
1715 cm1; 1H NMR (300 MHz, CDCl3) d 0.95 (s, 3H), 1.63 (m, 1H),
1.66 (s, 3H), 2.00e2.40 (m, 4H), 2.82 (dd, J¼12.0, 8.0 Hz, 1H), 3.09 (t,
J¼7.5 Hz, 1H), 3.23 (dd, J¼12.0, 7.5 Hz, 1H), 4.61 (s, 1H), 4.72 (s, 1H),
4.84 (t, J¼7.5 Hz, 1H); 13C NMR (75 MHz, CDCl3) d 10.5, 20.4, 36.3,
37.2, 42.7, 44.5, 49.7, 65.4, 74.5, 109.9, 149.3, 200.0; C12H18O2S
(226.34): calcd C 63.68, H 8.02; found C 63.75, H 7.90.
4.3.5. 1-[4-Hydroxy-2-(2,6,6-trimethyl-cyclohex-1-enyl)-tetrahy-
drothiophen-3-yl]-ethanone (19). White solid (0.31 g, 45%). IR (neat)
3400, 1725 cm1; 1H NMR (300 MHz, CDCl3) 0.85 (s, 3H), 1.05 (s,
3H), 1.40e1.60 (m, 5H), 1.98 (s, 3H), 2.00 (m, 1H), 2.40 (s, 3H), 3.00
(d, J¼9.0 Hz, 1H); 3.30 (m, 1H), 3.60 (dd, J¼9.0, 5.0 Hz, 1H), 4.20 (s,
1H), 4.50 (d, J¼10.0 Hz, 1H), 4.80 (br s, 1H); 13C NMR (75 MHz,
CDCl3) d 20.3, 20.4, 29.0, 30.8, 34.4, 37.3, 38.3, 39.2, 51.2, 63.4, 79.7,
133.7, 135.0, 211.3; C15H24O2S (268.42): calcd C 67.12, H 9.01; found
C 67.20; H 8.90.
4.4. Synthesis of compounds 21, 23, and 27e29
4.4.1. 3-Formylamino-4-hydroxy-tetrahydrothiophene-3-carboxylic
acid, methyl ester (21). Dithiane 6 (0.94 g, 6.20 mmol) and K2CO3
(1.71 g, 12.4 mmol) were added to a solution of acrylate 20 (1.60 g,
12.4 mmol) in CH2Cl2 (20 mL). The reaction mixture was stirred at
room temperature for 24 h, then ﬁltered and evaporated. The res-
idue obtained was puriﬁed by column chromatography (silica gel,
EtOAc/cyclohexane 3:1) to furnish tetrahydrothiophene 21 (1.27 g,
50%) as an oil. Data for the major isomer: IR (neat) 3450, 1740,
1670 cm1; 1H NMR (300 MHz, CDCl3) d 2.82e3.17 (m, 2H), 3.18 (d,
J¼10.7 Hz, 1H), 3.60 (d, J¼10.7 Hz, 1H), 3.81 (s, 3H), 4.62 (t, J¼7.1 Hz,
1H), 6.70 (br s, 1H), 8.23 (s, 1H); the 13C NMR data have not been
recorded as the compound slowly decomposes under the long ac-
cumulation times required to obtain the spectrum; C7H11NO4S
(205.23): calcd C 40.97, H 5.40, N 6.82; found C 41.06, H 5.33, N 6.75.
Selected data for the minor isomer: 1H NMR (300 MHz, CDCl3)
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d 2.75e3.01 (m, 3H), 3.50 (d, J¼10.0 Hz, 1H), 3.75 (s, 3H), 4.80 (t,
J¼7.0 Hz, 1H), 6.40 (br s, 1H), 8.15 (s, 1H).
4.4.2. 3-Acetylamino-4-hydroxy-tetrahydrothiophene-3-carboxylic
acid, ()-menthyl ester (23). K2CO3 (0.22 g, 1.58 mmol) and a few
drops of triethylamine were added to a stirred suspension of
dithiane 6 (0.24 g,1.58mmol) and acrylate 22 (0.42 g,1.58 mmol) in
THF (4 mL). The reaction mixture was stirred at room temperature
for 4 days, then ﬁltered, and evaporated. The residue obtained was
puriﬁed by column chromatography (silica gel, EtOAc/cyclohexane
1:1) to furnish tetrahydrothiophene 23 (0.16 g, 30%) as an oil. Data
for the major isomer: IR (neat) 3500, 1660, 1750 cm1; 1H NMR
(300 MHz, CDCl3) d 0.75 (d, J¼7.0 Hz, 3H), 0.90 (d, J¼7.0 Hz, 6H),
0.95e2.20 (m, 9H), 2.05 (s, 3H), 2,85 (dd, J¼7.0, 14.0 Hz,1H), 3.05 (d,
J¼14.2 Hz, 1H), 3.15 (dd, J¼6.8, 14.0 Hz, 1H), 3.55 (d, J¼14.2 Hz, 1H),
4.58 (m, 1H), 4.75 (m, 1H), 6.50 (br s, 1H); 13C NMR (75 MHz, CDCl3)
d 20.5, 20.6, 22.3, 23.1, 23.6, 28.1, 30.9, 34.1, 37.6, 38.4, 41.2, 47.1, 74.9,
76.4, 78.5, 169.9, 171.8; C17H29NO4S (343.48): calcd C 59.44, H 8.51,
N 4.08; found C 59.50, H 8.47, N 4.00. Selected data for the minor
isomer: 1H NMR (300 MHz, CDCl3) d 0.70 (d, J¼7.0 Hz, 3H), 0.89 (d,
J¼7.0 Hz, 6H), 0.95e1.95 (m, 9H), 2.04 (s, 3H), 2.80 (dd, J¼14.0,
7.0 Hz, 1H), 3.10 (d, J¼14.0 Hz, 1H), 3.20 (dd, J¼7.0, 14.0 Hz, 1H), 3.60
(d, J¼14.0 Hz, 1H), 4.80 (m, 1H), 6.40 (br s, 1H); 13C NMR (75 MHz,
CDCl3) d 19.5, 20.0, 23.1, 24.2, 24.8, 27.9, 32.0, 35.0, 38.5, 39.6, 40.3,
46.1, 75.2, 77.1, 79.1, 170.0, 172.0.
4.4.3. 3-Acetylamino-4-hydroxy-1,1-dioxo-tetrahydro-1l6-thio-
phene-3-carboxylic acid, ()-menthyl ester (27). A solution of 23
(0.27 g, 0.80 mmol) in CH2Cl2 (10 mL) was treated with m-chlor-
operbenzoic acid (0.49 g, 2.00 mmol, 70%) and stirred at room
temperature for 24 h. Aqueous saturated NaHCO3 solution was
added under stirring and the mixture was extracted with CH2Cl2
(310 mL). The combined organic layers were washed with brine,
dried, and evaporated under reduced pressure, yielding 27 (0.15 g,
50%) as an oil, which was sufﬁciently pure to be used in the next
step without further puriﬁcation. Data for the major isomer: IR
(neat) 3450, 1660, 1750 cm1; 1H NMR (300 MHz, CDCl3) d 0.78 (d,
J¼7.0 Hz, 3H), 0.90 (d, J¼7.0 Hz, 6H), 0.95e2.20 (m, 9H), 2.05 (s, 3H),
3.35 (dd, J¼6.5, 14.0 Hz, 1H), 3.45 (dd, J¼6.5, 14.0 Hz, 1H), 3.65 (d,
J¼14.4 Hz, 1H), 4.15 (d, J¼14.4 Hz, 1H), 4.58 (m, 1H), 4.75 (m, 1H),
6.90 (br s, 1H); 13C NMR (75 MHz, CDCl3) d 20.6, 20.7, 22.3, 23.1,
23.6, 28.1, 30.9, 34.1, 38.4, 47.1, 59.0, 59.8, 70.6, 73.5, 78.5, 169.7,
171.8; C17H29NO6S (375.48): calcd C 54.38, H 7.78, N 3.73; found C
54.35, H, 7.82, N 3.78. Selected data for the minor isomer: 1H NMR
(300 MHz, CDCl3) d 0.72 (d, J¼7.0 Hz, 3H), 0.89 (d, J¼7.0 Hz, 6H),
0.95e1.95 (m, 9H), 2.04 (s, 3H), 3.30 (dd, J¼7.0, 14.0 Hz, 1H), 3.40
(dd J¼7.0, 14.0 Hz, 1H), 3.70 (d, J¼14.0 Hz, 1H), 4.20 (d, J¼14.0 Hz,
1H), 4.70 (m, 1H), 4.80 (m, 1H), 6.50 (br s, 1H); 13C NMR (75 MHz,
CDCl3) d 20.5, 20.6, 22.1, 23.2, 24.1, 28.9, 31.0, 35.2, 38.7, 47.6, 59.3,
60.1, 71.2, 77.6, 79.5, 170.1, 172.3.
4.4.4. Synthesis of 4-acetoxy-3-acetylamino-1,1-dioxo-tetrahydro-
1l6-thiophene-3-carboxylic acid, ()-menthyl ester (28). Pyridine
(0.16mL, 2.00mmol) and acetyl chloride (0.14mL, 2.00mmol) were
added to a solution of compound 27 (0.15 g, 0.40 mmol) in CH2Cl2
(10 mL). The reaction mixture was stirred for 2 h at room temper-
ature, then water was added, the organic layer separated and se-
quentially washed with HCl 1 N and aqueous saturated NaHCO3
solution. The organic extracts were dried and evaporated to give
crude 28 (0.15 g, 93%) as an oil, which was used in the next step
without further puriﬁcation. Data for the major isomer: IR (neat)
1660, 1735, 1750 cm1; 1H NMR (300 MHz, CDCl3) d 0.78 (d,
J¼7.0 Hz, 3H), 0.90 (d, J¼7.0 Hz, 6H), 0.95e2.20 (m, 9H), 2.10 (s, 3H),
2.18 (s, 3H), 3.41 (dd, J¼6.2, 14.0 Hz, 1H), 3.65 (dd, J¼6.2, 14.0 Hz,
1H), 4.05 (d, J¼16.0 Hz, 1H), 4.10 (d, J¼16.0 Hz, 1H), 4.58 (m, 1H),
5.65 (m, 1H), 6.35 (br s, 1H); 13C NMR (75 MHz, CDCl3) d 20.5 (2),
21.3, 22.3, 23.1, 23.6, 28.1, 30.9, 34.1, 38.4, 47.1, 56.9, 59.4, 72.8, 73.9,
78.5, 168.6, 171.2, 171.8; C19H31NO7S (417.52): calcd C 54.66, H 7.48,
N 3.35; found: C 54.60, H 7.55, N 3.40. Selected data for the minor
isomer: 1H NMR (300 MHz, CDCl3) d 0.75 (d, J¼7.0 Hz, 3H), 0.87 (d,
J¼7.0 Hz, 6H), 0.95e2.00 (m, 9H), 2.15 (s, 3H), 2.50 (s, 3H), 3.40 (dd,
J¼7.0, 14.0 Hz, 1H), 3.75 (dd J¼7.0, 14.0 Hz, 1H), 4.00 (d, J¼14.0 Hz,
1H), 4.15 (d, J¼14.0 Hz, 1H), 4.80 (m, 1H), 5.60 (m, 1H), 6.50 (br s,
1H); 13C NMR (75 MHz, CDCl3) d 20.5 (2), 21.8, 23.2, 23.8, 29.0,
31.0, 38.7, 38.9, 47.6, 59.5, 60.1, 71.2, 76.6, 79.5, 170.2, 173.0.
4.4.5. Synthesis of 3-acetylamino-1,1-dioxo-2,3-dihydro-1H-1l6-
thiophene-3-carboxylic acid, ()-menthyl ester (29). Compound 28
(0.22 g, 0.53mmol)was dissolved in toluene (8mL) and treatedwith
DBU (0.16mL,1.06mmol). The reactionmixturewas stirred at room
temperature for 24 h and evaporated. The oily residuewas dissolved
inCH2Cl2 (10mL) and sequentiallywashedwithHCl 1Nandaqueous
saturated NaHCO3 solution. The organic extracts were dried and
evaporated, and the crude product was puriﬁed by column chro-
matography (silica gel, EtOAc/cyclohexane 1:2) to give 29 (0.18 g,
95%) as an oil. IR (neat) 1660, 1735 cm1; 1H NMR (300MHz, CDCl3)
d0.78 (d, J¼7.0Hz, 3H), 0.90 (d, J¼7.0Hz, 6H), 0.95e2.02 (m,9H), 2.03
(s, 3H), 3.50 (d, J¼16.0 Hz, 1H), 3.95 (d, J¼16.0 Hz, 1H), 4.75 (m, 1H),
6.80 (d, J¼7.0 Hz, 1H), 7.45 (d, J¼7.0 Hz, 1H), 9.20 (br s, 1H); 13C NMR
(75 MHz, CDCl3) d 20.7, 20.8, 21.9, 22.7, 23.0, 26.0, 31.4, 33.9, 40.0,
46.7, 56.8, 63.5, 78.3, 135.0, 137.0, 167.1, 170.0; C17H27NO5S (357.47):
calcd C 57.12, H 7.61, N 3.92; found C 57.20, H 7.55, N 3.85.
4.5. X-ray structure determinations of compounds 13 and 19
X-ray diffraction data for compounds 13 and 19 were collected
at room temperature, 295 K, on a Nonius Kappa CCD diffractometer
with graphite monochromated Mo Ka radiation (l¼0.7107 A). The
structures were solved by direct methods (SIR97)21 and reﬁned
(SHELXL-97)22 by full matrix least squares with anisotropic non-
hydrogen atoms. For compound 13 the hydrogen atoms were re-
ﬁned isotropically while for compound 19 the hydrogens were in-
cluded on calculated positions, riding on their carrier atoms, except
the OeH ones, which were reﬁned isotropically.
Crystal data: 13, C8H12O2S; monoclinic, space group P21/a,
a¼11.5646(3), b¼6.3291(2), c¼12.5747(4) A, b¼114.702(1),
V¼836.16(4) A3, Z¼4, Dc¼1.368 g cm3. Intensity data collected
with q30; 2393 independent reﬂections measured; 2070 ob-
served [I>2s(I)]. Final R index¼0.0433 (observed reﬂections),
wR¼0.1138 (all reﬂections), S¼1.023. CCDC N. 827486.
ORTEP23 view of compound 13 is shown in Fig. 2. The molecules
in the crystal are linked in chains by means of intermolecular
O2eH/O1(1/2þx, 1/2y, z) hydrogen bond with O2/O1 dis-
tance of 2.830(2) A.
Compound 19, C15H24O2S; monoclinic, space group P21/a,
a¼15.0396(3), b¼7.2266(1), c¼28.0275(7) A, b¼104.504(1),
V¼2949.1(1) A3, Z¼8, Dc¼1.209 g cm3. Intensity data collected
with q26; 5767 independent reﬂections measured; 3570 ob-
served [I>2s(I)]. Final R index¼0.0483 (observed reﬂections),
wR¼0.1247 (all reﬂections), S¼1.009. CCDC N. 827487.
The asymmetric unit contains two independent molecules.
ORTEP23viewofmoleculeA is shown inFig. 3. Bothmoleculesdisplay
an intramolecular O2eH/O1 hydrogen bond having O2/O1 dis-
tances of 2.737(3) and2.750(3)A, formolecules A andB, respectively.
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